Report Sections

See All Reports

  • drug2514: Placebo oral tablet
  • Placebo (459) Hydroxychloroquine (102) Standard of Care (41) Azithromycin (38) Tocilizumab (36) Remdesivir (34) Placebo oral tablet (33) Questionnaire (32) Convalescent Plasma (28) Standard of care (27) No intervention (24) Favipiravir (23) Ivermectin (23) Convalescent plasma (21) Placebos (17) Enoxaparin (16) Methylprednisolone (15) Nitazoxanide (15) Survey (15) Colchicine (14) Vitamin C (14) placebo (14) Dexamethasone (12) Hydroxychloroquine Sulfate (12) Questionnaire Administration (12) Blood sample (11) Vitamin D (11) Anakinra (10) Control (10) Ruxolitinib (10) Saline (10) Usual Care (10) blood sample (10) no intervention (10) Camostat Mesilate (9) Losartan (9) Questionnaires (9) Standard care (9) questionnaire (9) Baricitinib (8) Blood sampling (8) Lopinavir/ritonavir (8) Zinc (8) survey (8) Gam-COVID-Vac (7) Nasopharyngeal swab (7) Quality-of-Life Assessment (7) Standard treatment (7) Chloroquine (6) Clazakizumab (6) DAS181 (6) LY3819253 (6) Lung ultrasound (6) Oseltamivir (6) Prone position (6) Rivaroxaban (6) Saliva collection (6) Sarilumab (6) Vitamin D3 (6) convalescent plasma (6) Aspirin (5) Best Practice (5) COVID-19 (5) COVID-19 Convalescent Plasma (5) COVID-19 convalescent plasma (5) Camostat (5) Cholecalciferol (5) Data collection (5) Doxycycline (5) Hydroxychloroquine (HCQ) (5) Lopinavir / Ritonavir (5) Nafamostat Mesilate (5) Online Survey (5) Online questionnaire (5) Online survey (5) Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (5) Standard Medical Treatment (5) Standard of Care (SOC) (5) UC-MSCs (5) blood sampling (5) hydroxychloroquine (5) questionnaire assesment (5) Acalabrutinib (4) Ad26.COV2.S (4) Ascorbic Acid (4) BCG Vaccine (4) BCG vaccine (4) BNT162b2 (4) Best Supportive Care (4) Biospecimen Collection (4) CELLECTRA® 2000 (4) Colchicine Tablets (4) HCQ (4) Heparin (4) Interferon Beta-1A (4) Interview (4) Lopinavir/Ritonavir (4) Mavrilimumab (4) Melatonin (4) Nitric Oxide (4) Normal Saline (4) Normal saline (4) Observation (4) Observational (4) Opaganib (4) Oxygen (4) Placebo Administration (4) Povidone-Iodine (4) Prednisone (4) Prone positioning (4) REGN10933+REGN10987 combination therapy (4) RLS-0071 (4) SARS-CoV-2 (4) SARS-CoV-2 convalescent plasma (4) Sargramostim (4) Standard Care (4) Survey Administration (4) Telemedicine (4) Telerehabilitation (4) anti-SARS-CoV-2 convalescent plasma (4) standard care (4) 0.9% saline (3) 3D Telemedicine (3) ACE inhibitor (3) AG0302-COVID19 (3) AZD1222 (3) AZD7442 (3) Abatacept (3) Allocetra-OTS (3) Anti-SARS-CoV2 Serology (3) Apremilast (3) BCG-Denmark (3) BNT162b1 (3) Blood draw (3) Blood samples (3) COVID-19 RT-PCR (3) COViage (3) Chloroquine or Hydroxychloroquine (3) Chloroquine phosphate (3) Clinical assessment (3) Clinical data (3) Clopidogrel (3) Control group (3) Cyclosporine (3) DWRX2003 (3) EIDD-2801 (3) Echocardiography (3) Famotidine (3) Hydrocortisone (3) INO-4800 (3) Ibrutinib (3) Inactivated SARS-CoV-2 Vaccine (Vero cell) (3) Interferon Beta-1B (3) Interferon beta-1a (3) Interferon beta-1b (3) Lenzilumab (3) Leronlimab (700mg) (3) Mesenchymal Stromal Cells (3) Mesenchymal stromal cells (3) Methotrexate (3) Naltrexone (3) Niclosamide (3) Nitric Oxide Gas (3) No Intervention (3) PLACEBO (3) Phase 2 (3) Placebo (Normal saline solution) (3) Placebo oral capsule (3) Plasma (3) Povidone-Iodine Nasal Spray and Gargle (3) Probiotic (3) Prone Positioning (3) Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health (3) RT-PCR (3) Ravulizumab (3) Remestemcel-L (3) Ribavirin (3) Saline Placebo (3) Selinexor (3) Serological test (3) SnPP Protoporphyrin plus Sunlight exposure (3) Standard of care (SOC) (3) Supportive Care (3) Suspension of heat killed (autoclaved) Mycobacterium w (3) TY027 (3) Telmisartan (3) Tofacitinib (3) Usual care (3) VPM1002 (3) Vitamin Super B-Complex (3) Yoga (3) blood donation SMS (3) exhaled breath sampling (3) hzVSF-v13 (3) mRNA-1273 (3) observational (3) self-administered questionnaire (3) serology (3) standard of care (3) standard therapy (3) 0.9% Saline (2) 100 mg/mL Virazole (2) 2D Telemedicine (2) 300 mg of omega3-FA (2) 50 mg/mL Virazole (2) AG0301-COVID19 (2) ARB (2) AVIGAN 200 MG Film Tablets (2) Abidol hydrochloride (2) Acebilustat (2) Aeonose (2) Aerobic Exercise Training (2) Alteplase 50 MG [Activase] (2) Ampion (2) Angiotensin 1-7 (2) Angiotensin converting enzyme inhibitor (2) Angiotensin-(1-7) (2) Apixaban 2.5 MG (2) Assessment of behavioral response to emotional stimulation (2) Assessment of work-related stress (2) Atorvastatin (2) Attention Placebo (2) Ayurveda (2) Azithromycin Tablets (2) Bacille Calmette-Guérin (BCG) (2) Baricitinib Oral Tablet (2) Bemiparin (2) Bevacizumab Injection (2) Bicalutamide 150 Mg Oral Tablet (2) Biological data (2) Biological sample collection (2) Blood collection on admission and longitudinally (2) Blood collection on their first consultation and 10 to 14 days later (2) Blood test (2) Blood tests (2) Breath Biopsy face masks with removable filters and fitted PVA strip (2) Brequinar (2) Bucillamine (2) COVID Convalescent Plasma (2) COVID-19 Serology (2) COVID-19 Therapeutic Biologics - Spike-GM-CSF Protein Lactated Ringer's Injection (2) COVID-19 exposure (2) COVID-19 pandemic (2) COVID-19 patients (2) COVID-19 survey (2) CT-P59 (2) CT-Scan (2) CVnCoV Vaccine (2) CYT107 (2) Camostat Mesylate (2) Canakinumab (2) Cannabidiol (2) Cardiac and electrodermal recordings (2) Carrimycin (2) ChAdOx1 nCoV-19 (2) Chloroquine Sulfate (2) Chloroquine or hydroxychloroquine (2) Ciclesonide (2) Clinical Examination (2) Convalescent COVID 19 Plasma (2) Convalescent Plasma (CP) (2) Convalescent Plasma (anti-SARS-CoV-2 plasma) (2) Convalescent Plasma Transfusion (2) Conventional treatment (2) Corticosteroid (2) Crizanlizumab (2) Daclatasvir (2) Data Collection (2) Data record (2) Deferoxamine (2) Defibrotide (2) Dexamethasone injection (2) Diagnostic Laboratory Biomarker Analysis (2) Diagnostic test (2) Disulfiram (2) Dornase Alfa Inhalation Solution [Pulmozyme] (2) Double-Trunk Mask (2) Duvelisib (2) EC-18 (2) ECG (2) EDP1815 (2) EXO 1 inhalation (2) EXO 2 inhalation (2) Early-Dexamethasone (2) Ebselen (2) Eculizumab (2) Electronic Health Record Review (2) Electronic questionnaire (2) Enoxaparin 40 Mg/0.4 mL Injectable Solution (2) Exercise (2) Exercise & Nutrition (2) Exercise training (2) Exposure (2) Expressive writing (2) Famotidine 20 MG (2) Favipiravir Placebo (2) Fisetin (2) Flow cytometric analysis (2) Fluoxetine (2) Fluvoxamine (2) Follow up (2) Fostamatinib (2) Guduchi Ghan Vati (2) HB-adMSCs (2) HFNC (2) High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule (2) Human Amniotic Fluid (2) Human biological samples (2) Human immunoglobulin (2) Hydroxychloroquine + azithromycin (2) Hydroxychloroquine - Weekly Dosing (2) Hydroxychloroquine 200 Mg Oral Tablet (2) Hydroxychloroquine Sulfate 200 MG (2) Hydroxychloroquine Sulfate 200 MG [Plaquenil] (2) Hydroxychloroquine Sulfate Loading Dose (2) Hydroxychloroquine Sulfate Regular dose (2) Hydroxychloroquine Sulfate Tablets (2) Hydroxychloroquine and Azithromycin (2) Hyperbaric oxygen (2) ICU treatment (2) IMU-838 (2) IVIG (2) Icosapent ethyl (2) Infliximab (2) Interleukin-7 (2) Intramuscular injection (2) Iodine Complex (2) Ion Mobility Spectrometry (IMS) (2) Ivermectin Oral Product (2) Ivermectin Pill (2) Ivermectin and Doxycycline (2) KB109 + Self Supportive Care (SSC) (2) Ketogenic diet (2) L-ascorbic acid (2) LY3832479 (2) Leflunomide (2) Lopinavir-Ritonavir (2) Low Dose Radiation Therapy (2) Low Dose Radiotherapy (2) Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule (2) Low molecular weight heparin (2) M5049 (2) MSC (2) MW33 injection (2) MW33 injection placebo (2) MagPro X100 Stimulator, B70 Fluid-Cooled Coil (2) Matching Placebo (2) Meditation (1 x 20-minute guided audio training) (2) Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule (2) Meplazumab for Injection (2) Metformin (2) Methylprednisolone Sodium Succinate (2) Mindfulness (2) Mindfulness Based Intervention (2) Molnupiravir (2) N-Acetyl cysteine (2) N-acetylcysteine (2) NORS (Nitric Oxide Releasing Solution) (2) Nasal swab (2) Nasopharyngeal swabs (2) Niclosamide Oral Tablet (2) Nigella Sativa / Black Cumin (2) Nitrogen gas (2) Observational study (2) Olokizumab 64 mg (2) Online Questionnaire (2) Ophthalmologic exam (2) PLX-PAD (2) PUL-042 Inhalation Solution (2) Patient-Reported Online Questionnaire on Olfactory & Taste Disturbances (2) Peginterferon Lambda-1A (2) Pentoxifylline (2) Peripheral blood draw (2) Phase 1 (2) Physiotherapy (2) Pirfenidone (2) Placebo (NaCl 0.9%) (Group 2D) (2) Placebo Comparator (2) Placebo inhalation (2) Placebo on a 0- and 28-day schedule (2) Poly-ICLC (Hiltonol®) (2) Practice details (2) Pulmonary Rehabilitation (2) Pulmozyme (2) RECOP unit patient (2) RLF-100 (aviptadil) (2) RTB101 (2) Radiation therapy (2) Remdesivir placebo (2) Routine care for COVID-19 patients (2) Ruxolitinib Oral Tablet (2) SAB-185 (2) SARS-CoV-2 PCR (2) SARS-CoV-2 diagnostic rapid test (2) SARS-CoV-2 rS/Matrix-M1 Adjuvant (2) SARS-Cov2 testing (2) SCTA01 (2) SOC (2) SOC + Placebo (2) Saline solution (2) Saliva sample collection (2) Sample collection (2) Self Supportive Care (SSC) Alone (2) Semi-directive interview (2) Seraph 100 (2) Serology test for COVID-19 (2) Serum testing (2) Sevoflurane (2) Silmitasertib (2) Siltuximab (2) Simple cognitive task intervention (2) Simvastatin (2) Single Dose of Hydroxychloroquine (2) Sirolimus (2) SivoMixx (200 billion) (2) Spirometry (2) Standard Therapy (2) Standard of Care (SoC) (2) Standard of Care Treatment (2) Standard of care treatment (2) Stellate Ganglion Block (2) TD-0903 (2) Taking blood samples (capillary and venous), saliva sampling and nasopharyngeal sampling. (2) Therapeutic Plasma Exchange (2) Therapeutic anticoagulation (2) Throat swab (2) Thymalfasin (2) Tocilizumab (TCZ) (2) Tocilizumab Injection (2) Tofacitinib 10 mg (2) Tranexamic acid (2) Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 (2) Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 (2) Two doses of placebo at the schedule of day 0,28 (2) Unfractionated heparin (2) Volatile Organic Compounds analysis (2) basic treatment (2) blood draw (2) blood samples (2) blood test (2) conjunctival swab (2) human monoclonal antibody DZIF-10c (Group 1A-2D) (2) lung ultrasound (2) nasopharyngeal swab (2) online survey (2) other (2) oxygen therapy (2) pregnant women with laboratory-confirmed 2019-n-CoV (2) retrospective analysis (2) unfractionated Heparin (2) venous ultrasound (2) vv-ECMO + cytokine adsorption (Cytosorb adsorber) (2) vv-ECMO only (no cytokine adsorption) (2) "Calm" is a mindfulness meditation mobile app (1) "Sham"-block with Placebo (Isotone NaCl) (1) "Vernonia amygdalina" (1) (Standard of Care) SoC (1) - Synthetic anti-malarial drugs (1) 0.075% Cetylpyridinium Chloride (1) 0.12% Chlorhexidine Gluconate (1) 0.12% Chlorhexidine Gluconate Mouth Rinse (1) 0.12% Chlorhexidine oral/nasal rinse (1) 0.5% Povidone Iodine (1) 0.5% Povidone/Iodine oral/nasal rinse (1) 0.9% (w/v) saline (1) 0.9% Normal Saline (1) 0.9% Sodium-chloride (1) 0.9% sodium chloride (normal saline) (1) 0.9%NaCl (1) 0.9%sodium chloride (1) 1% Hydrogen Peroxide (1) 1% w/v Povidone-iodide (1) 1. Characterize the immune response after infection with SARS-CoV-2 (1) 1.5-2% w/v Hydrogen Peroxide (1) 10% Povidone-iodine nasal decolonization swab plus 0.12% CHG oral rinse (1) 150 ppm Nitric Oxide delivered through LungFit Delivery System (1) 18F-αvβ6-BP (1) 1: ILT101 (1) 1: Naproxen (1) 1: Prone positioning (1) 1: Usual practice (1) 1: discontinuation of RAS blocker therapy (1) 2 post-mortem transcutaneous lung biopsies (1 anterior ; 1 posterior) using anatomical landmarks (1) 20 Mg Prednisone for 14 days (1) 2019-nCoV IgG/IgM Rapid Test Cassette (1) 2019-nCoV PCR (1) 21% Ethanol plus essential oils (1) 24 hour Holter ECG (1) 25-OH cholecalciferol (1) 2: No instruction regarding positioning (1) 2: Placebo Comparator (1) 2: Standard of care (1) 2: Usual practice + SYMBICORT RAPIHALER (1) 2: continuation of RAS blocker therapy (1) 35 ml blood, 5 tubes LITHIUM HEPARINATE at each time (cured Patients) (1) 35 ml blood, 5 tubes LITHIUM HEPARINATE at each time (hospitalized Patients ) (1) 38 questions questionnaire (1) 38-questions questionnaire (1) 40-Steps-test (1) 40ml blood sample (1) 4Plants/Azythromycin (1) 5-ALA-Phosphate + SFC (5-ALA + SFC) (1) 6 minute walk test (1) 80 ppm Nitric Oxide delivered through LungFit Delivery System (1) A $10 Survey Incentive (1) A $20 Survey Incentive (1) A short video intervention (1) A vignette intervention (1) AAZ Covid-19 rapid test (1) ABBV-47D11 (1) ABPM (1) ABX464 (1) ACE Inhibitors and Calcium Channel Blockers (1) ACE inhibitor, angiotensin receptor blocker (1) ACEI (1) ACEI/ARB (1) ACEIs (1) ACP Decisions Video Program (1) ACT-20-CM (1) ACT-20-MSC (1) ADAM Sensor (1) ADM03820 (1) AI model (1) AK119 (1) ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS (1) AMA Acknowledgement Drug Pricing (1) AMY-101 (1) AN69-Oxiris (1) AN69-Standard (1) ANNE One (1) APL-9 (1) APPS (1) ARBIDOL 100 MG KAPSUL (1) ARBOX (1) ARBs and/or ACE inhibitors (1) ARCT-021 Dose 1 (1) ARCT-021 Dose 2 (1) ARCT-021 Dose 3 (1) ARCT-021 Dose 4 (1) ARCT-021 Dose Regimen 1 (1) ARCT-021 Dose Regimen 2 (1) ARCT-021 single dose priming (1) ARCT-021 two higher dose priming (1) ARCT-021 two lower dose priming (1) ARDSNet (1) ARFC mask (1) ART Therapy (1) AS03-adjuvanted SCB-2019 vaccine (1) ASC09/ritonavir group (1) ASC09F+Oseltamivir (1) AT-001 (1) AT-100 (1) AT-527 (1) ATAFENOVIR 200 MG KAPSUL (1) ATI-450 (1) ATYR1923 1 mg/kg (1) ATYR1923 3 mg/kg (1) AV-COVID-19 (1) AVICOD 200 MG Film Tablet (1) AVIGAN (1) AVIGAN 200 mg FT (1) AVIGAN 200 mg Film Tablets (1) AVM0703 (1) AWARD advice (1) AWARD plus COVID-specific advice (1) AZD1656 (1) AZVUDINE (1) AZVUDINE placebo (1) Abdominal ultrasound (1) Abidol Hydrochloride combined with Interferon atomization (1) Abivertinib (1) Acacia Senegal (1) Acalabrutinib Treatment A (1) Acalabrutinib Treatment B (1) Acalabrutinib Treatment C (1) Acalabrutinib Treatment D (1) Accuchek Inform II platform (1) Accuracy of CAD4TB and Afinion CRP assay for pulmonary TB (1) Acetyl L-Carnitine (1) Acetylsalicylic acid (1) Acknowledgement Racial Injustice AMA (1) Active COVID-19 disease (1) Active Comparator (1) Active PBMT/sMF (1) Active control:Healthy Living (1) Activity (1) Ad5-nCoV (1) AdCLD-CoV19 (1) AdCOVID (1) Additional and minimal collection of products of the human body carried out during a sample for standard of care (1) Additional biological samples (1) Adenosine (1) Adenovirus Type-5 Vectored COVID-19 Vaccine (1) AdimrSC-2f (1) Adipose tissue (1) Administration of Equine immunoglobulin anti SARS-CoV-2 (1) Admission to ICU for COVID-19 (1) Adsorbed COVID-19 (inactivated) Vaccine (1) Aerobic Exercises (1) Aerobic training (1) Aerolized Hydroxychloroquine Sulfate (1) Aerosol Box (1) Aerosol-reducing Mask (1) Aerosolized 13 cis retinoic acid (1) Aerosolized 13 cis retinoic acid plus Inhalation Inhaled testosterone (1) Aerosolized 13 cis retinoic acid plus Inhalation administration by nebulization captopril 25mg (1) Aerosolized All trans retinoic acid (1) Aerosolized All-Trans Retinoic acid plus oral Tamoxifen (1) Aerosolized Isotretinoin plus Tamoxifen (1) African American Sender Acknowledgement (1) African American Sender in Informational Videos. (1) After COVID-19 Pandemic (1) AirFLO2 (1) AirGo Respiratory Monitor (1) Airwave Oscillometry (1) Airway pressure release ventilation (1) Alexa Amazon (1) Alisporivir (1) AlloStim (1) Allogeneic NK transfer (1) Allogeneic and expanded adipose tissue-derived mesenchymal stromal cells (1) Allogenic pooled olfactory mucosa-derived mesenchymal stem cells (1) Almitrine (1) Alpha-interferon alpha, abidol, ribavirin, Buzhong Yiqi plus and minus formula, Huhuang Detoxicity Paste, Baimu Qingre Jiedu Paste, fumigation/inhalation of vitamin C (1) Alpha-interferon, abidol, ribavirin, Buzhong Yiqi plus and minus formula, Huhuang Detoxicity Paste, Baimu Qingre Jiedu Paste and 5% glucose (1) Alpha-interferon, abidol, ribavirin, Buzhong Yiqi plus and minus formula, Huhuang Detoxicity Paste, Baimu Qingre Jiedu Paste and high-dose vitamin C treatment (1) Alteplase (1) Alvelestat (1) Ambrisentan (1) Amiodarone (1) Amlodipine (1) Amoxicillin-clavulanate (1) An auto-questionnaire comprising three psychometric scales (1) Anakinra +/- Ruxolitinib (stages 2b/3) (1) Anakinra 100Mg/0.67Ml Inj Syringe (1) Anakinra 149 MG/ML Prefilled Syringe [Kineret] (1) Anakinra Prefilled Syringe (1) Anakinra alone (stages 2b/3) (1) Anakinra and Ruxolitinib (Advanced stage 3) (1) Anakinra and Ruxolitinib (overcome stage 3) (1) Anakinra plus oSOC (1) Analogs, Prostaglandin E1 (1) Analysis of cytokine response, innate and adaptive immune response, complement activation, and serum neurofilaments as a marker of neurological damage. (1) Anger message (1) Angiography scanner (1) Angiotensin II (1) Angiotensin II Receptor Blockers (1) Angiotensin Receptor Blockers (1) Angiotensin receptor blocker (1) Angiotensin-Converting Enzyme Inhibitors (ACE-I) and Angiotensin II Receptor Blockers (ARB) (1) Anluohuaxian (1) Anti SARS-CoV 2 Convalescent Plasma in critical COVID-19 patients (1) Anti SARS-CoV 2 Convalescent Plasma in severe COVID-19 patients (1) Anti- SARS-CoV-2 Plasma (1) Anti-COVID-19 human immunoglobulin (1) Anti-SARS-CoV-2 Human Convalescent Plasma (1) Anti-SARS-CoV-2 IgT seropositivity (1) Anti-SARS-CoV-2 convalescent plasma (1) Anti-SARS-CoV-2 equine immunoglobulin fragments (INOSARS) (1) Anti-SARS-CoV-2 immunoglobulin (1) Anti-SARS-CoV2 serological controls and serum neutralization (1) Anti-Sars-CoV-2 Convalescent Plasma (1) Anti-coronavirus antibodies (immunoglobulins) obtained with DFPP form convalescent patients (1) Anti-coronavirus antibodies (immunoglobulins)obtained with DFPP from convalescent patients (1) Antibiotic (1) Antibiotics (1) Antibody Test (1) Antibody test (SARS-CoV2) (1) Antibody testing (1) Antibody titration (1) Antibody-Rich Plasma from COVID-19 recovered patients (1) Anticoagulant Therapy (1) Anticoagulation Agents (Edoxaban and/or high dose LMWH) (1) Antihypertensive Agents (1) Antioxidation Therapy (1) Antithrombin III (1) Antithrombotic Therapy (anticoagulant and/or antiplatelet) before admission for Covid19 (1) Antiviral Agents (1) Antroquinonol (1) Anxiety Reduction Training (1) Apilimod Dimesylate Capsule (1) Apixaban (1) Apixaban 5MG (1) Apo-Hydroxychloroquine (1) Appendectomy (1) Apple Watch Series 5 (1) Aprepitant injectable emulsion (1) Aprotinin (1) Arbidol (1) Arbidol Hydrochloride Granules (1) Argatroban (1) Artemesia annua (1) ArtemiC (1) Artemisia Annua Leaf (1) Artemisinin / Artesunate (1) Arterial Blood Gas test (ABG) (1) Arterial blood gas (1) Artesunate (1) Artesunate-amodiaquine (1) Ascorbic Acid and Zinc Gluconate (1) Ashmolean Website (1) Aspirin 100mg (1) Aspirin 75mg (1) Aspirin 81 mg (1) Assembled mask (1) Assessing antibody responses, neutralizing capacity and memory B-cell function (1) Assessing impact of COVID19 (1) Assessment of Dietary Changes in Adults in the Quarantine (1) Assessment of cardiovascular diseases and cardiovascular risk factors (1) Assessment of coagulopathy, Platelets activation and Platelets-Neutrophils interplay (1) Assessment of lung mechanics and heart-lung interactions (1) Assessment of postnatal depression using the the Edinburgh questionnaire between 4 and 6 weeks after delivery (1) Assessment of ventilator-associated pneumonia criteria (1) Assigned Strategies: Active Choice (1) Assigned Strategies: Enhanced Active Choice (1) Assigned Strategies: Opt-in (1) Association of diltiazem and niclosamide (1) AstroStem-V (1) Asunercept (1) Asynchronies detection (1) Atazanavir (1) Atazanavir and Dexamethasone (1) Atorvastatin 20 Mg Oral Tablet (1) Atorvastatin 20mg (1) Atorvastatin 40mg (1) Atovaquone/Azithromycin (1) Attention control (1) Audio-Visual Triage System (AVT) (1) Auditory Evoked Potentials (AEP) (1) Auricular neuromodulation (1) Auricular percutaneous neurostimulation (1) Auscul-X (1) Auto-questionnaires (patients co infected HIV Sras-CoV-2) (1) Autologous Adipose MSC's (1) Autologous Non-Hematopoietic Peripheral Blood Stem Cells (NHPBSC) (1) Automated oxygen administration - FreeO2 (1) Autophagy inhibitor (GNS651) (1) Auxora (1) Avdoralimab (1) Aviptadil 67μg (1) Aviptadil by intravenous infusion + standard of care (1) Awake Prone Positioning (1) Awake Proning (1) Awake prone positioning (1) Awake proning (1) Ayurvedic Kadha (1) Azinc (1) Azithromycin (Azithro) (1) Azithromycin / Ivermectin / Ribaroxaban / Paracetamol (1) Azithromycin / Ribaroxaban / Paracetamol (1) Azithromycin 250 MG (1) Azithromycin 250 MG Oral Capsule (1) Azithromycin 500 milligram (mg) oral Tablet (1) Azithromycin 500Mg Oral Tablet (1) Azithromycin Capsule (1) Azithromycin and hydroxychloroquine (1) Azithromycin with amoxicillin/clavulanate (1) Açaí palm berry extract - natural product (1) BACMUNE (MV130) (1) BAT (1) BAT + Calcifediol (1) BAT2020 (1) BBV152 (1) BBV152A - Phase I (1) BBV152A - Phase II (1) BBV152B - Phase I (1) BBV152B - Phase II (1) BBV152C - Phase I (1) BCG (1) BCG GROUP (1) BCG vaccine (Freeze-dried) (1) BCG-10 vaccine (1) BDB-001 Injection (1) BGB DXP593 (1) BGB-DXP593 (1) BI 764198 (1) BIO 300 Oral Suspension (1) BIO101 (1) BIOMARKERS IN THE LONG TERM IMPACT OF CORONAVIRUS INFECTION IN THE CARDIORRESPIRATORY SYSTEM (1) BIOVITALS (1) BLD-2660 (1) BM-Allo.MSC (1) BM-MSCs (1) BMS-986253 (1) BNT162a1 (1) BNT162b3 (1) BNT162c2 (1) BRII-196 (1) BRII-198 (1) BTL-TML-COVID (1) BVA-100 (1) Background questionnaire (1) Bactek-R (1) Bacterial species isolated (1) Bamlanivimab (1) Bardoxolone methyl (1) Bariatric procedures (1) Baricitinib (janus kinase inhibitor) (1) Baricitinib 4 MG Oral Tablet (1) Baricitinib or Anakinra (1) Base therapy (1) Baseline and during hospitalization blood samples (1) Baseline blood sample (1) Baseline message (1) Basic Body Awareness Therapy (1) Beck Depression Inventory (BDI) (1) Bedside lung ultrasound (1) Behavioral Activation SSI (1) Behavioral: OCAT (1) Behavioral: OCAT-sham (1) Behaviour Change Technique Intervention to Improve Quality of Life (1) Bemiparin sodium (1) Bempegaldesleukin (1) Berberine (1) Bereavement Virtual Support Group (1) Best Available Therapy (1) Best Message + Augmented Message or Implementation Strategy (1) Best Message Alone (1) Best Standard of Care (1) Best Standard of Care + CARDIO (1) Best available care (1) Best available treatment (1) Best standard of care (1) Best supportive care" which includes antivirals /antibiotics/ hydroxychloroquine; oxygen therapy (1) Bevacizumab (1) Bicalutamide 150 mg (1) BioMedomics COVID-19 IgM-IgG Rapid Test (1) Bioarginina® (1) Biobehavioral Tele-rehabilitation Sessions (1) Biocollection (1) Biological (1) Biological Sample Collection (1) Biological collection (patients co infected HIV Sras-CoV-2) (1) Biological collection with nasopharyngeal samples, saliva, blood, stool and urine (1) Biological sample and clinical data collection (1) Biological samples specific to research (1) Biological sampling (1) Biological test (1) Biological/Vaccine: Angiotensin peptide (1-7) derived plasma (1) Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cell) low-dose group (1) Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cells) high-dose group (1) Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cells) placebo group (1) Biological: COVID-19 convalescent plasma (1) Biological: mRNA-1273: 100 mcg (1) Biological: mRNA-1273: 50 mcg (1) Biological: oral polio vaccine (1) Biomarker (TropT, Myoglobin, CK, CK-MB, LDH, D-dimer, CRP, PCT) (1) Biomarkers expression (1) Biosensor (1) Biosensors (1) Biospecimen collection (1) Bivalirudin Injection (1) Blink and Masseter Inhibitory Reflex (1) Blood D-dimer assay (1) Blood Sample (1) Blood analysis (1) Blood and derivatives. (1) Blood collection (1) Blood collection at Day 8, Day 16, Day 24, Month 6 and Month 12 after first symptoms from SARS-CoV-2 infection (1) Blood donation from convalescent donor (1) Blood for anti-drug antibody (ADA) (1) Blood for pharmacokinetic samples (1) Blood for research purposes (1) Blood group determination (1) Blood plasma (1) Blood sample and data record (1) Blood sample collection (1) Blood sample for serological test (1) Blood sample for serology to measure past infection with SARS-CoV-2 (1) Blood sample for whole genome sequencing (1) Blood samples (collection of 5 mL of blood in a dry tube) (1) Blood samples collection (1) Blood sampling (venesection) (1) Blood test for IgG antibodies against SARS-CoV-2 (1) Blood tests sputum, nasal lavage and brushing (1) Bloodwork (1) Bolus placebo (1) Bolus vitamin D3 (1) Bone Marrow Harvest (1) Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment (1) Bone conduction headphones (1) Botulinum Neurotoxin (1) Bovine Lactoferrin (1) Bovine Lipid Extract Surfactant (1) Brain MRI (1) Brain MRI scan (1) Brainstem Responses Assessment Sedation Score (BRASS) (1) Brazilian Green Propolis Extract (EPP-AF) (1) Breath Biopsy (1) Breath Biopsy Analysis (1) Breath Test & Cheek Swab (1) Breath biopsy sampling using the ReCIVA Breath Sampler (1) Breath sample (1) Breath test (1) Breathing exercise, intensive spirometry use, supported cough, progressive mobilisation and ambulation (1) Brexanolone (1) Bridge therapy (1) Brief Behavioral Activation with Mental Imagery (1) Brief Interpersonal Telepsychotherapy (1) Brief Psychiatric Rating Scale (1) Brief Skills for Safer Living (1) Brief cognitive behavioral therapy (1) Brief educational video (1) Brief informational infographic (1) Bromhexine 8 MG (1) Bromhexine Hydrochloride (1) Bromhexine Hydrochloride Tablets (1) Bromhexine Oral Tablet and/or hydroxychloroquine tablet (1) Bromhexine and Spironolactone (1) Broncho-Vaxom® (1) Bronchoalveolar Lavage (BAL) (1) Budesonide (1) Budesonide Nasal (1) Budesonide dry powder inhaler (1) Burnout (1) Butterfly (1) Butterfly iQ (1) C-reactive protein (1) C21 (1) C2Rx (1) C3+ Holter Monitor (1) CAD4COVID+WBC and COVID-19 RDT for SARS-CoV-2 infection (1) CAG length <22 (1) CAG length >=22 (1) CAP-1002 (1) CAP-1002 Allogeneic Cardiosphere-Derived Cells (1) CAStem (1) CBD Isolate (1) CCP (1) CD24Fc (1) CERC-002 (1) CHAMindWell (1) CHEST CT SCAN (1) CHLORPROMAZINE (CPZ) (1) CHX0.12+CPC0.05 oral rinse (PerioAidActive Control) (1) CIG Axial (1) CIG Tilted (1) CK0802 (1) CLBS119 (1) CLIA of IgG and IgM against SARS-Cov-2 (1) CM4620-IE (Injectable Emulsion) (1) CNM-ZnAg (1) CNS magnetic resonance imaging (MRI) imaging (1) COM-COVID anonimous survey (1) COMPASS (1) CONTROL GROUP (1) CONVALESCENT PLASMA (1) COPAN swabbing and blood sample collection (1) COR-101 (1) CORVax (1) COSH Self-help smoking cessation booklet (1) COVI-AMG (1) COVI-GUARD (1) COVI-VAC (1) COVICU (1) COVID 19 Convalescent Plasma (1) COVID 19 Diagnostic Test (1) COVID 19 Self-Questionnaire (1) COVID 19 diagnostic test by PCR (1) COVID 19 impact (1) COVID 19 serology (1) COVID WHELD (1) COVID Watch (1) COVID positive via testing (1) COVID visitation restrictions (1) COVID-19 Androgen Sensitivity Test (CoVAST) (1) COVID-19 Antibody testing (1) COVID-19 Antigen/Antibody Rapid Testing, mobile device image capture and telemedicine support (1) COVID-19 Breastfeeding Support (1) COVID-19 Convalescent Plasma (CCP) (1) COVID-19 Convalscent Plasma (1) COVID-19 Diagnostic and Assessment Tests (1) COVID-19 FACILITY (1) COVID-19 IgG / IgM rapid test (whole blood, serum, plasma) (1) COVID-19 IgG/IgM Rapid Test Cassette test (Healgen Scientific, Houston, Texas, USA) (1) COVID-19 PCR (1) COVID-19 PCR Swab (1) COVID-19 PCR and Serology (1) COVID-19 PCR and serology testing (1) COVID-19 Pandemic (1) COVID-19 Pneumonia (1) COVID-19 Specific T Cell derived exosomes (CSTC-Exo) (1) COVID-19 Swab (1) COVID-19 and Intensive Care (1) COVID-19 antibodies testing (1) COVID-19 antibody point of care test kit (1) COVID-19 barrier box (1) COVID-19 convalescent hyperimmune plasma (1) COVID-19 convalescent plasma (CCP) plus standard of care (SOC) (1) COVID-19 convalescent plasma treatment (1) COVID-19 diagnostic PCR (1) COVID-19 diagnostic test (1) COVID-19 e-package: Psychological wellbeing for healthcare workers (1) COVID-19 experience surveys (1) COVID-19 infection (1) COVID-19 infection status (1) COVID-19 positive via testing (1) COVID-19 related health warning leaflet (1) COVID-19 standard care (1) COVID-19 swap test PCR (1) COVID-19 test (1) COVID-19 test, polymerase chain reaction for SARS-CoV-2 (1) COVID-19 testing (1) COVID-19 treatment (1) COVID-19 treatments (1) COVID-19+ observational (1) COVID-HIGIV (1) COVID-VIRO® test (1) COVID-surgRES questionaire (1) COVID19 (1) COVID19 convalescent plasma infusion (1) COVID19 immunization testing (1) COVID19 vaccine (1) COVIDSeq Test (1) COVSurf Drug Delivery System (1) CPAP (1) CPAP treatment (1) CPI-006 (1) CRI management (1) CSL324 (1) CSL760 (1) CT of the chest (1) CT score (1) CT-P59/Placebo (1) CT-V (1) CT-imaging (1) CT-scan (1) CT-scan with minimal invasive autopsy (1) CTUS examination (1) CUROSURF® (poractant alfa) (1) CVnCoV (1) CVnCoV 12 μg (1) CVnCoV 12μg (1) CVnCoV 6 μg (1) CYNK-001 (1) CYP-001 (1) Calcium Channel Blockers (1) Calm Meditation App (1) Cambridge Validated Viral Detection Method (1) CanSwab (1) Canakinumab 150 MG/ML [Ilaris] (1) Canakinumab Injection 300mg (1) Canakinumab Injection 600mg (1) Candesartan (1) Canine odor detection of Volatile Organic Compounds (1) Cannabidiol, pharmaceutically produced with < 5 ppm THC (1) Cannabis, Medical (1) Capillary Collection & Testing (1) Capillary and salivary sampling (1) Capnography (1) Caption AI (1) Cardiac CT (1) Cardiac MRI (1) Cardiac Magnetic resonance imaging (1) Cardiac surgery (1) Cardiopulmonary resuscitation (1) Cardiorespiratory Exercise (1) Cardiovascular Magnetic Resonance (CMR) Imaging (1) Caring Contacts (1) Carotid Artery Reactivity Testing (1) Carrageenan nasal and throat spray (1) Cartography of air contamination, environment contamination and biological fluid by Sars-Cov2 during visceral surgery in COVID19 patients. (1) Case fatality rate (1) Cash transfer (1) Ceftaroline (1) Ceftriaxone (1) Cell therapy protocol 1 (1) Cell therapy protocol 2 (1) Cellular response (1) Cenicriviroc (1) Cenicriviroc (CVC) (1) Centricyte 1000 (1) Centrum Adult (under 50) multivitamin (1) Cerebral compliance and hemodynamics monitoring (1) Cerebrospinal fluid sampling, meningeal and brain parenchyma biopsies (1) Certified cloth face mask plus preventive information (1) ChAdOx1 nCoV-19 (Abs 260) (1) ChAdOx1 nCoV-19 (Abs 260) + 2.2x10^10vp (qPCR) boost (1) ChAdOx1 nCoV-19 (qPCR) (1) ChAdOx1 nCoV-19 0.5mL boost (1) ChAdOx1 nCoV-19 0.5mL prime plus boost (1) ChAdOx1 nCoV-19 full boost (1) ChAdOx1 nCoV-19 half boost (1) ChAdOx1 nCoV-19 single dose + paracetamol (1) ChAdOx1 nCoV-19 two dose + paracetamol (1) Change in knowledge, motivation, skills, resources (1) Change in preference to surgery under COVID-19 pandemic. (1) Chat-based instant messaging support (1) Chat-based support (1) Chemotherapy (1) Chest MRI (1) Chest computed tomography (CT) (1) Chest physiotherapy post-covid19 (1) Chest physiotherapy using a non-invasive oscillating device (1) Chinese Herbal Medicine (1) Chinese medicine treatment (1) Chiropractic care (1) Chiropractic care (more than one visit) (1) Chiropractic care (one visit) (1) Chloroquine Diphosphate (1) Chloroquine Phosphate Tablets (1) Chloroquine diphosphate (1) Chlorpromazine (1) Choice of Assignment: Active Choice (1) Choice of Assignment: Enhanced Active Choice (1) Choice of Assignment: Opt-in (1) Choices and judgements (1) ChulaCov19 mRNA vaccine (1) Ciclesonide Inhalation Aerosol (1) Ciclesonide Metered Dose Inhaler [Alvesco] (1) Clarithromycin (1) Clarithromycin 500mg (1) Clazakizumab 12.5 mg (1) Clazakizumab 25 mg (1) Clevudine (1) Clinical Observation (1) Clinical Trial Matching (1) Clinical diagnosis of COVID-19 by a health care professional (1) Clinical examination (1) Clinical interview (1) Clinical, functional and radiological lung involvement evolution (1) Clinical, laboratory and imaging characteristics of pneumonia (1) Cliniporator (1) CloSYS mouthwash (1) Clofazimine (1) Clopidogrel 75mg (1) Closed face shield with Surgical face mask use (1) Closed-loop control of oxygen supplementation by O2matic (1) Cloth Face Mask (1) Clungene rapid test cassette (1) Co-mestring (co-coping) (1) Cod liver oil (1) Cognitive Behavioral Brief-Telepsychotherapy (1) Cognitive Behavioural Group Therapy for Perinatal Anxiety (1) Cognitive and behavioral intervention. (1) Cognitive behavior therapy (CBT), specifically using the Facing Your Fears (FYF) curriculum (1) Cognitive testing (1) Cognitive training (1) Cohort (1) Colchicine 0.5 MG (1) Colchicine 1 MG Oral Tablet (1) Colchicine Pill (1) Colchicine plus symptomatic treatment (paracetamol) (1) Colgate Peroxyl mouthwash (1) Colgate Total mouthwash (1) Colgate periogard mouthwash (1) Collagen-Polyvinylpyrrolidone (1) Collection of Biological Samples (1) Collection of blood samples in order to create a biocollection (1) Collection of blood, salivary and nasopharyngeal samples. (1) Collection of breath sample (1) Collection of odour samples (1) Collection of samples (1) Collection of tears and saliva. (1) Colonoscopy (1) Colorectal resections (1) Combination (1) Combination of oral polio vaccine and NA-831 (1) Combined ART/hydroxychloroquine (1) Combined use of a respiratory broad panel multiplex PCR and procalcitonin (1) Communication (1) Communication type (1) Community interest message (1) Community popular opinion leader (POL) based intervention (1) Community-based, mobile van testing (1) Community-driven messages to promote COVID-19 testing (1) Comparable Placebo (1) Comparable Placebo of Oral Polio Vaccine and Placebo of drug (1) Comparable Placebo of drug (1) Comparative Observational Cohort Study (1) Comparator (1) Compassion focused intervention (1) Complement dosage (1) Complete blood picture, bone marrow aspiration cytology (1) Complete thrombophilic profile testing by multiplex PCR (1) Completion of post telemedicine encounter survey (1) Completion of pre-pandemic survey (1) Completion of survey after peak of pandemic (1) Complex diagnostic panel (1) Comprehensive treatment (1) Computed Tomography (CT) (1) Computer task questionnaires (1) Conestat alfa (1) Confinement and Communication During the COVID-19 Pandemic (1) Conjunctival swab and nasopharyngeal swab (1) Connected devices measurements (1) Connor-Davidson Resilience Scale 10 items (CD-RISC 10) (1) Contain COVID Anxiety SSI (1) Continuation of ACEi/ARB (1) Continuation of ARB/ACEI (1) Continuous Positive Airway Pressure (1) Continuous positive airway pressure (CPAP) treatment (1) Continuous renal replacement therapy (1) Continuous vital sign monitoring - Isansys Patient Status Engine (1) Contrast-enhanced CMR (1) Control (albumin 5%) (1) Control Blend (1) Control Group (1) Control Group (pharmacotherapy and/or psychotherapy, n=10) (1) Control Period (1) Control Test (1) Control arm (1) Control message (1) Control patients (1) Control swab (1) ConvP (1) Convalescent Immune Plasma (1) Convalescent Plasma 1 Unit (1) Convalescent Plasma 2 Units (1) Convalescent Plasma Infusion (1) Convalescent Plasma as Therapy for Covid-19 patients (1) Convalescent Plasma from COVID-19 donors (1) Convalescent Plasma of patients with COVID-19 (1) Convalescent SARS COVID-19 plasma (1) Convalescent Serum (1) Convalescent anti-SARS-CoV-2 MBT Plasma (1) Convalescent anti-SARS-CoV-2 MBT plasma (1) Convalescent anti-SARS-CoV-2 plasma (1) Convalescent plasma (CP) (1) Convalescent plasma transfusion (1) Convalesscent Plasma (1) Conventional N95 respirator (1) Conventional Oxygen Therapy (1) Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) (1) Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) and Traditional Chinese Medicines (TCMs) granules (1) Conventional oxygen therapy (1) Conventional physical therapy (1) Conventional therapy first (1) Coping strategies video (1) Cordio App (1) Core Warming (1) Corn oil (placebo) (1) Coromec Registry with ECL-19 (1) CoronaCideTM COVID-19 IgM/IgG Rapid Test and Premier Biotech COVID-19 IgM/IgG Rapid Test (1) CoronaVac (1) Coronavirus Anxiety Scale , COVID-19 Phobia Scale (1) Coronavirus Disease 2019 (1) Corticosteroid injection (1) Corticosteroid with or without colchicine (1) Corticosteroids and Derivatives (1) Cospherunate/Azythromycine (1) Cospherunate/Phytomedicine/Azythromycien (1) Cost-Benefit Frame (1) CovX (1) Covax-19™ (1) Covid ICU containment measures (1) Covid-19 + patients (1) Covid-19 Antibody testing (IgG and IgM) (1) Covid-19 PCR , IGM (1) Covid-19 Rapid Test Kit (RAPG-COV-019) (1) Covid-19 Standard of Care (1) Covid-19 presto test (1) Covid-19 swab PCR test (1) Covid19 (1) Covid19 RT-PCR (1) Covidfree@home (1) Covigenix VAX-001 (1) Covigenix VAX-001 placebo (1) Crest Pro-Health Multi-Protection mouthwash (1) Crisis intervention therapy (1) Crisis management coaching (1) Cross Sectional study using scientifically validated psychometric Scales (1) Cross-sectional observational study (1) Cross-sectional study examining the impact of information sources to obtain information about COVID-19 on depression and anxiety symptoms (1) Cross-sectional study investigating the association of NPIs with mental health (1) Cross-sectional survey (1) Curently used therapy for COVID-19 non-critical patients (1) Current care per UCLA treating physicians (1) Customized questionnaire (1) Cyclosporin A (1) CytoSorb (1) CytoSorb 300 mL device (1) CytoSorb-Therapy (1) Cytokine Adsorption (1) Cytokines dosage (1) Cytokines measurement (1) D-beta-hydroxybutyrate-(R)-1,3 butanediol monoester (1) D-dimer,CBC.ESR,CRP, (1) DAS181 COVID-19 (1) DAS181 OL (1) DASS-21 instrument (depression and anxiety) (1) DB-001 (1) DFV890 (1) DIG Axial (1) DIG Tilted (1) DUR-928 (1) DWJ1248 (1) Daclatasvir 60 mg (1) Daily Coping Toolkit (1) Daily Monitoring (1) Daily Vitamin D3 (1) Daily placebo (1) Dalcetrapib (1) Danoprevir+Ritonavir (1) Dapagliflozin (1) Dapagliflozin 10 MG (1) Darunavir and Cobicistat (1) Darunavir/Cobicistat (1) Data Collection: Clinical Care Assessments (1) Data collection and clinical testing of subjects (1) Data collection and rhinopharyngeal swab (1) Data collection from blood draw (1) Data collection from lumbar puncture (1) Data collection from medical files (1) Data collection up to 1 year (1) Data monitoring for 48h within the first 12 hours of admission for COVID-19 (1) Data registry (1) Data research, database analysis (1) Ddrops® products, 50,000 IU, Oral (1) Decidual Stromal Cells (DSC) (1) Decitabine (1) Deep Breathing training (1) Deep Venous Disease Diagnostic (1) Defibrotide 25 mg/kg 24 hours continuous infusion for 15 days (1) Defibrotide Injection (1) Degarelix (1) DeltaRex-G (1) Dental pulp mesenchymal stem cells (1) Depression, Anxiety and Stress Scale (1) Descartes 30 (1) Description of groups caracteristics (1) Desferal 500 MG Injection (1) Desidustat (1) Detection of anti-COVID-19 antibody level (1) Determination of physical activity, quality of life, stress levels of isolated people at home with the danger of coronavirus. (1) Device used to record voice for screening (1) Dexamethasone (high dose) (1) Dexamethasone 2 MG/ML (1) Dexamethasone and Hydroxychloroquine (1) Dexcom G6 (1) Dexmedetomidine Injectable Product (1) DiaBetter Together (1) DiaNose (1) Diabetes type 2 (1) Diagnosis of SARS-Cov2 by RT-PCR and : IgG, Ig M serologies in the amniotoc fluid, the blood cord and the placenta (1) Diagnostic Test: serology test for COVID-19 (1) Diagnostic examination for venous thromboembolism (1) Diagnostic test Covid-19 (1) Diagnostic test for SARS-Cov2 for patients and health staff (1) Diagnostic test for detection of SARS-CoV-2 (1) Dialectical Behavioral Therapy (DBT) Skills (1) Dialyzable Leukocyte Extract (1) Diet tracking and survey (1) Dietary Supplement containing resistant starch (1) Dietary counselling on Food Groups according to IYC Feeding practices, WHO (1) Dietary supplementation in patients with covid disease admitted to hospital (1) Differences in triage (1) Differential Leucocyte Count (CLDC) device and algorithm (1) Difficulties lived by disabled children's parents in the period of COVID-19 pandemic (1) Diffusing capacity of carbon monoxide (1) DigiVis visual acuity app (1) Digital Health Online Platform (1) Digital cardiac Counseling (1) Digital oximeter monitoring (1) Digital problem solving tool (1) Diphenhydramine (1) Dipyridamole (1) Dipyridamole 100 Milligram(mg) (1) Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally AND Standard of care (1) Direct Antigen Tests for COVID-19 (1) Direct laryngoscopy (1) Discontinuation of ACEi/ARB (1) Discontinuation of ARB/ACEI (1) Discussion Board for Social Support +Basic Feedback (1) Discussion Board for Social Support+Personalized Feedback (1) Disease-modifying antirheumatic drugs (DMARDs) (1) Distilled water (1) Dociparastat sodium (1) Doctella telehealth monitoring (1) Doctor Spot (1) Doctorgram Patient Kit (1) Doppler Echo (1) Dornase Alfa (1) Dornase Alfa Inhalation Solution (1) Dose Finding Phase (MTD) (1) Dose of Tinzaparin or Dalteparin (1) Dose of tinzaparin or dalteparin (1) Double-Blind NT-I7 (1) Double-Blind Placebo (1) Doxycyclin (1) Doxycycline Hcl (1) Drug COVID19-0001-USR (1) Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment (1) Drug: GS-5734 - 1.00 mg/kg (1) Drug: GS-5734 - 2.00 mg/kg (1) Drug: Isotretinoin plus Tamoxifen (1) Drug: Isotretinoin(Aerosolized 13 cis retinoic acid) (1) Drug: Isotretinoin(Aerosolized 13 cis retinoic acid) plus Aerosolized Itraconazole (1) Drug: NA-831 (1) Drug: NA-831 - 0.10 mg/kg (1) Drug: NA-831 - 0.20 mg/kg (1) Drug: Standard treatment Standard treatment (1) Drugs and supportive care (1) Drugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg) (1) Drugs: NA-831 (0.20 mg/kg) plus GS-5734 (2.00 mg/kg) (1) DuACT (1) Duplex ultrasound and Computed Tomography Angiography (1) During COVID-19 Pandemic (1) Dutasteride (1) Duty Frame (1) Dysphagia Handicap Index (DHI) (1) ECCO2R (1) ECG from handheld device (1) ECG-Holter (1) ECMO Implantation (1) EEG (1) EG-HPCP-03a (1) EG-HPCP-03a Placebo (1) EIT-Group (1) ELISA (1) ELISA and Rapid test to detect antibodies against COVID-19 (1) ELISPOT (1) ELMO PROJECT AT COVID-19: PROOF OF CONCEPT AND USABILITY (1) ELMO PROJECT AT COVID-19: STUDY IN HUMANS (1) EMDR (1) ENT exam (1) EP (1) EPDS (Edinburgh Postnatal Depression Scale) (1) EPIC risk score display (1) EQ001 (1) EQ001 Placebo (1) ESOGER (1) EUROIMMUN assay (1) EXTRA-CVD Virtual Care (1) EarSats Pulse Oximeter Probe (1) Early rehabilitation (1) EasyCov POC (1) Eating habits (1) Echo-Doppler (1) Economic benefit message (1) Economic freedom message (1) Edinburgh Postnatal Depression Scale (EDPS) (1) Edoxaban Tablets (1) Education (1) Education sessions (1) Educational meetings and visual prompts (1) Eicosapentaenoic acid gastro-resistant capsules (1) Ejaculated semen sample (1) Elective Cancer Surgery (1) Electric pad for human external pain therapy (1) Electrical Impedance Tomography (EIT) (1) Electrical Impedance tomography (1) Electro impedance tomography (1) Electrocardiogram (ECG) (1) Electrocardiogram, telemetry, echocardiogram, laboratory values (1) Electrocardiogram, transthoracic echocardiography and clinico-biological parameters in routine care (1) Electroencephalogram with EKG lead (1) Electronic Survey questionnaire (1) Electronic survey (1) Elisa-test for IgM and IgG to SARS-CoV-2 (1) Eltrombopag (1) Emapalumab (1) Embarrassment message (1) Emergency Laparotomy (1) Emergency Ventilator Splitter (1) Emergency surgery (1) Emotion Regulation Training via Telehealth (1) Emotional Freedom Technique (1) Emotional Support Plan (1) Emphasis of Academic Researchers Involvement (1) Emphasis of Government Involvement (1) Emtricitabine/Tenofovir Alafenamide 200 MG-25 MG Oral Tablet (1) Emtricitabine/tenofovir (1) Emtricitabine/tenofovir disoproxil (1) Endoscopic intervention (1) Endoscopic management according to standard of care (1) Endoscopic procedure (1) Endothelial damage and angiogenic biomarkers (1) Endotracheal intubation (1) Enduring Happiness and Continued Self-Enhancement (ENHANCE) for COVID-19 (1) Enhanced hygiene measures (1) Enoxaparin 1 mg/kg (1) Enoxaparin 40Mg/0.4Ml Inj Syringe 0.4Ml (1) Enoxaparin Higher Dose (1) Enoxaparin Prefilled Syringe [Lovenox] (1) Enoxaparin Prophylactic Dose (1) Enoxaparin sodium (1) Enoxaparin/Lovenox Intermediate Dose (1) Enriched Survey Feedback (1) Ensifentrine Dose 1 (1) Entrée: Behavioral skills (1) Entrée: Cognitive skills (1) Entrée: Interpersonal skills (1) Environmental exposure and clinical features (1) Enzalutamide (1) Enzalutamide Pill (1) EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19) (1) Equipment with smartwatch throughout hospital stay on the general ward (1) Eritoran (1) Escin (1) Essential Oil Blend (1) Essential oils (1) Estradiol patch (1) Estrogen Therapy (1) Ethanol with Asprin (1) Etoposide (1) Evaluate HACOR score effectivity in this patients (1) Evaluation of changes in the diagnostic-therapeutic pathway for patients affected by pancreatic cancer (1) Evaluation of clinical, instrumental and laboratory diagnostics tests (1) Evaluation of the epidemiological characteristics of coronavirus infection (SARS-CoV-2) (1) Ex vivo expanded Wharton's Jelly Mesenchymal Stem Cells (1) Examinations for the research: (1) Examine the impact of COVID-19 during pregnancy (1) Exebacase (1) Exercise Group (1) Exercise booklet (1) Exercise brochure (1) Exercise capacity (1) Exercise physiology (1) Exercise program (1) Exercise test ECG (1) Exercise training group (1) Experience of pandemic (1) Experiences in Close Relationship Scale questionnaire (ECR-S) (1) Experimental Group (1) Experimental drug (1) Experimental: Questionnaire without precaution information (1) Experts consensus (1) Expiratory training device (1) Exposure (not intervention) - SARS-CoV-2 infection (1) Exposure to the Dutch measures due to the Covid-19 pandemic. (1) Exposure to the SARS-CoV-2 (1) Exposure to the SARS-CoV-2 and its consequences (1) Exposure: Covid-19 infection (1) Expression of receptors and activating proteases (1) Extended sampling and procedures (1) External evacuation device (EED) (1) Extra blood sample (1) Extracorporeal blood purification using the oXiris® (AN69ST) hemofilter (1) Extracorporeal left hemicolectomy anastomosis (1) Extracorporeal membrane oxygenation (1) Extraoral vacuum aspirator (EVA) (1) Extravascular Lung Water Index (1) Eye Movement Desensitisation and Reprocessing Recent traumatic Event Protocol (1) F-652 (1) FAVICOVIR 200 mg Film Tablet (1) FAVIR 200 MG FT (1) FAVIRA 200 MG Film Tablet (1) FFP (1) FFP2 (1) FMD (1) FNC dummy tablet+Standard of Care (1) FNC+Standard of Care (1) FOY-305 (1) FSD201 (1) FT516 (1) FX06 (1) Face Mask + Soap (1) Face mask (1) Face mask awareness (1) Face mask sampling (1) Facebook Ads on the importance of staying safe during the Thanksgiving holiday (1) Facial fractures reduction or osteosynthesis (1) Facial mask (1) Family Nurture Intervention (FNI) (1) FamilyChildCare (provisional name of app) (1) Farmalarm (1) Fast dissolving film (1) Favipiravir (3200 mg + 1200 mg) (1) Favipiravir (3200 mg + 1200 mg) combined with Azithromycin (1) Favipiravir (3200 mg + 1200 mg) combined with Hydroxychloroquine (1) Favipiravir (3600 mg + 1600 mg) (1) Favipiravir + Currently used therapy (1) Favipiravir + Standard of Care (1) Favipiravir Combined With Tocilizumab (1) Favipiravir and Hydroxychloroquine (1) Favipiravir plus Nitazoxanide (1) Feeling Good Digital App (1) Fenofibrate (1) Fiberoptic Bronchoscopy (FOB) (1) Fibreoptic Endoscopic Evaluation of Swallowing (FEES) (1) Fibrin generation markers assays (1) File Scanning (1) File scanning (1) FilmArray PCR on respiratory samples (1) FilmArray Pneumonia (1) Filtration Test (1) Fingerstick (1) Fingolimod 0.5 mg (1) Fit test (1) Five-days oseltamivir (1) Fixed site standard of care testing (1) Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration (PH FDC SC) (1) Fixed-duration Hydrocortisone (1) Fixed-duration higher dose Hydrocortisone (1) Flow controlled ventilation (Evone-ventilator) (1) Flow cytometry (1) Flu shot (1) Flucelvax (1) Fluvirin (1) Fluzone High Dose (1) FoTv (1) Focused/Targeted Message (1) Folic Acid (1) Follow up calls (1) Follow-up at 14 days (1) Follow-up of patients with COVID-19 (1) Follow-up phone call (1) Follow-up visit (1) Fondapariniux (1) Fondaparinux (1) Freestyle Libre 14 day CGM system (1) Full Spectrum CBD Oil (1) Functional MRI (1) Fuzheng Huayu Tablet (1) Fuzheng Huayu tablet (1) GAD-7 (7-item Generalized Anxiety Disorder) (1) GAD-7 (General Anxiety Disorder) scale (1) GAD-7 General anxiety disorder scale (1) GAMUNEX-C (1) GC4419 (1) GC5131 (1) GENETIC (1) GLS-1027 (1) GLS-1200 (1) GLS-5310 (1) GNS561 (1) GO2 PEEP MOUTHPIECE (1) GPs reports of potential patient safety incidents, non-COVID-19 related (1) GRAd-COV2 (1) GX-19 (1) Galidesivir (1) Gam-COVID-Vac Lyo (1) Gamification (1) Ganovo+ritonavir+/-Interferon nebulization (1) Garadacimab, Factor XIIa Antagonist Monoclonal Antibody (1) Gargle/Mouthwash (1) Gas exchange measurement (1) Gas exchanges at different PEEP (1) Gastrointestinal endoscopy (1) General Communication Message (1) General Public cohort (1) General health education (1) Generalized Anxiety Disorder-7 (GAD 7) (1) Generalized Anxiety Disorder-7 (GAD-7) (1) Gimsilumab (1) Global Longitudinal Strain (1) Glucose tablets (1) Glycaemic levels (1) Glycine (1) Graded exercise test (1) Grocery store gift cards (1) Group 1 (1) Group 1: Rivaroxaban 20mg/d followed by enoxaparin/unfractionated heparin when needed (1) Group 2: control group with enoxaparin 40mg/d (1) Group A (AG0302-COVID19) (1) Group A (Placebo) (1) Group A HCQ (1) Group A: oropharygeal spray and immunostimulant (1) Group B (AG0302-COVID19) (1) Group B (Placebo) (1) Group B Control (1) Group B: Placebo oropharyngeal spray + Active principle immunostimulant (1) Group C:Active principle oropharyngeal spray + Placebo taken PO (1) Group D:Placebo oropharyngeal spray + Placebo taken PO (1) Group1 (1) Growth Hormone (1) Growth Mindset SSI (1) Guided online support program (1) Guilt message (1) HADS (1) HADS questionnaire (1) HB-adMSC (1) HCFWO (1) HCQ & AZ (1) HCQ & AZ vs HCQ+SIR (1) HCQ+AZT (1) HFB30132A (1) HFNO (1) HIT-exercise (1) HLX70 (1) HLX71 (1) HOME-CoV rule implementation (1) HOPE intervention (1) Health Care Worker Survey (1) Health Enhancement Program (1) Health Questionnaire (1) Health supplements (1) Health warning leaflet (1) Health-related quality of life (1) Healthy Minds Program Foundations Training (1) Healthy lifestyle advise (1) Helmet CPAP (1) Helmet Continuous Positive Airway Pressure (CPAP) (1) Helmet non-invasive ventilation (1) Hemodynamics changes at different PEEP (1) Hemopurifier (1) Heparin - Prophylactic dosage (1) Heparin - Therapeutic dosage (1) Heparin Infusion (1) Heparin SC (1) Heparin sodium (1) Hepatitis A vaccine (1) Hesperidin and Diosmin mixture (1) Heterologous stimuli (1) Hidroxicloroquina (1) High Dose of KBP-COVID-19 (1) High Flow Nasal Oxygen (HFNO) (1) High Flow Nasal Therapy (1) High Intensity Interval Training group (1) High PEEP with end inspiratory pause (1) High PEEP without end inspiratory pause (1) High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule (1) High dose Interferon-beta 1a (1) High dose radiation 100 cGy (1) High flow nasal cannula (1) High flow nasal cannula HFNC (1) High intensity interval training (1) High volume evacuation (HVE) (1) High-Concentration Essential Oil (1) High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma (1) High-Titer COVID-19 Convalescent Plasma (HT-CCP) (1) High-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Three dose regimen (1) High-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen (1) High-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Three dose regimen (1) High-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Two dose regimen (1) High-dose placebo (18-59 years) & Three dose regimen (1) High-dose placebo (18-59 years) & Two dose regimen (1) High-dose placebo (60-85 years) & Three dose regimen (1) High-dose placebo (60-85 years) & Two dose regimen (1) High-flow nasal cannula treatment (1) High-titer Convalescent COVID-19 Plasma (CCP1) (1) Home Pulse Oximetry Monitoring (1) Home Sleep Apnea Testing or In-hospital Polysomnography (1) Home exercise (1) Home exercise program (1) Home sample collection of concerning mole with physician supervision (1) Home-based exercise (1) Home-based exercise training (1) Home-use Test and Follow-up Questionnaire (1) Honey (1) Hormones (1) Hospital admission (1) Hospital anxiety and depression scale (1) Hospital: DD-CA (1) Hospital: Usual Care (UC) (1) Hospitalized Patients for COVID-19 Infection (1) Huaier Granule (1) Human Biological samples (1) Human Coach first, then Virtual Assistant (1) Human Ezrin Peptide 1 (HEP1) (1) Human milk donors (1) Human umbilical cord derived CD362 enriched MSCs (1) Human umbilical cord mesenchymal stem cells + best supportive care (1) Humoral and cellular immunity (1) Hydrogen Oxygen Generator with Nebulizer (1) Hydrogen Peroxide (1) Hydrogen-Oxygen Generator with Nebulizer, AMS-H-03 (1) Hydroxychloroquin with Azithromycin (1) Hydroxychloroquine (placebo) (1) Hydroxychloroquine + Azithromycin (1) Hydroxychloroquine + Metabolic cofactor supplementation (1) Hydroxychloroquine + Sorbitol (1) Hydroxychloroquine + azithromycin + / - tocilizumab (1) Hydroxychloroquine + lopinavir/ritonavir (1) Hydroxychloroquine + placebo (1) Hydroxychloroquine , Sofosbuvir, daclatasvir (1) Hydroxychloroquine - Daily Dosing (1) Hydroxychloroquine - Daily dosing (1) Hydroxychloroquine Only Product in Oral Dose Form (1) Hydroxychloroquine Oral Product (1) Hydroxychloroquine Pill (1) Hydroxychloroquine Pre-Exposure Prophylaxis (1) Hydroxychloroquine SAR321068 (1) Hydroxychloroquine Sulfate (HCQ) (1) Hydroxychloroquine Sulfate + Azithromycin (1) Hydroxychloroquine Sulfate + Azythromycin (1) Hydroxychloroquine Sulfate 200 milligram (mg) Tab (1) Hydroxychloroquine Sulfate 400 mg twice a day (1) Hydroxychloroquine Sulfate 600 mg once a day (1) Hydroxychloroquine Sulfate 600 mg twice a day (1) Hydroxychloroquine Sulfate Tablets plus Lopinavir/ Ritonavir Oral Tablets (1) Hydroxychloroquine and azithromycin treatment (1) Hydroxychloroquine and azithromycin treatment arm. (1) Hydroxychloroquine as post exposure prophylaxis (1) Hydroxychloroquine combined with Azithromycin (1) Hydroxychloroquine in combination of Azithromycin (1) Hydroxychloroquine plus Nitazoxanide (1) Hydroxychloroquine plus standard preventive measures (1) Hydroxychloroquine sulfate (1) Hydroxychloroquine sulfate &Azithromycin (1) Hydroxychloroquine, Azithromycin (1) Hydroxychloroquine, Clindamycin (1) Hydroxychloroquine, Clindamycin, Primaquine - high dose. (1) Hydroxychloroquine, Clindamycin, Primaquine - low dose. (1) Hydroxychloroquine, Doxycycline (1) Hydroxychloroquine, lopinavir/ritonavir or azithromycin and placebo (standard therapy) (1) Hydroxychloroquine/Azithromycine (1) Hydroxychloroquine/Chloroquine (1) Hydroxycloroquine and Azythromycine (1) Hyperbaric Chamber (1) Hyperbaric Oxygen (1) Hyperbaric Oxygen Therapy (1) Hyperbaric Oxygen Therapy (HBOT) (1) Hyperbaric oxygen therapy (1) Hyperbaric oxygen treatment (HBOT) i.e. inhalation of pressurized oxygen delivered by a hyperbaric chamber (drug/device) (1) Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG) (1) Hyperimmune plasma (1) Hyperpolarized Xe129 (1) Hyperpolarized Xenon-129 MRI of the lungs (1) Hypertension (1) Hypothermia (1) Hypothermia Via Cooling Machine- Arctic Sun 5000 (1) IC14 (1) IC14, a monoclonal antibody against CD14 (1) ICU Recovery + Physical Therapy (1) ID NOW vs. Accula (1) IER-R (posttraumatic stress) (1) IIBR-100 high-dose (prime) (1) IIBR-100 low-dose (prime-boost) (1) IIBR-100 medium dose (prime) (1) IIBR-100, low dose (prime) (1) IIEF-5 questionnaire (1) IL-12 plasmid (1) IMM-101 (1) IN01 vaccine (1) INB03 (1) INC424 / Ruxolitinib (1) INM005 (1) INOpulse (1) IP-10 in CDS protocol (1) IPSS questionnaire (1) ISIS 721744 (1) IV Deployment Of cSVF In Sterile Normal Saline IV Solution (1) IV Dexamethasone (1) IVERMECTIN (IVER P®) arm will receive IVM 600 µg / kg once daily plus standard care. CONTROL arm will receive standard care. (1) Ibudilast (1) Ibuprofen (1) Icatibant (1) Icosapent ethyl (IPE) (1) Identification by PCR of the SARS-COV-2 virus in samples taken from the fetus (1) Identification of genetic variants (1) IgG (1) IgG SARS CoV 2 antibodies (1) IgG SARS CoV2 (1) IgG antibodies immunoassay (1) IgG test (1) IgIV (1) IgM and IgG antibodies assay (1) IgM and IgG diagnostic kits to SARS-CoV-2 (1) Iloprost (1) Imaging (1) Imaging by thoracic scanner (1) Imaging of the lungs (1) Imatinib (1) Imatinib Mesylate (1) Imatinib tablets (1) Immediate vs. delayed provision of antibody test results (1) Immune response study (1) Immunfluorescence (1) ImmunoFormulation (1) Immunofree tablets and Reginmune capsule (1) Immunoglobulin (1) Immunoglobulin of cured patients (1) Immunoglubulins (1) Immunological profiling (1) Immunosuppressive (1) Immunosuppressive Agents (1) Impact Event Score (1) Impact of COVID-19 questionnaire (1) Impact of Event Scale-Revised (1) Impact of respiratory isolation on quality of life (1) In-person instruction (1) In-person postoperative visit (1) Inactivated SARS CoV 2 vaccine (Vero cell). Wuhan (1) Inactivated SARS-CoV-2 vaccine (Vero cell) (1) Inactivated convalescent plasma (1) Increasing Willingness and Uptake of COVID-19 Testing and Vaccination (1) Individualised Ayurveda (1) Individualized-Chinese herbal medicine (1) Indomethacin (1) Infectious Disease and Cardiology Clinical Consultations (1) Inflammatory cytokines and chemokines profiles of patients with dexmedetomidine administration (1) Information (1) Informational videos and social media campaigns encouraging cancer screening. (1) Informed consent (1) Infrared Energy and Dietary Supplement (1) Infusion IV of Mesenchymal Stem cells (1) Infusion placebo (1) Inhaled Hypertonic ibuprofen (1) Inhaled ILOPROST (1) Inhaled Supplemental Oxygen (1) Inhaled budesonide (1) Inhaled nitric oxide (iNO) (1) Inhaled nitric oxide gas (1) Inhaled sedation (1) Injection and infusion of LV-SMENP-DC vaccine and antigen-specific CTLs (1) Innova Lateral Flow Device (1) Inspiratory training device (1) Instrumental Activities of Daily Living Shaping (1) Insulin (1) Insulin film (1) Insulin regimen (1) Interferon alfa (1) Interferon-Alpha2B (1) Interferon-Beta (1) Interferon-ß-1a (1) Interferon-β 1a (1) Interferon-β1a (1) Interleukin 6 (IL6) Antagonist (1) Interleukin 6 (IL6) Antagonist and corticosteroids (1) Interleukin assessment in semen (1) Interleukin-1 receptor antagonist (1) Interleukin-6 Gene-174C detection (1) Intermediate dose thromboprophylaxis (1) Intermittent prone positioning instructions (1) Internet Cognitive Behavioral Therapy plus CHAMindWell (1) Internet-based Cognitive Behavioral Therapy (1) Internet-based guided self-help based on CBT principles (1) Internet-based self-help (1) Internet-based self-help after 3 weeks (1) Internet-delivered cognitive behavior therapy (ICBT) for dysfunctional worry related to the Covid-19 pandemic (1) Interpersonal Psychotherapy (1) Intervention (1) Intervention App (1) Intervention for COVID-19 preventive protocols (1) Intervention for TECC Model (1) Intervention group CoronaCope (1) Intervention group_rehabilitation program (1) Intervention program (1) Intervention training: (1) Intervention, TBN (1) Interview by psychologists (1) Intracorporeal left hemicolectomy anastomosis (1) Intramuscular Vaccine (1) Intramuscular vaccine (1) Intranasal heparin sodium (porcine) (1) Intraosseous access (1) Intravenous Immune Globulin (1) Intravenous Immunoglobulin (1) Intravenous Infusions of Stem Cells (1) Intravenous access (1) Intravenous drug (1) Intravenous saline injection (Placebo) (1) Intravenous sedation (1) Intubation Box (1) Invasive mechanical ventilation (1) Invasive mechanical ventilation using the Unisabana-Herons Ventilator during 24 hours (1) Investigation of smell and taste disorders (1) Investigation of the prevalence of test positivity (1) Investigational Product - ViraCide (1) Iota carrageenan nasal spray and Ivermectin oral drops (used as buccal drops) (1) Iota-Carrageenan (1) Isoflurane Inhalant Product (1) Isoprinosine (1) Isoquercetin (1) Isoquercetin (IQC-950AN) (1) Isotonic saline (1) Isotonic saline 0.9% (1) Isotretinoin Only Product in Oral Dose Form (1) Isotretinoin(Aerosolized 13 cis retinoic acid) +standard treatment (1) Itolizumab IV infusion (1) Ivermectin (IVM) (1) Ivermectin + Doxycycline (1) Ivermectin + Doxycycline + Placebo (1) Ivermectin + Placebo (1) Ivermectin 3mg Tab (1) Ivermectin 5 MG/ML oral solution, Aspirin 250 mg tablets (1) Ivermectin 5 MG/ML oral solution, Dexamethasone 4-mg injection, Enoxaparin injection. Inpatient treatment with mechanical ventilation in ICU. (1) Ivermectin 5 mg/mL oral solution, Dexamethasone 4-mg injection, Aspirin 250 mg tablets (1) Ivermectin 6 MG Oral Tablet (2 tablets) (1) Ivermectin Injectable Solution (1) Ivermectin Tablets (1) Ivermectin and Doxycyline (1) Ivermectin nasal (1) Ivermectin oral (1) Ivermectin plus Nitazoxanide (1) JS016 (anti-SARS-CoV-2 monoclonal antibody) (1) Janus Kinase Inhibitor (ruxolitinib) (1) KELEA Excellerated Water (1) KIR phenotype evaluation (1) Kaletra and beta interferon (1) Kamada Anti-SARS-CoV-2 (1) Kaplan Meier analysis (1) Ketamine (1) Ketogenic diet with phytoextracts (1) Ketotifen 1 MG (1) Kevzara sc (1) Knowledge, Attitude, Practice, Awareness, Preference (1) Kukaa Salama: mHealth intervention (1) Kundalini Yoga and Anxiety Reduction Training (1) L-Citrulline (1) L-citrulline (1) LAMP (1) LAU-7b (1) LB1148 (1) LEAF-4L6715 (1) LMWH (1) LSALT peptide (1) LY3127804 (1) LYMPHOCYTE MONOCYTE RATIO (1) LYT-100 (1) Lab workup (on admission and regularly during follow up). (1) Laboratory Analyses (1) Laboratory test positive for SARS-CoV-2 virus (1) Laboratory tests (1) Lactobaciltus rhamnosus GG (1) Lactobaciltus rhamnosus GG Placebo (1) Lactoferrin (1) Lactoferrin (Apolactoferrin) (1) Lambda 180 mcg S.C (1) Lanadelumab (1) Late dexamethazone (1) Late-Dexamethasone (1) Lateral Position (left and right lateral decubitus) (1) Learning running subcuticular sutures on the Gamified Educational Network (1) Lenalidomide as a 5 mg capsule PO daily, days 1, 3, and 5. (1) Let It Out (LIO)-C (1) Leukapheresis (1) Levamisole (1) Levamisole Pill + Budesonide+Formoterol inhaler (1) Levamisole and Isoprinosine (1) Levamisole and isoprinosine (1) Levilimab (1) Lianhua Qingwen (1) Liberase Enzyme (Roche) (1) Licensed seasonal influenza vaccine (1) Licorice extract (1) Lidocaine 2% (1) Life2000® Ventilator (1) LifeSignals Biosensor 1AX* (1) Lifelight® Data Collect Blood Pressure Group (1) Lifelight® Data Collect Oxygen Saturation Group (1) Lifestyle change promotion program (1) Lift (1) Limbix Spark (1) Linagliptin (1) Linagliptin 5 MG (1) Linagliptin tablet (1) Liquid Alpha1-Proteinase Inhibitor (Human) (1) Listerine Mouthwash Product (1) Liu-Wei-Di-Huang formula (1) Liver function tests (1) Liver function tests ,serum ferritin and PCR for COVID-19 . (1) Liver injury (1) Liver, lung, heart and kidney biopsy (1) Local standard of care (1) Lock-down and social distancing (1) Longeveron Mesenchymal Stem Cells (LMSCs) (1) Lopinavir (1) Lopinavir / ritonavir tablets combined with Xiyanping injection (1) Lopinavir / ritonavir, alpha-interferon nebulization,Abidor Hydrochloride (1) Lopinavir 200 MG / Ritonavir 50 MG [Kaletra] (1) Lopinavir 200Mg/Ritonavir 50Mg FT Reference (1) Lopinavir 200Mg/Ritonavir 50Mg FT Test (1) Lopinavir 200Mg/Ritonavir 50Mg Tab (1) Lopinavir and ritonavir (1) Lopinavir-Ritonavir Drug Combination (1) Lopinavir/ Ritonavir (1) Lopinavir/ Ritonavir Oral Tablet (1) Lopinavir/ Ritonavir Placebo (1) Lopinavir/Ritonavir + hydoxychloroquine (1) Lopinavir/Ritonavir 200 MG-50 MG Oral Tablet (1) Lopinavir/Ritonavir 400 mg/100 mg (1) Lopinavir/ritonavir treatment (1) Losartan 50 mg and Spironolactone 25 mg pillules oral use (1) Losmapimod oral tablet (1) Lovenox 40 MG in 0.4 mL Prefilled Syringe (1) Low Dose (10 mg) Control (1) Low Dose Radiation Therapy (LD-RT) (1) Low Dose of KBP-COVID-19 (1) Low Molecular Weight Heparin (1) Low PEEP - FiO2 high (1) Low PEEP - FiO2 low (1) Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule (1) Low dose Interferon-beta 1a (1) Low dose Low molecular weight heparin or Placebo (1) Low dose Radiotherapy (1) Low dose prednisolone (1) Low dose radiation 35 cGy (1) Low dose radiation therapy (1) Low dose whole lung radiotherapy for older patients with COVID-19 pneumonitis (1) Low flow ECMO driving by CVVH machine (1) Low or upper respiratory tract sample (1) Low-Concentration Essential Oil (1) Low-Intensity Psychosocial Interventions through Telemental health (1) Low-dose Chest CT (1) Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Three dose regimen (1) Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen (1) Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Three dose regimen (1) Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Two dose regimen (1) Low-dose placebo (18-59 years) & Three dose regimen (1) Low-dose placebo (18-59 years) & Two dose regimen (1) Low-dose placebo (60-85 years) & Three dose regimen (1) Low-dose placebo (60-85 years) & Two dose regimen (1) Low-dose radiotherapy (1) Lower-dose prophylactic anticoagulation (1) Lucinactant (1) Lung CT (1) Lung CT scan analysis in COVID-19 patients (1) Lung Function Test (1) Lung Function tests (1) Lung Low Dose Radiation (1) Lung Ultrasound (1) Lung impedance technique (1) Lung ultrasound use in patients hospitalized with COVID (1) LungFit™ (1) MAGEC Spine Rod (1) MANAGEMENT OF COVID-19 (1) MAS825 (1) MCC IMS (1) MCN (Methylene blue, vitamin C, N-acetyl cysteine) (1) MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 15mcg (1) MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 45mcg (1) MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg (1) MFS (1) MK-5475 (1) MLS Laser (1) MMR vaccine (1) MPT0B640 (1) MR or M-M-R II ® vaccine (1) MR-Pro-ADM (1) MRG-001 (1) MRI (1) MRI (heart, brain, lungs, liver) (1) MRI scans (1) MRx-4DP0004 (1) MSC Treatment (1) MSCT (1) MSCs (1) MSCs-derived exosomes (1) MSTT1041A (1) MSTT1041A-matched Placebo (1) MVA-SARS-2-S vaccinations (days 0 & 28) (1) MVC-COV1901 (1) Machine Learning/AI Algorithm (1) Machine learning model (1) Macrolide administered for 3-5 days (1) Macrolide administered for up to 14 days (1) Magnetic Resonance Imaging (1) Magnetic Resonance Spectroscopy (MRS). (1) Maintenance or reduction of immunosuppression (1) MakAir (1) Male Sexual Health Questionnaire (MSHQ) (1) Maltodextrin (1) Mannitol (1) Manremyc (1) Maraviroc (1) Maraviroc + Currently used therapy (1) Maraviroc 300 mg (1) Maraviroc+Favipiravir+CT (1) Marker Therapeutics D2000 Cartridge (D2000) for use with the Spectra Optia® Apheresis System (Optia SPD Protocol) (1) Masimo, LidCO (1) Masitinib (1) Mask with Mask Adhesive/Arm 1 (1) Mask without Mask Adhesive / Arm 2 (1) Masked Saline Placebo (1) Maslach Burnout Inventory (MBI) (1) Massive parallel sequencing of host genome (1) Matched Placebo (1) Matched Placebo Hydroxychloroquine (1) Matched placebo (1) Matching placebo (1) Maternal attachment, Edinburgh depression scoring and postpartum anxiety scale scores (1) Maternal stress (1) Maximal effort test (1) Measles-Mumps-Rubella Vaccine (1) Mechanical Trombectomy (1) Mechanical ventilation with the automated BVM compressor (1) Media Intervention (1) Medical Mask (1) Medical Music (1) Medical Ozone procedure (1) Medical Record Review (1) Medical Record Review - Inpatient Treatment (1) Medication Review (1) Meditation Therapy (1) Meditation and Anxiety Reduction Training (1) Meditation app usage (1) Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule (1) Medium dose prednisolone (1) Mefloquine (1) Mefloquine + azithromycin + / - tocilizumab (1) MejoraCare (1) Melatonin 2mg (1) Melatonin intravenous (1) Melphalan (1) MenACWY (1) MenACWY boost (1) MenACWY prime & saline placebo boost + paracetamol (1) MenACWY single dose + paracetamol (1) MenACWY vaccine (1) MenCare+/Bandebereho fathers'/couples' group education (1) Mental Health questionnaire (1) Mental imagery (1) Merimepodib (1) Mesenchymal Stem Cell (1) Mesenchymal Stem Cells derived from Wharton Jelly of Umbilical cords (1) Mesenchymal Stromal Cells infusion (1) Mesenchymal Stromal Stem Cells - KI-MSC-PL-205 (1) Mesenchymal cells (1) Mesenchymal stem cell (1) Mesenchymal stem cell therapy (1) Mesenchymal stem cells (1) Mesenchymal stromal cell-based therapy (1) Message directing subjects to information on COVID-19 vaccine safety and efficacy (1) Messaging (1) MetaNeb® System (1) Metformin Glycinate (1) Methotrexate-LDE phase 1 (1) Methotrexate-LDE phase 2 (1) MethylPREDNISolone 80 Mg/mL Injectable Suspension (1) Methylene Blue (1) Methylene Blue 5 MG/ML (1) Methylene-Blue Photodisinfection (1) Methylprednisolone Injectable Product (1) Methylprednisolone Injection (1) Methylprednisolone, Placebo (1) Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF) (1) Microcrystalline Cellulose, NF (1) Micronized and ultra-micronized Palmitoylethanolamide (mPEA and umPEA, 300mg + 600mg) oral suspension (1) Microscopy of defined brain regions on autopsy specimens (1) MindRhythm Harmony (1) Mindfullness based cognitive program (1) Mindfulness + Compassion Intervention (MC) (1) Mindfulness Alone (MO) Intervention (1) Mindfulness Based Cognitive Therapy for Resilience During COVID-19 plus CHAMindWell (1) Mindfulness Rounds (1) Mindfulness based intervention (1) Mindfulness intervention (1) Mindfulness program (1) Mindfulness session(s) (1) Mindfulness training (1) Mindfulness training (MT) Connect (1) Mindfulness-Based Cognitive Therapy (1) Minimal Attention Control Intervention (1) MinnRAP Peer Support Program (1) Mixture 3,6% H2 in N2 (96.4%) (1) Mobile Mental Health App - 1 (1) Mobile Mental Health App - 10 (1) Mobile Mental Health App - 2 (1) Mobile Mental Health App - 3 (1) Mobile Mental Health App - 4 (1) Mobile Mental Health App - 5 (1) Mobile Mental Health App - 6 (1) Mobile Mental Health App - 7 (1) Mobile Mental Health App - 8 (1) Mobile Mental Health App - 9 (1) Model Building (1) Model validation (1) Moderate Intensity Aerobic Exercises (1) Modified Bai He Gu Jin Tang (1) Modified CariesCare International management (1) Modified Rankin score (1) Molgramostim nebuliser solution (1) Monalizumab (1) Monitoring Visit - Baseline (1) Monitoring Visit - Week 4 (1) Monitoring Visit - Week 8 (1) Monitoring for aggravation (1) Monitoring physiological data with the Hexoskin smart shirt (1) Montelukast 10mg (1) Montmorrillonite (1) Motivational social support from nurse (1) Motivational social support from nurse with additional support from significant other (1) Motivational telephone intervention (1) Moxibustion plus Cupping (1) Moxifloxacin or Levofloxacin (1) Mucodentol (1) MultiStem (1) Multicapillary column coupled ion mobility spectrometry (1) Multifrequency Bioimpedance Spectroscopy (1) Multiple Doses of Anti-SARS-CoV-2 convalescent plasma (1) Muscle Relaxation Therapy (1) Muscle ultrasound (1) MuscleSound Ultrasound (1) Museum virtual guided tours (1) Music Therapy (1) N terminal pro B type natriuretic peptide (NTproBNP), D-Dimer, and serum Tropinin - I (1) N-803 (1) N-95 Respirator (1) N-acetyl cysteine (1) N95 respirator (1) NA (no intervention) (1) NA-831 (1) NA-831 and Atazanavir (1) NA-831and Dexamethasone (1) NAD+ (1) NBT-NM108 (1) NETosis markers (1) NG Biotech (1) NG test (1) NGM621 (1) NHANES smell and taste tests (1) NIO® (Intraosseous access) (1) NIVOLUMAB (1) NK Cells (1) NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells (1) NK-1R antagonist (1) NO intervention planned due to the observational study design - only a diagnostic testing (1) NO intervention planned due to the observational study design only a diagnostic testing (1) NO-Immunosuppressive (1) NOX66 (1) NP-120 (Ifenprodil) (1) NRICM101 (1) NT-I7 (1) NaCl (1) NaCl 0.9% (1) NaCl Solution (1) Nafamostat Mesylate (1) Nanomix eLab® COVID-19 Rapid Antigen Panel (non-interventional) (1) Narrative Writing (1) Nasal Brushing (1) Nasal Dexamethasone (1) Nasal Irrigation (1) Nasal Spray (1) Nasal Swab (1) Nasal lavage (1) NasoVAX (1) Nasopharyngeal (NP) swab (1) Nasopharyngeal Swab (1) Nasopharyngeal and throat/oropharyngeal swabs analyses by RT-PCR and ddPCR (1) Nasopharyngeal swab and main laboratory (1) Nasopharyngeal, oropharyngeal, or saliva swab (1) Natural Honey (1) Natural Killer Cells infusion (1) Nebulised heparin (1) Nebulised unfractionated heparin (UFH) (1) Nebulized Furosemide (1) Nebulized Platelet Lysate (1) Nebulized Saline (1) Nebulized Sterile Saline (1) Nebulized administration of RLF-100 or Placebo (1) Negative COVID Test Result - Hypothetical Scenario (1) Neonatal resuscitation with PPE for the prevention of SARS-Cov-2 infection (1) Neonatal resuscitation without PPE for the prevention of SARS-Cov-2 infection (1) NestaCell® (1) Neural network diagnosis algorithm (1) Neurocognitive assessment (1) Neuromuscular Blocking Agents (1) Neuromuscular Electrical Stimulation (1) Neuromuscular evaluation (1) Neutral writing control (1) Neutralizing antibodies (1) New QIAstat-Dx fully automatic multiple PCR detection platform (1) New screening strategy (1) Newsfeed function (1) Next generation Sequencing (NGS) analysis (1) Niclosamide suspension (1) Nicotinamide riboside (1) Nicotine 7 mg/ 24h Transdermal Patch - 24 Hour (1) Nicotine patch (1) Nigella sativa (1) Nil intervention (1) Nintedanib (1) Nintedanib 150 MG (1) Nintedanib 150 MG [Ofev] (1) Nitazoxanide 500 MG (1) Nitazoxanide 500Mg Oral Tablet (1) Nitazoxanide Tablets (1) Nitazoxanide and atazanavir/ritonavir (1) Nitazoxanide with ivermectin (1) Nitric Oxide 0.5 % / Nitrogen 99.5 % Gas for Inhalation (1) Nitric Oxide delivered via LungFit™ system (1) Nitric Oxide lozenges, 30 mg (1) Nitric Oxide-Continuous and Sessions (1) Nitric Oxide-Releasing Drug (1) Nitric Oxide-Sessions (1) Nivolumab (1) Nivolumab Injection (1) No Messaging (1) No Personal protective equipment (PPE) (1) No Racial Inequality Highlighting (1) No intervention (survey study for medical doctors). (1) No intervention - exposure is to COVID-19 (1) No intervention - quality of life measure (1) No intervention / Compare the difference in respiratory rate between H0 and H12 of the initiation of morphine between the control and interventional groups (1) No intervention / Evaluation of the ferritin and glycosylated ferritin by standard approved serological tests (1) No intervention on patients (1) No intervention, observational (1) No intervention, this is an observational study that uses validated questionnaires and qualitative interviews.. (1) No interventions (1) No interventions planned (1) No interverntion (1) No research related technology based social interactions (1) No special intervention (1) Non Intervention (1) Non applicable (1) Non interventional study (1) Non invasive visual acuity testing (1) Non-ACEI/ARB (1) Non-Interventional (1) Non-Mindfulness intervention (1) Non-contact ECG (1) Non-contact MCE system (1) Non-convalescent Plasma (control plasma) (1) Non-convalescent fresh frozen plasma (Standard plasma) (1) Non-enhanced CT scan of the chest (1) Non-hospitalization procedures (1) Non-interventional (1) Non-interventional study (1) Non-invasive cardiac imaging (1) Non-invasive red LLLT treatment to chest of patient. (1) Non-invasive ventilatory support (1) None - NA (1) Noninvasive ventilation treatment (1) Normal Saline 0.9% (1) Normal Saline Infusion + standard of care (1) Normal Saline intranasal (1) Normal saline 0.9% (1) Normal saline solution (NSS), Placebo - Phase 1 (1) Normal saline solution (NSS), Placebo - Phase 2 (1) Normal saline solution (NSS), Placebo, Day 189 - Phase 2 (1) Normal saline solution (NSS), Placebo, Day 21 - Phase 1 (1) Normal saline solution (NSS), Placebo, Day 21 - Phase 2 (1) Not bravery message (1) Novaferon (1) Novel laser inferometry test for CORONA virus (1) NuSepin® 0.1 mg (1) NuSepin® 0.2 mg (1) Nudge (1) Nursing care to reduce anxiety, fear and loneliness (1) Nutrition (1) Nutrition Consult and Protein Supplementation (1) Nutrition support (1) Nutritional assessment (1) Nutritional support system (NSS) (1) Nuvastatic (1) NİCaS (1) OCTAPLAS (1) OLO-1 Medical Molecular Sieve Oxygen Generator (1) OP-101 (1) Obesity (1) Observation for study group (1) Observation of behavior and COVID-19 infection will be conducted. (1) Observation of different courses of SARS-CoV-2 infection in different phases (acute vs. post-acute) and settings (1) Observation of patients with known, suspected, or at risk for COVID-19 infection (1) Observation only (1) Observational (registry) (1) Observational Study (1) Observational cohort study on the natural history of hospitalized SARS-COV-2 patients. (1) Observational measurement of biometric data. No change to health care provided. (1) Observational only (1) Observational study only (1) Obtainment of nasopharyngeal, oropharyngeal, buccal, nasal and saliva samples (1) Obvio-19 app (1) Occupational health workers (1) Octagam (1) Octagam 10% (1) Odd/Even birth year intervention groups (1) Olfaction testing (1) Olfactometry (1) Olfactory retraining (1) Omega 3/Nigella Sativa Oil (1) Omega 3/Nigella Sativa Oil/Anise seed capsule (1) Omega 3/Nigella Sativa Oil/Deglycyrrhizinated Licorice (1) Omega 3/Nigella Sativa Oil/Indian Costus (1) Omega 3/Nigella Sativa Oil/Quinine pills (1) Omega-3 Fatty Acid Supplement (1) Omegaven® (1) Omeprazole 20mg (1) Omnibiotic AAD (1) On-Line Survey (1) One COVID-19 vaccine candidate (TMV-083) administration - High dose (1) Online Intervention Grief COVID-19 (1) Online Intervention Mental Health COVID-19 (1) Online Questionnaires (1) Online Survey about Dietary and Lifestyle Habits (1) Online bibliotherapy programme (1) Online cognitive behavioral therapy (CBT) (1) Online instruction (1) Online questionnaire and interviews (1) Online support Group (1) Only Standard Treatment (1) Ophtamesone (1) Opt-in Recruitment Email (1) Opt-out Recruitment Email (1) Optical Coherence Tomography (OCT) (1) Optical coherence tomography angiography (1) Optimized Management of Covid-19 Positive Kidney Transplant Recipients: Single Center Experience from the Middle East (1) Optional blood completion (1) Optional questionnaire completion (1) Oral (1) Oral 25-Hydroxyvitamin D3 (1) Oral administration of Colchicine plus Herbal Phenolic Monoterpene Fractions (1) Oral fluid swab (1) Oral supplement enriched in antioxidants (1) Oral-B Mouth Sore mouthwash (1) Oropharyngeal Swab (1) Orthopaedic Surgical Procedures (1) Oseltamivir 75mg (1) Other (1) Others(No intervention) (1) Otilimab (1) Outpatient MRI (1) Ovotransferrin (1) Oxaloacetate Medical Food/Dietary Supplement (1) Oxidative Stress ELISA Kit (1) Oxygen Hood (1) Oxygen Therapy (1) Oxygen gas (1) Oxygen supply (1) Oxygen-ozone therapy, probiotic supplementation and Standard of care (1) Oxytocin (1) Ozanimod (1) Ozone auto-hemotherapy (1) Ozonized oil (HOO (1) P2Et (Caesalpinia spinosa extract) (1) PCL COV05 - COVID 19 Ag Rapid FIA test (Rapid Antigen Test) (1) PCR (1) PCR Value (1) PCR for COVID-19 (1) PCR, lung ultrasound (1) PD-1 blocking antibody+standard treatment (1) PEEP trial (1) PEP flute (1) PET-CT of 18F-FDG (1) PF-06650833 (1) PF-07304814 (1) PH94B (1) PHQ-9 (9-item Patient Health Questionnaire) (1) PHQ-9 (Patient Health Questionnaire) Depression Scale (1) PHQ-9 Depression Scale (1) PHR160 Spray (1) PLACEBO GROUP (1) PLN-74809 (1) POOL LAMP (1) POOL RT-PCR (1) PRAYER (1) PRO-SERO-COV (1) PROTECTIVE VENTILATION (1) PSC-04 (1) PSG (1) PSQI (1) PSS (Perceived Stress Scale) (1) PT-PCR test for SARS-CoV-2 (1) PT-Pal (1) PT-X and IMT (1) PTC299 (1) PTSD (1) PWV (1) Pacebo: Calcium citrate (1) Pacritinib (1) Pamrevlumab (1) Pandemic control measures (1) Paracetamol (1) Paraclinical examination (1) Part 1 - TL-895 (1) Part 2 - Placebo (1) Part 2 - TL-895 (1) Partially HLA-matched SARS-CoVSTs (1) Participate in a massive musical event (1) Passed infection of SARS-CoV-2 (1) Passive Microwave Radiometry (1) Patch, Nicotine (1) Patch, Placebo (1) Pathogen-specific aAPC (1) Patient Characteristics (1) Patient Education (1) Patient Health Questionnaire (PHQ-9) (1) Patient Health Questionnaire-9 (PHQ-9) (1) Patient Status Engine (1) Patient management suffering of coronavirus infection (1) Patient sampling (1) Patient with SAR-CoV-2 infection (1) Patient-centred advice on Telephone Consultation in TB Patients: (1) Patients admitted in Intensive Care Units (1) Patients admitted to Intensive Care Unit with SARS-CoV2 (1) Patients received standard of care treatment during hospitalization (1) Patients with the treatment agains COVID19 (1) Pectin (1) Peer Mentor Delivery (1) Peer Resilience Champion (1) Peginterferon Lambda-1a (1) Peginterferon beta-1a (1) Peginterferon lambda alfa-1a subcutaneous injection (1) Pegylated Interferon-α2b (1) Pegylated interferon lambda (1) Pembrolizumab (MK-3475) (1) Pemziviptadil (PB1046) (1) Percutaneous Coronary Revascularization for STEMI (1) Performance of the test antigenic and test RT-PCR (1) Performing of lung ultrasound (1) Performing routine care (clinical and paraclinical tests) (1) Peripheral Blood (1) Peripheral blood sampling (1) Peripheral venous ultrasound (1) Personal Exercise Intervention (1) Personal Protective Testing Booth (1) Personal behaviours (1) Personal freedom message (1) Personal protective equipment (1) Personal protective equipment (PPE) (1) Personal protective equipment from biological hazard (1) Personalized ambulatory training (1) Personalized health education (1) Phage Therapy (1) Philips Lumify Ultrasound System (1) Phlebotomy (1) Phone call (1) Phone call interview (1) Phone interviews (1) Phone-call screening and management by a medical student/general practitioner tandem (1) Phsyiotherapy (1) Physical Exercises (1) Physical Therapy (1) Physical Therapy Exercise (1) Physical and Cognitive Activity (1) Physical examination (1) Physical exercise (1) Physical exercise training (1) Physiological saline solution (1) Physiological serum (1) Physiology (1) Piclidenoson (1) Pilot a rapid SARS-CoV-2 testing strategy (1) Pioglitazone (1) Pioglitazone 30 mg (1) Pioglitazone 45 mg (1) Piperacillin-tazobactam (1) Piperacillin/tazobactam (1) Placebo (0.9% normal saline) (1) Placebo (1 tablet daily during 60 days) + Personal Protective Equipment (PPE) (1) Placebo (Methylcellulose) capsule (1) Placebo (PB0) (1) Placebo (PBO) (1) Placebo (Plasma-Lyte 148) (1) Placebo (carrier control) (1) Placebo (human albumin 1%) (1) Placebo (potato starch and magnesium stearate) (1) Placebo (saline) (1) Placebo (sodium chloride bufus, solvent for the preparation of dosage forms for injection 0.9%) (1) Placebo (two doses), priming (1) Placebo - Phase I (1) Placebo - Starch Powder Soft gels (1) Placebo 0.10 mg + 1.00 mg/kg (1) Placebo 0.20 mg + 2.00 mg/kg (1) Placebo 0.9% NaCl solution (1) Placebo 250 cc 24 hours continuous infusion for 15 days (1) Placebo Atazanavir (1) Placebo Atrovastatin (1) Placebo Control (1) Placebo Daclatasvir 60 mg (1) Placebo EC-18 (1) Placebo Group (1) Placebo Hydroxychloroquine (1) Placebo Nitazoxanide (1) Placebo Oil (1) Placebo PBMT/sMF (1) Placebo Ribavirin (1) Placebo Saline (1) Placebo Sofusbuvir + Daclatasvir 60 mg (1) Placebo Starch (1) Placebo Subcutaneous Solution (1) Placebo Tablet (1) Placebo Vaccine (1) Placebo booster (1) Placebo capsules (1) Placebo comparator: DW-NI (1) Placebo comparator: DW-NS (1) Placebo control (non-behavioral infographic) (1) Placebo control + best supportive care (1) Placebo for "Deficiency of Qi and Yang" (1) Placebo for "Deficiency of Qi and Yin" (1) Placebo for ABBV-47D11 (1) Placebo for Azithromycin (1) Placebo for Hydroxychloroquine (1) Placebo intravenous (1) Placebo mouthwash (water) (1) Placebo multiple (1) Placebo nebuliser solution (1) Placebo of FX06 (1) Placebo of Hydroxychloroquine (1) Placebo of LPV/r Tablets (1) Placebo of NICOTINE Transdermal patch (1) Placebo of excipient(s) will be administered (1) Placebo on a 0- and 14-day schedule (1) Placebo oral (1) Placebo oral capsule; From August 2020 'no additional treatment' (1) Placebo pMDI (1) Placebo patch (1) Placebo plus standard preventive measures (1) Placebo single (1) Placebo solution (1) Placebo to Match RDV (1) Placebo videos (1) Placebo- 0.10 mg/kg (1) Placebo- 0.20 mg/kg (1) Placebo- 1.00 mg/kg (1) Placebo- 2.00 mg/kg (1) Placebo-LDE phase 2 (1) Placebo/Aluminum Adjuvant of Inactivated SARS-CoV-2 vaccine (1) Placebo/Control (1) Placebo: Emtricitabine/tenofovir disoproxil Placebo (1) Placebo: Hydroxychloroquine (1) Placebo; 0.9% saline (1) Placenta-Derived MMSCs; Cryopreserved Placenta-Derived Multipotent Mesenchymal Stromal Cells (1) Plant Polyphenol (1) Plaquenil 200Mg Tablet (1) Plasma Donation (1) Plasma IgG levels (1) Plasma exchange (1) Plasma exchange and convalescent plasma (1) Plasma expansion with Ringer's Acetate (1) Plasma from COVID-19 convalescent patient (1) Plasma from a volunteer donor (1) Platelet count, platelet, mean platelet volume and platelet distribution Width in COVID-19 (1) Pleth variability index (1) Plethysmography & DLCO (1) Plitidepsin 1.5 mg/day (1) Plitidepsin 2.0 mg/day (1) Plitidepsin 2.5 mg/day (1) Pneumococcal vaccine (1) Point-of-Care Ultrasonography (POCUS) (1) Point-of-care test for SARS-CoV-2 (1) Polymorphism of the HSD3B1 (1) Polyoxidonium (1) Positive COVID Test Result - Hypothetical Scenario (1) Positive feedback (1) Post COVID-19 Functional Satus Scale (1) Post Traumatic Stress Disorder questionnaire (PTSD-8) (1) Post-intensive Care unit syndrome (1) Postpartum women under investigation for Coronavirus or diagnosed with COVID-19 (1) Postural Positioning (1) Povidine iodine nasal swabs (1) Povidone-Iodine 0.4% NI (1) Povidone-Iodine 0.5% (1) Povidone-Iodine 0.5% NI (1) Povidone-Iodine 0.5% NS (1) Povidone-Iodine 0.6% NI (1) Povidone-Iodine 0.6% NS (1) Povidone-Iodine 2% (1) Povidone-Iodine Solution 1.25% w/w [0.125% available iodine] USP (1) Povidone-iodine (1) Prasugrel (1) Prasugrel Hydrochloride 10 MG Oral Tablet (1) Prazosin (1) Prediction Market (1) Predictive factors for clinical response in patients with COVID-19. (1) Predictors adverse evolution (1) Predictors of health care provide (1) Prednisolone 5 mg (1) Prednisone tablet (1) Pregnant women under investigation for Coronavirus or diagnosed with COVID-19 (1) Premier Biotech COVID-19 IgG/IgM Rapid test Cassette (1) Presence of specific anti-SARS-CoV-2 antibodies (1) PreserVision AREDS formulation gel tabs (1) Preservative-free saline (1) Prevalence of COVID-19 (1) Preventive information (1) Previfenon® (1) Primary care (1) Primary care professionals reports of potential patient safety incidents, non-COVID-19 related (1) Primary exposure is hypoxia (no intervention) (1) PrimePro (1) Pro BNP , Vitamin D (1) Probiorinse (1) Probiotics (1) Probiotics (2 strains 10x10^9 UFC) (1) Problem-solving and relationship improvement intervention. (1) Produce prescription program (1) Progesterone 100 MG (1) Prognostic score (1) Progressive cycling exercise test to exhaustion (1) Progressive muscle relaxation (1) Project ECHO (1) Prolastin (1) Prolectin-M; a (1-6)-alpha-D-Mannopyranose class (1) Prolonged Exposure Therapy (1) Prolonged Proned Positioning (1) Prone (1) Prone Position (PP) (1) Prone Positioning (PP) (1) Prone decubitus (1) Prone position ventilation (1) Prone positioning (PP) (1) Prophylactic/Intermediate Dose Enoxaparin (1) Propofol (1) Propranolol Hydrochloride (1) Proprietary extract of Nerium oleander (1) Prosocial acts (1) Prospective Chart Review (1) Prospective oberservational registry (1) Prospective observation (1) Prospective study across two time-points examining the impact of viral mitigation protocols on mental health (1) Prospective study with two measurement points investigating the impact of viral mitigation protocols on parental burnout (1) Protocolised mechanical ventilation strategy (1) Prototype swab (1) Proxalutamide (1) Psychiatric counseling (1) Psycho-Social Questionnaire (1) Psycho-education (1) Psychoeducation (1) Psychoeducational intervention (1) Psychological and Behaviour Change Support (1) Psychological stress and adaptation at work score (PSAS) (1) Psychological treatment (1) Public Health England Gold Standard (1) Public space exposure (1) Pulmonary Function Tests (PFT) (1) Pulmonary Physiotherapy Techniques (1) Pulmonary Vascular Permeability Index (1) Pulmonary and Motor Rehabilitation (1) Pulmonary function testing (1) Pulmonary function tests (1) Pulmonary tele-rehabilitation (1) Pulmonary ultrasound (1) Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase) (1) Pulse Oximeter (1) Pulse oximetry (1) Pyridostigmine Bromide (1) Pyronaridine-Artesunate (1) Pyronaridine-artesunate (1) Q-NRG Metobolic Cart Device (1) Q16 testing (1) QUANTIFERON (1) QazCovid-in® - COVID-19 inactivated vaccine (1) QuadraMune(TM) (1) Qualitative interviews (in 40 patients : 20 with COVID-19 and 20 without COVID-19) (1) Quality of Life (1) Quality of life assessment (1) Quality of life promotion (1) Quantitative IgG Test (1) Quantitative analysis of SARS-CoV-2 antibodies (1) Quantitative analysis of anti-SARS-CoV-2-antibodies (1) Quantitative and qualitative assessments of mental health (1) Quantra System (1) Quasistatic pressure-volume curve (1) Quercetin (1) Quercetin Phytosome (1) Quercetin Prophylaxis (1) Quercetin Treatment (1) Querying the INSEE database (1) Questionaire (1) Questionnaire : Preparedness for Caregiving Scale (1) Questionnaire and interview (1) Questionnaire by phone call (1) Questionnaire collection (1) Questionnaire completion (1) Questionnaire for evaluation of confinement on deviant sexual fantasies (1) Questionnaire forms (1) Questionnaire including validated tools such as Patient Health Questionnaire (PHQ-9), the 7-item Generalised Anxiety Disorder (GAD- 7), the 7-item insomnia severity index (1) Questionnaire with precaution information (1) Questionnaire, phone call (1) Questionnaire, same tools as before, with inclusion of PCL5 questionnaire too. (1) Questionnaire-based observational study (1) Questionnaires for specific phobia (1) Questionnaires on psychological quality of life (1) Questionnaires, spirometry (1) Questionnary (1) Quetiapine (1) Quidel Sofia SARS Antigen FIA (1) Quinquina-Stevia/Azythromycin (1) RAAS inhibitor [continued standard of care] (1) RAPA-501-Allo off-the-shelf Therapy of COVID-19 (1) RAPID-3 (1) RBA-2 (1) RBT-9 (90 mg) (1) RD-X19 (1) RDV (1) RECHARGE (1) REGN10933 + REGN10987 (1) REGN10933+REGN10987 (1) RESP301, a Nitric Oxide generating solution (1) REmotely Monitored, Mhealth (REMM) supported High Intensity Interval Training (HIIT) (1) RIA-device (Remote Investigation and Assessment) (1) RPH-104 80 mg (1) RT PCR SARS-CoV-2 (1) RT-PCR Covid-19 (1) RT-PCR SARS-Cov2 (1) RT-PCR and antibody testing (1) RT-qPCR test (1) RUTI® vaccine (1) Racial Inequality Highlighted (1) Racial/Ethnic Frame (1) Radiological Detection (1) Radiotherapy (1) Raman analysis of saliva, characterization of the Raman database and building of the classification model (1) Ramelteon 8mg (1) Ramipril 2.5 MG Oral Capsule (1) Random Donor Plasma (1) Randomized booster (1) Rapamycin (1) Rapid Antigen Test (1) Rapid Diagnostic Test vs PCR (1) Rapid Onsite COVID-19 Detection (1) Rapid Pathogen Detection (1) Rapid detection test (1) Rapid molecular test (1) Rarefaction (1) Rayaldee 30Mcg Extended-Release (ER) Capsule (1) Razuprotafib (1) Razuprotafib Subcutaneous Solution (1) Reading a Book (1) Recombinant Bacterial ACE2 receptors -like enzyme of B38-CAP (rbACE2) (1) Recombinant Bacterial ACE2 receptors -like enzyme of B38-CAP (rbACE2) plus Aerosolized 13 cis retinoic acid (1) Recombinant Human Interferon α2b Spray (1) Recombinant Interferon Alfa-2b (1) Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) -placebo (1) Recombinant human angiotensin-converting enzyme 2 (rhACE2) (1) Recombinant human interferon α1β (1) Recombinant human plasma gelsolin (Rhu-pGSN) (1) Recombinant new coronavirus vaccine (CHO cell) group (1) Recombinant new coronavirus vaccine (CHO cells) placebo group (1) Recombinant novel coronavirus vaccine (Adenovirus type 5 vector) (1) Recombinase aided amplification (RAA) assay (1) Reference: Favipiravir 200 mg (Avigan) (1) Referral card (1) Regadenoson (1) Registery Data Collection (1) Regular Inpatient Medical Care (1) Rehabilitation (1) Rehabilitation by Concentric exercises (1) Rehabilitation by Eccentric exercises (1) Rehabilitation exercise protocol (1) Rehabilitation-focused program (1) Reinforcement learning message delivery (1) Relation between frailty and clinical outcomes in elderly patients with COVID-19. (1) Remain COVID Free SSI (1) Remdesivir (RDV) (1) Remdesivir-HU (1) Remimazolam (1) Remote Automated Monitoring System (1) Remote Cognitive Behavioral Therapy for Insomnia (1) Remote Ischemic Conditioning (1) Remote Problem Management Plus (1) Remote consultation (1) Remote controlled exercise (1) Remote pulmonary rehabilitation (1) Removal of dead space filter (1) Renin-angiotensin system inhibitors (1) Repeat SARS-CoV-2 IgG antibodies at 45-65 days (1) Reporting of anosmia, ageusia and other clinical symptoms (1) ResCure™ (1) Resilience Program (1) Respiratory Exercise Training (1) Respiratory Mechanics (1) Respiratory Training (1) Respiratory and psychological rehabilitation (1) Respiratory infections (1) Respiratory mechanics measurement (1) Respiratory monitoring (1) Respiratory muscles ultrasound (1) Respiratory physiotherapy (1) Respiratory rehabilitation (1) Respiratory rehabilitation program (RR). (1) Respiratory symptoms, symptoms of anxiety and depression, and post-traumatic stress screening (1) Respiratory tele-rehabilitation program (TRR). (1) Resting 12 lead ECG (1) Resveratrol (1) Resveratrol Placebo (1) Retrospective case-control analysis (1) Retrospective data collection (1) Reverse transcription polymerase chain reaction (1) Reverse-transcription polymerase chain reaction (RT-PCR) (1) Review of medical patient file (1) Reward Re-Training (1) RhACE2 APN01 (1) Rhea Health Tone® (1) Ringer solution (1) Ringer's lactate (1) Rintatolimod (1) Risankizumab (1) Risk factors (1) Ritonavir (1) Ritonavir+Oseltamivir (1) Ritonavir/lopinavir (1) Rivaroxaban 10 MG (1) Rivaroxaban 2.5 MG (1) RoActemra iv (1) RoActemra sc (1) Robot Assisted Percutaneous Cardiovascular Intervention (1) Robotic therapy (1) Rosuvastatin (1) Routine care (no SARS-CoVSTs) (1) Routine standard of care (1) Rt PCR (1) Ruconest (1) Ruxolitinib 5 MG (1) Ruxolitinib administration (1) Ruxolitinib plus simvastatin (1) SAMBA II (Diagnostic for the Real World) (1) SAR443122 (1) SARILUMAB (1) SARS-CoV 2 RNA PCR Semen (1) SARS-CoV 2 RNA PCR Urine (1) SARS-CoV-2 Ab (1) SARS-CoV-2 Antibody Analysis (1) SARS-CoV-2 IgG (1) SARS-CoV-2 IgG Antibody Testing Kit (1) SARS-CoV-2 S1/S2 IgG (1) SARS-CoV-2 Specific T Cells (1) SARS-CoV-2 and/or MIS-C Exposure (1) SARS-CoV-2 antibody based IVIG therapy (1) SARS-CoV-2 antibody immunoassays (1) SARS-CoV-2 antibody test (1) SARS-CoV-2 antibody testing (1) SARS-CoV-2 convalescent plasma treatment (1) SARS-CoV-2 inactivated vaccine (1) SARS-CoV-2 non-immune Plasma (1) SARS-CoV-2 plasma (1) SARS-CoV-2 questionnaire survey (1) SARS-CoV-2 rS - Phase 1 (1) SARS-CoV-2 rS/Matrix M1-Adjuvant (1) SARS-CoV-2 rS/Matrix-M Adjuvant - Day 189 - Phase 2 (1) SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1 (1) SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 1 (1) SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 2 (1) SARS-CoV-2 rS/Matrix-M Adjuvant, Days 0 and 21 - Phase 2 (1) SARS-CoV-2 rapid diagnostic test (COVID-PRESTO® IgM/IgG, AAZ, Boulogne-Billancourt, France) (1) SARS-CoV-2 research in nasopharyngeal swab, sperm and serologics (1) SARS-CoV-2 serological assessment (IgG) (1) SARS-CoV-2 serology (1) SARS-CoV-2 testing on the Eppendorf Thermal Cycler PCR system using self-collected saliva as the specimen (1) SARS-CoV-2 vaccine (inactivated) (1) SARS-CoV-2 vaccine formulation 1 with adjuvant 1 (1) SARS-CoV-2 vaccine formulation 1 with adjuvant 2 (1) SARS-CoV-2 vaccine formulation 2 with adjuvant 1 (1) SARS-CoV-2 vaccine formulation 2 with adjuvant 2 (1) SARS-CoV-2 vaccine formulation 2 without adjuvant (1) SARS-CoV-2 viral composition (1) SARS-CoV-2-test (1) SARS-CoV2 Autoantibody detection (1) SARS-CoV2 Infection (1) SARS-CoV2 nasal swab (1) SARS-CoV2 serum antibody testing (1) SARS-Cov-2 infection (1) SARSCoV2 Convalescent Plasma (1) SBI-101 (1) SCB-2019 (1) SCB-2019 with AS03 adjuvant (1) SCB-2019 with CpG 1018 adjuvant plus Alum adjuvant (1) SCD (1) SCH Intervention (1) SECRET questionnaire (1) SELF-BREATHE (1) SF12, EQ-5D-5L and work status standardized quantitative assessments (1) SHG (1) SHINGRIX (Zoster Vaccine REcombinant, Adjuvanted) (1) SIR1-365 (1) SLEDD with a L-MOD (1) SMS message support (1) SMS-based support (1) SNDX-6352 (1) SNG001 (1) SNO (1) SOC + IFX-1 (1) SOC + Intravenous Famotidine (1) SOC plus 15mg/kg EB05 IV (1) SOC plus Placebo IV (1) SPEQ (Specific Psychotic Experiences Questionnaire) - Paranoia and Grandiosity Subscales (1) SPIN-CHAT Program (1) SSE educational intervention (1) STC-19 score (1) STI-5656 (1) STP + COVID-19 Convalescent Plasma (CP) (1) STP + Standard Plasma (SP) (1) Saline Control (1) Saline Nasal Irrigation (1) Saline containing 1% Human serum albumin(solution without UC-MSCs) (1) Saline nasal and throat spray (1) Saline oral/nasal rinse (1) Saline with Baby Shampoo Nasal Irrigation (1) Saline-sodium citrate (SSC) buffer (1) Saliva Assay (1) Saliva and NPS test (1) Saliva based assay: crude RNA extraction (1) Saliva sample (1) Saliva specimen (1) Saliva test kit (1) Saliva-based testing (1) Sample (1) Sample Collection/Performance Evaluation (A) (1) Sample Collection/Performance Evaluation (B) (1) Sampler skills (1) Sampling (1) Sampling (EDTA blood, pharyngeal and nose swabs, bronchoalveolar lavage ,urine) (1) Sampling of SARS-CoV-2 RNA from nasopharyngeal swab specimen or saliva collected via Salivette Cortisol (1) Sampling of tissue (1) Sampling salivary (1) Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA] (1) Sarilumab 400 MG/2.28 ML Subcutaneous Solution [KEVZARA] (1) Sarilumab Prefilled Syringe (1) Sarilumab SAR153191 (1) Sars-Cov-2 serology (1) Sars-Cov2 serology (1) Satisfaction evaluation (1) Savicell's ImmunoBiopsy™ (1) Scanning Chest X-rays and performing AI algorithms on images (1) Schirmer Test I (1) Screening test for covid ( RT PCR and CT Chest) (1) Secukinumab 150 MG/ML Subcutaneous Solution [COSENTYX] (1) Self Study (1) Self measurement with pulse oximeter (1) Self-Compassion for Chronic Pain Virtual Group Treatment Program (1) Self-Help Therapy (1) Self-acupressure (1) Self-administered questionnaires (1) Self-collected, home-based testing (1) Self-focused acts (1) Self-guided exercises (1) Self-help booklet (1) Self-interest message (1) Self-management booklet (SWitCh: Stay well during COVID-19) (1) Self-prone position recommendation (1) Self-questionnary (1) Semen Qualitative Analysis (1) Semi-structured telephone questionnaire (1) Sending thorax ct video images via smartphone applications (1) Senicapoc (1) Sensbiosys (1) SensiumVitals wearable sensor (1) Sequencing (1) Seraph®-100 Microbind® Affinity Blood Filter (1) Serelogy testing, RT PCR (1) Serial seroconversion measurements in hospital employees during the COVID-19 pandemic (1) Serologic SARS-CoV-2 screening (1) Serologic assays for antibodies to SARS-CoV-2 (1) Serologic immunoassays to SARS-CoV-2 antibodies (1) Serologic testing (1) Serological Assay or IgG for SARS-CoV-2 (1) Serological analyses to be lead on a pre-existing biobank (1) Serological screening for IgG and IgM antibodies against COVID-19 (1) Serological test and phone interview (1) Serological test for COVID-19. (1) Serological testing (1) Serological tests will be applied on patients blood sampling (1) Serology (1) Serology SARS-CoV2 (1) Serology Test (1) Serology for Covid-19 (1) Serology test follow-up (1) Seroprevalence of SARS-CoV-2 infection in patients with HIV infection (1) Serum SARs COV 2 IGg screening in health care workers (1) Serum protein level analysis (1) Serum test (1) Serum tube collection (1) Serum zinc, vitamin d vitamin b12 levels . (1) Severe Acute Respiratory Syndrome CoronaVirus 2 detection (1) Sevoflurane inhalant product (1) Sham (1) Sham Device Treatment (1) Sham intervention (1) Sham irradiation (1) Shanshamani Vati Plus (1) Shared Decision Making (1) Shock-dependent hydrocortisone (1) Sildenafil (1) Sildenafil citrate tablets (1) Silymarin (1) Simha Kriya (1) Simple chest tomography (1) Simulation Intervention (1) Simulation of Repurposed Drugs for COVID-19 (1) Single fraction whole lung radiotherapy (1) Single high dose vitamin D (1) Single passive leg movement (1) Sirolimus 1 MG/ML (1) Sirukumab (1) Sitagliptin (1) Six Minute Walk Test (6MWT) (1) Six-minute walk test (6MWT) (1) Six-month ARV dispensing (1) Skin biopsy (1) Slef questionnaires fulfilment (1) Smartphone-based voice and self-reported symptom collection (1) Social Distancing Advertisements (1) Social media & news consumption (1) Socialization (1) Sodium Bicarbonate (1) Sodium Bicarbonate 150Meq/L/D5W Inj (1) Sodium Chloride 9mg/mL (1) Sodium Nitrite (1) Sodium bicarbonate (1) Sodium chloride (1) Sofosbuvir (1) Sofosbuvir 400 MG plus Daclatasvir 200mg (1) Sofosbuvir and Ledipasvir (1) Sofosbuvir ledipsavir (1) Sofosbuvir plus Ledipasvir (1) Sofosbuvir/Daclatasvir (1) Sofosbuvir/daclatasvir (1) Software Messaging (1) Sofusbuvir + Daclastavir 60 mg (1) Soluble Urokinase Plasminogen Activator Receptor (1) Solution-Focused Support Program (1) Sonclot Coagulation and platelet function Analyzer SCP1, Sienco, USA (1) Sonoclot (1) Soterix taVNS model 0125-LTE Stimulator - Active-Active Group (1) Soterix taVNS model 0125-LTE Stimulator - Sham-Active Group (1) Spartan COVID-19 System (1) Spartan COVID-19 Test (1) Spartan COVID-19 v2 System (1) Spartan Cube Point-of Care Covid-19 test (1) Specific anti-SARS-CoV-2 antibodies (1) Specimen Collection (1) Speed of Processing Training (1) Sphenopalatine Ganglion Block with Local Anesthetic (1) Sphenopalatine Ganglion Block with Placebo (Isotone NaCl) (1) Spironolactone 100mg (1) Sputum analysis (1) St. George's Respiratory Questionnaire (SGRQ) (1) Staff Wellbeing Centres (1) Stakeholder of TIP-OA Program (1) Standar medical treatmen (1) Standar of care (1) Standard (specific) therapy for COVID-19 (1) Standard 12-lead ECG, NT-proBNP, echocardiography (1) Standard COVID-19 care (1) Standard COVID-19 therapies (1) Standard Care Plus Monitoring (1) Standard Care Therapy (1) Standard Donor Plasma (1) Standard Mask (1) Standard Of Care (SOC) (1) Standard Of Care (SOC) + Placebo (1) Standard Oxygen Delivery System (1) Standard Plasma (FFP) (1) Standard Public Health measures (1) Standard Therapy Protocol (STP) (1) Standard Treatment (1) Standard Ventilation Strategy (1) Standard administration of oxygen flow (1) Standard care delivered in the isolation hospitals. (1) Standard care therapy (1) Standard charity resources (1) Standard interface (1) Standard medical care (1) Standard of Care (Intravenous access) (1) Standard of Care (SOC) + ANG-3777 (1) Standard of Care (SOC) and Colchicine+Rosuvastatin (1) Standard of Care thromboprophylaxis (1) Standard of care (Paracetamol) (1) Standard of care (SOC) plus placebo (1) Standard of care for SARS-CoV-2 infection (1) Standard of care management (1) Standard of care therapies (1) Standard of care therapy (1) Standard of care. (1) Standard oxygen therapy (1) Standard screening strategy (1) Standard supportive care (1) Standard therapeutic protocol (1) Standard therapy (1) Standard therapy for COVID-19 according to the stablished hospital protocols. (1) Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin inhalation (1) Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin intramuscular injection (1) Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin intramuscular injection combined with Dalargin inhalation (1) Standard therapy recommended by the Ministry of Health of the Russian Federation. (1) Standard treatment according to the Clinical protocols (1) Standard treatment for COVID-19 (1) Standard-of-care (1) Standard-of-care treatment (1) Standard-titer Convalescent COVID-19 plasma (CCP2) (1) Standardised questionnaires (1) Standardized crisis management and coping protocol plan toward Coronavirus disease 2019 (COVID-19) (1) Standards of Care (1) State-trait anxiety inventory scale (1) Statins (Cardiovascular Agents) (1) Stem Cell Educator-Treated Mononuclear Cells Apheresis (1) Stem Cell Product (1) Sterile Normal Saline for Intravenous Use (1) Sterile Water for Injection (1) Sterile normal saline (0.9%) (1) Stimulation test with arginine infusion in order to verify the possible existence of damage to the beta cell function induced by COVID-19 infection (1) Stool collection (1) Stool collection or fecal swab (1) Stools (1) Storage of operating waste (1) Stress and emotion management (1) Study A (1) Study Arm (1) Study B (1) Study C (1) Study D (1) Study Group (1) Study of immune-mediated mechanisms in patients tested positive for SARS-CoV-2 (1) Subacute rehabilitation (1) Sublingual Methylene blue (1) Sudarshan Kriya Yoga (SKY) (1) Sulfonatoporphyrin(TPPS) plus Sunlight exposure. (1) Sulfur hexafluoride lipid-type A microspheres (1) Sulodexide (1) Supine Positioning (1) Supine position (1) Support treatment (1) Supportive Therapy (1) Supportive Therapy SSI (1) Supportive tratment (1) Surfactant (1) Surfactant assessment (1) Surge capacity (1) Surgery (1) Surgery: Dynamic Hip Screw, hemiarthroplasty, hip replacement, intramedullary nail (1) Surgical Mask (1) Surgical face mask use only (1) Surgical facial mask (1) Surgical procedures performed under general anesthesia (1) Survey Group (1) Survey administration (1) Survey and Questionnaire (1) Survey to assess Post traumatic stress and anxiety at inclusion and 6 months later (1) Surveys (1) Susceptibility to infection (1) Suspension or Maintenance of Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors (1) Swab (1) Swallowing evaluation with the EAT-10 and the volume-viscosity swallowing test (V-VST) (1) Symptom Survey (1) Symptom and Exposure Surveys (1) Symptomatic drugs (1) Symptomatic treatment (paracetamol or best symptomatic treatment based on doctor recommendations) (1) Symptomatology, Treatment. daily Activities and Anxiety for Cardiovascular patients Survey (STRATA) (1) Symptoms entered into the CovidX application (1) Symptoms questionnare (1) Synthetic neutralising antibodies (1) Systemic indirect endovenous ozone therapy (1) T memory cells and NK cells (1) T-Detect™ SARS-CoV-2 Assay (1) T-cell receptor (TCR) repertoire (1) T3 solution for injection (1) T89 (1) T89 capsule (1) TAK-671 (1) TAK-671 Placebo (1) TAK-919 (1) TAK-981 (1) TAPE-Software (1) TAVR or SAVR (1) TCC-COVID mHealth solution (1) TCM prescriptions (1) TD139 (1) TDR (1) TEM-tPA (1) TJ003234 (1) TLRs activation measurement (1) TM5614 (1) TNKase (1) TOF protocol (1) TRV027 (1) TXA127 (1) Tacrolimus (1) Tafenoquine Oral Tablet (1) Taking biological samples (1) Tap water (1) Taste and olfactory function evaluation (1) Tear Collection (1) Tears swab (1) Technology based social interactions (1) Tele-Pulmonary rehabilitation (1) Tele-Yoga Therapy (1) Tele-delivered psychological intervention (1) Tele-interventions related to diabetes management and mental well-being (1) Tele-medicine platform (1) Tele-yoga therapy (1) Teleconsultation either by phone or by computer consultation (1) Telehealth (1) Telehealth coaching sessions (1) Telehealth monitoring (1) Telehealth phone calls (1) Telemedicine to remote outpatient visit in bariatric patient (1) Telemedicine visit (1) Telephone follow-up (1) Telephone interview (1) Telephone survey (1) Telephonic interview during the Italian lockdown. (1) Telephonic medical visit (1) Telepsychoeducation (1) Telepsychoeducation with personalized videos (1) Telepsychoeducation without personalized videos (1) Telerehabilitation-Based (1) Telesimulation (1) Telmisartan 40Mg Oral Tablet (1) Telmisartan 40mg (1) Telmisartan arm will receive 80 mg Telmisartan twice daily plus standard care. (1) Temporarily holding the RAAS inhibitor [intervention] (1) Ten-days oseltamivir (1) Tenecteplase (1) Tenofovir/ Emtricitabine ( 300 mg / 200 mg daily during 60 days) + Personal Protective Equipment (PPE) (1) Test Group: experimental - UVC Therapy applied (1) Test PCR (1) Test for SARS-CoV-2 (1) Test: Favipiravir 200 mg (LOQULAR) (1) TestNPass (1) Tested for SARS-CoV-2 (regardless of the result) (1) Testing Sensitivity for SARS-CoV-2 Virus in Symptomatic Individuals (1) Testing for SARS-CoV-2 (1) Testing of SARS-CoV-2 antibodies (1) Testing procedure for Binding antibodies (1) Tetrandrine (1) Text material for psychoeducation and audio for relaxation techniques (1) Thalidomide (1) The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: (1) The PREPARE program (1) The Vie Scope laryngoscope (1) The control group will not receive hydroxychloroquine (1) The demographic, clinical, laboratory, and instrumental data (1) The psychosocial effects of COVID-19 pandemic on dental professionals (1) The standard Macintosh laryngoscope (1) The standard of care (1) The standard therapy (1) The study does not required (1) The use of the MentalPlus® digital game for assessment and rehabilitation of cognitive function after remission of the symptoms of COVID-19 (1) The usual treatment (1) Therapeutic Anticoagulation (1) Therapeutic Exercise and Education (1) Therapeutic Plasma Exchange (TPE) (1) Therapeutic Plasma exchange (1) Therapeutic plasma exchange (1) Therapeutic plasma exchange (TPE) (1) Therapist Guided E-Therapy (1) Therapy Intervention (1) There is no intervention (1) There is no intervention in this study (1) Thermography (1) Thiazide or Thiazide-like diuretics (1) This is an online survey with no intervention. (1) Thoracic CT Scan (1) Thorax CT (1) Thoraxic computed tomography (1) Three doses of high-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28 (1) Three doses of high-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 14, 28 (1) Three doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28 (1) Three doses of placebo at the schedule of day 0, 14, 28 #High-dose group# (1) Three doses of placebo at the schedule of day 0, 14, 28 #middle-dose group# (1) Three doses of placebo at the schedule of day 0, 14, 28(high-dose group) (1) Threshold IMT device (1) Throat swab sample for measuring current infection with SARS-CoV-2 (1) Thrombin Generation Assay (TGA) (1) Thrombin generation test assay (1) Thrombomodulin Modified Thrombin Generation Assay (TGA-TM) (1) Thromboprophylaxis (1) Thymosin+standard treatment (1) Thyroidectomy (1) Ticagrelor (1) Tice® BCG (for intravesical use) BCG LIVE strain of the BCG (Merck) vaccine (1) Tigerase® and best available care (1) Tinzaparin or unfractionated heparin (1) Tirofiban Injection (1) Tissue plasminogen activator (1) Titanium blood test (1) To assess for development of IgG antibodies against SARS-CoV2 (1) Tociliuzumab (1) Tocilizumab +/- ruxolitinib (stages 2b/3) (1) Tocilizumab 180 MG/ML (1) Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA] (1) Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]_#1 (1) Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]_#1 (2 doses) (1) Tocilizumab Injection [Actemra] (1) Tocilizumab Prefilled Syringe (1) Tocilizumab and Ruxolitinib (Advanced stage 3) (1) Tomeka® (1) Toraymyxin PMX-20R (PMX Cartridge) (1) Toremifene (1) Tracheal intubation and cardiopulmonary resuscitation (1) Tracheostomy (1) Tracheostomy with aerosol box in COVID-19 positive patients (1) Tracheotomy (1) Tradipitant (1) Traditional Chinese Medicine Prescription (1) Traditional Proning Arm (1) Traditional antirheumatic drugs (1) Training clinicians in basic critical care and the management of severe COVID-19 cases (1) Training for Awareness, Resilience, and Action (TARA) (1) Training load (1) Training of youth, community health assistants and community health workers. (1) Training session adressing information and health literacy (1) Training video on anxiety, fear and loneliness in the COVID-19 environment. (1) Tramadol (1) Tranexamic acid tablets (1) Trans Sodium Crocetinate (1) Transcendental Meditation (1) Transcutaneous Auricular Vagus Nerve Stimulation (1) Transfer Package from CI Therapy (1) Transfusion of COVID-19 convalescent plasma (1) Transfusion of SARS-CoV-2 Convalescent Plasma. (1) Transfusion of standard Plasma. (1) Transitional Online Peer Support Group (n=20) (1) Transparent mask (1) Transplant patient (1) Transpulmonary pressure measurements (1) Transpulmonary thermodilution (1) Transthoracic echocardiogram (TTE) (1) Trauma Informed Psychotherapy (1) Trauma Informed Yoga (1) Trauma-informed yoga video recording (1) Travelan OTC (1) Treamid (1) Treatment and prophylaxis (1) Treatment as usual (1) Treatment as usual vitamin D (1) Treatment for COVID-19 (1) Treatment group (1) Treatment group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days : (1) Treatment with Dexmedetomidine (1) TriCor® 145mg tablets (1) Triazavirin (Riamilovir) (1) Trier Social Stress Test (1) Trimodulin (1) Trust in science message (1) Tuberculin test (1) Two COVID-19 vaccine candidate (TMV-083) administrations - High dose (1) Two COVID-19 vaccine candidate (TMV-083) administrations - Low dose (1) Two dose ChAdOx1 nCoV-19/Covishield 0.25mL & 0.5mL (1) Two dose ChAdOx1 nCoV-19/Covishield 0.5mL (1) Two dose MenACWY vaccine (1) Two dose MenACWY vaccine min. 4 weeks apart (1) Two doses of commercial scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14 (1) Two doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule (1) Two doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule (1) Two doses of high dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 (1) Two doses of high-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14 (1) Two doses of high-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28 (1) Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule (1) Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule (1) Two doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14 (1) Two doses of middle-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28 (1) Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14 (1) Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14 in elderly (1) Two doses of placebo at the emergency vaccination schedule (1) Two doses of placebo at the routine vaccination schedule (1) Two doses of placebo at the schedule of day 0, 14 #High-dose group# (1) Two doses of placebo at the schedule of day 0, 14 #middle-dose group# (1) Two doses of placebo at the schedule of day 0, 28(high-dose group) (1) Two doses of placebo at the schedule of day 0, 28(middle-dose group) (1) Tympanic Temperature (1) Typical surgical covered mask (1) UB-612 (1) UCMSCs (1) ULTRAPROTECTIVE VENTILATION (1) UNI911 INHALATION (1) UNIKINON (Chloroquine phosphate) 200mg tablets (1) UTTR1147A (1) UTTR1147A-matched Placebo (1) UV Light Treatment (1) Ulinastatin (1) Ultra Brief Online Mindfulness-based Intervention (1) Ultra-Low-dose radiotherapy (1) Ultrasonography (1) Ultrasound lung imaging as part of FAST+ evaluation (1) Ultrasound of the lower limbs (1) Umbilical Cord Lining Stem Cells (ULSC) (1) Umbilical Cord Mesenchymal Stem Cells (1) Umbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care. (1) Umbilical cord Wharton's jelly-derived human (1) Umbilical cord derived mesenchymal stem cells (1) Umifenovir (1) Unavailable COVID Test Result - Hypothetical Scenario (1) Unfractionated Heparin IV (1) Unfractionated heparin SC (1) Unfractionated heparin nebulized (1) Unified Protocol for COVID-19 Parenting Stress (UP-COVID) (1) Uniform random message delivery (1) Unsupervised physical activities (1) Use of Facetime with child and parents during induction (1) Use of mobile application (1) Use of social media during COVID-19 (1) Use of the pinpointIQ solution (physIQ, Inc.) (1) Use of virus (Covid-19) genome sequence report to inform infection prevention control procedures (1) Usual Care Only (1) Usual antibiotic treatment (1) Usual care positioning with no instructions (1) V-SARS (1) V/Q SPECT-CT (1) V/Q Vest (1) V590 (1) V591 (1) VC (1) VCPM (1) VESTA respirator (1) VIB7734 (1) VIR-7831 (1) VITROS Anti-SARS-CoV-2 IgG test (1) VLA2001 (1) VR for psychoeducation and relaxation (1) VXA-CoV2-1 (1) Vacciantion status in health care workers (1) Vaccinated with polio vaccine (IPV) (1) Vaccine Therapy (1) Vaccine coverage assessment (1) Vaginal fluid Covid-19 PCR test (1) Validation of the LAMP assays (1) Validation of the NGS method (1) Validation of the POCT Antigen tests (1) Valproate (1) Valsartan (Diovan) (1) Vascular surgery (1) Vehicle + Heparin along with best supportive care (1) Vehicle Control (1) Venepuncture (1) Venous Draw & Testing (1) Venous blood was collected for biochemistry testing (1) Venous blood was collected for biochemistry testing. (1) VentaProst (inhaled epoprostenol delivered via a dedicated delivery system) (1) Verapamil (1) Veru-111 (1) VibroLUNG (1) Video Chat + Basic Feedback (1) Video Chat +Personalized Feedback (1) Video Dance classes (1) Video about safety and effectiveness of adult seasonal flu vaccination (1) Video based aerobic exercise (1) Video based exercise (1) Video-Based (1) Video-Based intervention (1) Videofluoroscopic Swallowing Study (VFSS) (1) Videofluoroscopy (1) Vie Scope laryngoscopy (1) Vielight RX Plus (1) Views and experiences of health care professionals working in intensive care units during the COVID-19 pandemic (1) Viral Specific T-cells (VSTs) (1) Virtual Assistant first, then Human Coach (1) Virtual Care and Remote Automated Monitoring (1) Virtual Care at Home (1) Virtual Family-Based Treatment (1) Virtual Group Exercise (1) Virtual Group Intervention (1) Virtual Peer Support Platform (1) Virtual Reality (1) Virtual reality therapy first (1) Virtual-Care Cognitive Behavioural Therapy (1) Viruxal Oral and Nasal Spray (1) Vit D (1) VitalConnect Vital Sign Patch (1) VitalTalk communication skills training (1) Vitamin B12 (1) Vitamin C tablets (1) Vitamin D 1000 IU (1) Vitamin D supplementation (1) Vitamin D3 (cholecalciferol) (1) Vitamin D3 or Placebo (1) Vitamin E (1) Vitamins (1) Vitamins and Minerals (1) Viusid and Asbrip (1) VivaDiag™ COVID-19 lgM/IgG Rapid Test (1) Voice Symptom Scale (VoiSS) (1) Volunteer of TIP-OA Program (1) WEB embolization (1) WFI 5% glucose (1) WFI water nebulization (1) WHO recommendations (waiting condition) (1) WHOQOL-BREF (1) WHOQOL-BREF survey (1) WJ-MSCs (1) Walk Test (1) Water Without an Elevated Level of KELEA (1) Wearable Medical Device (Empatica E4) (1) Wearing surgical face mask sprayed with hypertonic saline (1) Web Based Questionnaire (1) Web Based Survey (1) Web application users (1) Web-based REDCap survey (1) Web-based psychosocial peer-to-peer support (1) WebEx Physical Activity Program (1) Weck-cel Swab Collection (1) Weekly Assessment (1) Weight Counseling (1) Wharton's jelly derived Mesenchymal stem cells. (1) White Sender in Acknowledgement (1) White Sender in Informational Videos (1) Whole Exome Sequencing (1) Whole Genome Analysis (1) Whole exome sequencing (1) Withings ScanWatch (1) Woebot Substance Use Disorder (1) WofB (1) Written Information (1) Written Summary of Rounds (1) XAV-19 (1) XC221 (1) XC7 100 mg single (1) XC7 200 mg multiple (1) XC7 200 mg single (1) XCEL-UMC-BETA (1) Xiang-Sha-Liu-Jun formula (1) Xiyanping injection (1) Yin Hu Qing Wen Granula(low does) (1) YinHu QingWen Decoction (1) YinHu QingWen Decoction(low dose) (1) Yinhu Qingwen Granula (1) Yoga group (1) Yu-Ping-Feng formula (1) Zanubrutinib (1) Zaritt Burden Interview (1) Zavegepant (BHV-3500) (1) Zilucoplan® (1) Zinc (Placebo) (1) Zinc (zinc gluconate) (1) Zinc (zinc gluconate) & Vitamin D (cholecalciferol) (1) Zinc Citrate (1) Zinc Gluconate (1) Zinc Picolinate (1) Zinc Picolinate Placebo (1) Zinc Sulfate (1) Zinc Sulfate 220 MG (1) Zinc gluconate (1) Zithromax Oral Product (1) Zofin (1) ZofinTM (OrganicellTM Flow) (1) Zotatifin (1) [18F]FP-R01-MG-F2 (1) [68Ga]Ga-DOTA-(RGD)2 PET/CT (1) [TIMP-2]*[IGFBP-7] (1) a specifically designed self-administered questionnaire (1) a survey (1) acetylsalicylic acid (1) actigraphy (1) acute kidney injury (1) additional blood tubes (1) aerosol box (1) aerosolized DNase (1) after-each-case room disinfection (1) agenT-797 (1) airway management during sedation or general anesthesia (1) all treatment about COVID-2019 (1) allogeneic human dental pulp stem cells (BSH BTC & Utooth BTC) (1) allogeneic mesenchymal stem cell (1) alpha one antitrypsin inhalation (1) alpha1-proteinase inhibitor (1) alveolar recruitment (1) amoxicillin/clavulanate (1) anti-SARS-CoV-2 IgY (1) anti-SARS-CoV-2 human convalescent plasma (1) anti-SARS-CoV-2 plasma (1) antidiabetic treatment (1) appendectomy (1) assessment of the sequelae after hospitalization for Sars-COV-2 (1) attendance by ambulance crew (1) autologous adipose-derived stem cells (1) autopsy (1) avdoralimab (1) azithromycin (1) azoximer bromide (1) bacTRL-Spike (1) bamlanivimab (1) bidirectional oxygenation mouthpiece (1) biochemical analysis (1) biological assays in particular on the lipid metabolism (1) biological sample (1) biological samples collection (1) biological samples day of delivery (1) biological samples, questionnaires and interviews (1) biopsies of subcutaneous adipose tissue (1) blood collection via fingerprick (1) blood sample for seroepidemiological investigation (1) blood sampling for biobank (1) blood test for SARS-COV2 serology (1) blood tests (1) bovhyaluronidase azoxymer (1) brief mindfulness based intervention (1) bromelain (1) canakinumab (1) captopril 25mg (1) cardiac magnetic resonance (1) cardiovascular and respiratory systems monitoring (1) care as usual (1) care modalities (1) carotid-femoral pulse-wave velocity (1) cellulose-containing placebo capsules (1) cenicriviroc (1) chest radiography (1) chest x-ray (1) chlorine dioxide (1) chlorine dioxide 3000 ppm (1) chloroquine (1) cholecalciferol 200,000 IU (1) cholecalciferol 50,000 IU (1) clinical features and laboratory values (1) collection of biological samples (1) collection of mucosal lining fluid (1) collection of swabs (1) community health worker support (1) comparison of sample collection methods (1) complication (1) congenital malformation (1) conjunctival RT PCR (1) consultation (1) control (1) control group (1) convalescent plasma application to SARS-CoV-2 infected patients (1) convalescent plasma from recovered COVID 19 donor (1) conventional management of patients (1) conventional oxygen (1) corticosteroid nasal irrigation (1) covid-19 positive pregnant women (1) cries 13 questionnaire (1) current IPAC-UHN PPE (1) daily room disinfection (1) daily syndromic surveillance (1) dapansutrile capsules (1) data record (1) decisions of limitations and stop processing (1) demographic and clinical data obtained from hospital's electronic medical record. (1) diagnostic (1) diagnostic tests for COVID-19 infection (1) dialysis (1) double gloves (1) draw blood (1) duplex sonography (1) e-Psychotherapy (1) e-ink screen (1) eHealth (1) eHealth +counselling contacts (1) echocardiogram 2D (1) eculizumab (1) electrolytes (1) ensoETM device (1) evaluation of skin microvascular flow and reactivity (1) exchange blood transfusion from normal donor (1) exercise brochure (1) exercise capacity (1) exercise group (1) exercise training (1) exposure (1) faecal sample collector (1) favipiravir (1) favorable outcome (1) feces samples (COVI-BIOME ancillary study) (1) fingertip tests for POC assays (1) fostamatinib (1) fsfi survey (1) further processing of health data (1) gammaCore® (Vagus nerve stimulation) (1) gammaCore® Sapphire (non-invasive vagus nerve stimulator) (1) geko T3 (1) glenzocimab (1) global survey (1) glucose control and sensor usage (1) hAd5-S-Fusion+N-ETSD vaccine (1) heat therapy (1) high flow nasal cannula (HFNC) (1) high flow nasal cannula device (1) high-titer anti-Sars-CoV-2 plasma (1) home care monitoring (1) home spirometry (1) hormones (1) hospital bedroom booking (1) hospitalisation, necessity of ICU, mortality rate, lung involvement (1) hospitalization for premature birth (1) hospitalized children with Covid19 (1) host genotype (1) host immune factors (1) human cord tissue mesenchymal stromal cells (1) hydrocortisone (1) hydroxychloroquine + azithromycin (1) hydroxychloroquine in combination with camostat mesylate (1) hydroxychloroquine placebo (1) hydroxychloroquine sulfate 200 MG (1) hyper immunoglobulins containing anti-Corona VS2 immunoglobulin (1) hyperbaric oxygen therapy (HBOT) (1) hyperimmune plasma (1) hypoxia : 14.3 and 12.7% FIO2, hypercapnia 7% CO2, inspiratory mechanical constraint (1) iAMP test (1) iNO (inhaled nitric oxide) delivered via the INOpulse Delivery System (1) identify SARS-CoV-2 infection by serology (1) imPulse™ Una e-stethoscope (1) imaging, blood tests (1) immune plasma (1) impliminting Online Distance Learning (1) in-hospital mortality rate (1) indirect calorimetry (1) inhalable hydroxychloroquine (HCQ) (1) inhaled hydroxychloroquine (1) inhaled type I interferon (1) inspiratory muscle traiing (1) insurance navigation (1) integrated clinical evaluation (1) intensive care unit admission ratio (1) interleuken 6 level measurment (1) intermediate dose Enoxaparin/ unfractionated heparin (1) intradermal injection of BCG Vaccine (1) intramuscular accine (1) intravenous immunoglobulin therapy (1) it is a survey (1) iv Tocillizumab (TCZ) (1) laboratory biomarkers (1) labs (1) lactoferrin, green tea extract (1) lanadelumab (1) laparoscopic or open appendicectomy (1) lay telephone coaching (1) less-frequency hemodialysis (1) life questionnaires (1) liposomal lactoferrin (1) lopinavir/ritonavir (1) lopinavir/ritonavir group (1) lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate (1) low-molecular-weight heparin (1) lung mechanics at different PEEP (1) lung ultrasound (LUS) (1) mHealth Assessments (1) mMRC (Modified Medical Research Council) Dyspnea Scale (1) mRNA in urine test (1) management strategy of outpatient with mild to moderate SARS-CoV-2 pneumonia (1) maslach burnout inventory questionnair (1) mavrilimumab (1) measurement of circulating sFlt1 concentration (1) mechanical ventilation (1) mechanical ventilator settings and position (1) melatonin (1) mesenchymal stem cells (1) metenkefalin + tridecactide (1) metformin glycinate (1) methylprednisolone therapy (1) microcirculation recording (1) miniprobe Alveoflex (1) mobile internet survey on self-test (1) modification of the planned therapeutic management (1) modified IPAC-UHN PPE (1) molecular testing for virus RNA using RT-PCR (1) mometasone furoate nasal spray (1) monthly serologic IgM/G test (1) morning Yoga-based breathing support (1) mortality (1) mouthrinse with bêta-cyclodextrin and citrox (1) mouthrinse without bêta-cyclodextrin and citrox (1) multipeptide cocktail (1) muscle ultrasound (1) n/a - samples collected along routine care samples only (1) nCapp, a cell phone-based auto-diagnosis system (1) nangibotide (1) nasal pharyngeal (NP) swab samples (1) nasopharyngeal Covid 19 RT-PCR (1) nasopharyngeal and throat swab (1) nebulised recombinant tissue-Plasminogen Activator (rt-PA) (1) newborns from covid 19 positive mothers (1) no intervention-mechanistic study (1) no intervention. observational cohort study (1) no interventional study (1) non (1) non applicable (1) non interventional study (1) non-RAS blocking antihypertensives (1) non-contact magnetically-controlled capsule endoscopy (1) non-interventional (1) none - observational (1) none, this study is observational (1) noninvasive ventilation (1) normal saline (1) nosocomial infection/hospital acquired infection (1) not applicable (observational study) (1) not required (1) nutritional intervention (1) oSOC (1) observation (1) observation of covid 19 pneumonia (1) olfactory and gustatory tests (1) olfactory device (1) online KKH Sports Singapore Program with Usual Care (1) online mindfulness group (1) online questionnaires (1) oral co-trimoxazole (1) oral polio vaccine + information (1) oropharyngeal and intestinal microbiota (1) oropharyngeal swabs (1) oxygen treatment (1) oxyhydrogen (1) pathogen reduced SARS-CoV-2 convalescent plasma (1) patients COVID 19 (1) patients receiving nasal high flow (1) performance evaluation study of RealDetect RT-PCR Kit for COVID-19 detection (1) peripheral blood draw (1) personal protective Measures (1) phone call (1) photobiomodulation and photodynamic therapy (1) physical activity program (1) physiological effects of awake prone position in COVID 19 patients (1) placebo (hartmann plus albumine) (1) placebo capsules (1) placebo for clazakizumab (1) placebo rinse (1) plasma from convalescent patients with COVID-19 (1) plasma hyperimmune (1) plasma therapy using convalescent plasma with antibody against SARS-CoV-2 (1) poractant alfa (1) power breathe (1) prayer (1) pre-operative screening (1) pre_dinner Yoga-based breathing support (1) pre_lunch Yoga-based breathing support (1) predict admission of covid-19 patients to ICU and death with routine and quickly avalaible clinical, biological and radiological variables? (1) prone position (1) proper diet (1) prophylactic heparin (1) prophylactic lactoferrin daily (1) psycho-education video (1) psychological and sociological interviews (1) psychological assessment (1) pulmonary anomalies 4 months after documented COVID-19 pneumonia (1) pulmonary rehabilitation (1) pulmonary ultrasound (1) pulse oximeter (1) qRT-PCR and serology (1) quality of life questionnaires (1) quality of live assessment (1) quesionnair (1) questionaire to husband and wife (1) questionnair about Emerging Legal and Ehical Disputes Over Patient Confidentiality (1) questionnaire and optional interview (1) questionnaire filling (1) quetionnary (1) rNAPc2 (1) rapid salivary test (1) rapid serological test (1) realtime PCR (1) recombinant human interferon Alpha-1b (1) recovered covid 19 patients plasma (1) rectal swab (1) regular care (1) research specific blood sample (1) respiratory function rehabilitation training (1) retrospective metagenomics on clinical samples collected during hospitalization (1) revised HOME-CoV score (1) rhDNase I (1) rhTPO (1) risk factors (1) saint george respiratory questionnaire (1) saliva collection (1) saliva sample (1) samling of oropharynx and nasopharynx (1) sample of blood and saliva (1) self-administered structured questionnaire (1) self-care tools (1) semaglutide (1) semen analysis (1) serological test (1) serology test (1) serum NGAL and cystatin c (1) serum chemistry analysis (1) serum inflammatory biomarkers (1) service of questionnaire (1) severe covid-19 pneumonia with ET (1) severity of lung involvement with COVID-19. (1) smell household Items (1) sodium chloride 0.9% (1) sofosbuvir (1) specific exercise rehabilitation treatment (1) spirometry (1) spirometry, thoracic CT, CPET, 6 minute walking test, SF-36 questionnaire (1) standard concomitant therapy (1) standard medical treatment (1) standard operating procedures (1) standard procedure (1) standard prophylactic dose Enoxaparin/ unfractionated heparin (1) standard protocol (1) standard treatment (1) standard western medicine treatment (1) standardized Lung Ultrasound (LUS) examination (1) stem cells (1) stress and anxiety questionnaire (1) supportive and symptomatic treatment (1) survey work (1) surveys and questionnaires (1) suspected of COVID-19 infection (1) sweat samples (COVIDOG ancillary study) (1) teleconsultation (1) telehealth applications (1) telemedicine (1) telephone consult (1) test (1) thalidomide (1) therapeutic plasmaexchnage (1) theraputic heparin (1) this study is non- interventional (1) thoracic CT-scan (1) thoracic computed tomography scan (1) thoracic lung ultrasound (1) thromboprofylaxis protocol (1) thromboprophylaxis with low-molecular-weight heparin or fondaparinux (1) thymosin alpha 1 (1) topical steroids and cyclosporin-A (1) traditional communication tools (1) transparent sheet (1) treated with hyperimmune plasma (1) turkish physicians (1) unfractionated heparin (1) urinary NGAL, TIMP-2, IGFBP7, IL-6, viral load and metabolomic (1) users (1) vaccine (1) vaccine BCG (1) vadadustat (1) venipuncture in peripheral vein (1) ventilatory support with oxygen therapy (1) viral sequence (1) virgin coconut oil (VCO) (1) visual analogue scale (1) vitamin D (1) vitamin d (1) vv-ECMO (1) washed microbiota transplantation (1) web based survey (1) zinc (1) zinc acetate (1) zinc gluconate and ascorbic acid (1) ıt will be compared pain, sleep, fatigue, physical activity level and quality of life and questioning exercise habits before and after the covid-19 outbreak in patients with Behçet and FMF. (1) γ-Globulin (1) Оxygen therapy (1)

    Placebo oral tablet

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (80)


    Name (Synonyms) Correlation
    drug1472 Hydroxychloroquine Wiki 0.21
    drug338 Azithromycin 250 MG Oral Capsule Wiki 0.17
    drug828 Complete thrombophilic profile testing by multiplex PCR Wiki 0.17
    Name (Synonyms) Correlation
    drug1832 Low Dose of KBP-COVID-19 Wiki 0.17
    drug1826 Losmapimod oral tablet Wiki 0.17
    drug2197 Non-convalescent Plasma (control plasma) Wiki 0.17
    drug1500 Hydroxychloroquine Sulfate 600 mg once a day Wiki 0.17
    drug2041 Monitoring Visit - Baseline Wiki 0.17
    drug668 Calcium Channel Blockers Wiki 0.17
    drug647 CSL324 Wiki 0.17
    drug910 Covid-19 + patients Wiki 0.17
    drug18 0.9%NaCl Wiki 0.17
    drug1022 Dietary counselling on Food Groups according to IYC Feeding practices, WHO Wiki 0.17
    drug1888 MRG-001 Wiki 0.17
    drug1483 Hydroxychloroquine - Daily Dosing Wiki 0.17
    drug1576 IgG SARS CoV2 Wiki 0.17
    drug3531 Valsartan (Diovan) Wiki 0.17
    drug1591 Immunfluorescence Wiki 0.17
    drug3872 metformin glycinate Wiki 0.17
    drug1987 Metformin Glycinate Wiki 0.17
    drug3407 Tranexamic acid tablets Wiki 0.17
    drug223 Angiotensin receptor blocker Wiki 0.17
    drug3306 Tenofovir/ Emtricitabine ( 300 mg / 200 mg daily during 60 days) + Personal Protective Equipment (PPE) Wiki 0.17
    drug1490 Hydroxychloroquine Pre-Exposure Prophylaxis Wiki 0.17
    drug1783 Lidocaine 2% Wiki 0.17
    drug3105 Spironolactone 100mg Wiki 0.17
    drug1422 High dose Interferon-beta 1a Wiki 0.17
    drug2450 Placebo (1 tablet daily during 60 days) + Personal Protective Equipment (PPE) Wiki 0.17
    drug1959 Melatonin 2mg Wiki 0.17
    drug1838 Low dose Interferon-beta 1a Wiki 0.17
    drug1440 High-titer Convalescent COVID-19 Plasma (CCP1) Wiki 0.17
    drug2043 Monitoring Visit - Week 8 Wiki 0.17
    drug3814 hydroxychloroquine sulfate 200 MG Wiki 0.17
    drug1499 Hydroxychloroquine Sulfate 400 mg twice a day Wiki 0.17
    drug450 Biomarkers expression Wiki 0.17
    drug1501 Hydroxychloroquine Sulfate 600 mg twice a day Wiki 0.17
    drug261 Apo-Hydroxychloroquine Wiki 0.17
    drug2741 Random Donor Plasma Wiki 0.17
    drug740 Chloroquine Diphosphate Wiki 0.17
    drug1414 High Dose of KBP-COVID-19 Wiki 0.17
    drug3721 cenicriviroc Wiki 0.17
    drug1929 Matched Placebo Wiki 0.17
    drug3345 Thiazide or Thiazide-like diuretics Wiki 0.17
    drug2042 Monitoring Visit - Week 4 Wiki 0.17
    drug3607 Weekly Assessment Wiki 0.17
    drug1586 Imatinib Wiki 0.17
    drug3171 Standard-titer Convalescent COVID-19 plasma (CCP2) Wiki 0.17
    drug1035 Dipyridamole 100 Milligram(mg) Wiki 0.17
    drug1485 Hydroxychloroquine - Weekly Dosing Wiki 0.12
    drug870 Convalescent Plasma Transfusion Wiki 0.12
    drug3127 Standard Therapy Wiki 0.12
    drug986 Defibrotide Wiki 0.12
    drug866 Convalescent Plasma (anti-SARS-CoV-2 plasma) Wiki 0.12
    drug1616 Infliximab Wiki 0.12
    drug3406 Tranexamic acid Wiki 0.12
    drug1497 Hydroxychloroquine Sulfate 200 MG [Plaquenil] Wiki 0.12
    drug2536 Plasma Wiki 0.10
    drug2512 Placebo oral capsule Wiki 0.10
    drug68 ACE inhibitor Wiki 0.10
    drug1638 Interferon Beta-1B Wiki 0.10
    drug127 AZD7442 Wiki 0.10
    drug3205 Supportive Care Wiki 0.10
    drug130 Abatacept Wiki 0.10
    drug791 Colchicine Wiki 0.09
    drug4022 standard care Wiki 0.09
    drug1637 Interferon Beta-1A Wiki 0.09
    drug1818 Lopinavir/Ritonavir Wiki 0.09
    drug358 BCG Vaccine Wiki 0.09
    drug2858 SARS-CoV-2 Wiki 0.09
    drug1473 Hydroxychloroquine (HCQ) Wiki 0.08
    drug1805 Lopinavir / Ritonavir Wiki 0.08
    drug739 Chloroquine Wiki 0.07
    drug672 Camostat Mesilate Wiki 0.06
    drug333 Azithromycin Wiki 0.06
    drug849 Control Wiki 0.06
    drug2847 Ruxolitinib Wiki 0.06
    drug1995 Methylprednisolone Wiki 0.04
    drug2448 Placebo Wiki 0.04
    drug1705 Ivermectin Wiki 0.04
    drug2782 Remdesivir Wiki 0.03

    Correlated MeSH Terms (24)


    Name (Synonyms) Correlation
    D024821 Metabolic Syndrome NIH 0.17
    D020767 Intracranial Thrombosis NIH 0.17
    D015428 Myocardial Reperfusion Injury NIH 0.17
    Name (Synonyms) Correlation
    D015427 Reperfusion Injury NIH 0.17
    D018352 Coronavirus Infections NIH 0.17
    D045169 Severe Acute Respiratory Syndrome NIH 0.16
    D013577 Syndrome NIH 0.08
    D019851 Thrombophilia NIH 0.08
    D007239 Infection NIH 0.07
    D019337 Hematologic Neoplasms NIH 0.07
    D003141 Communicable Diseases NIH 0.06
    D020246 Venous Thrombosis NIH 0.05
    D012128 Respiratory Distress Syndrome, Adult NIH 0.05
    D003924 Diabetes Mellitus, Type 2 NIH 0.05
    D012127 Respiratory Distress Syndrome, Newborn NIH 0.04
    D055371 Acute Lung Injury NIH 0.04
    D006973 Hypertension NIH 0.04
    D014777 Virus Diseases NIH 0.04
    D013927 Thrombosis NIH 0.03
    D007249 Inflammation NIH 0.03
    D014947 Wounds and Injuries NIH 0.03
    D009369 Neoplasms, NIH 0.03
    D002318 Cardiovascular Diseases NIH 0.03
    D011014 Pneumonia NIH 0.02

    Correlated HPO Terms (8)


    Name (Synonyms) Correlation
    HP:0100724 Hypercoagulability HPO 0.09
    HP:0001909 Leukemia HPO 0.06
    HP:0002625 Deep venous thrombosis HPO 0.05
    Name (Synonyms) Correlation
    HP:0005978 Type II diabetes mellitus HPO 0.05
    HP:0000822 Hypertension HPO 0.04
    HP:0002664 Neoplasm HPO 0.03
    HP:0001626 Abnormality of the cardiovascular system HPO 0.03
    HP:0002090 Pneumonia HPO 0.02

    Clinical Trials

    Navigate: Correlations   HPO

    There are 33 clinical trials


    1 Hydroxychloroquine Treatment for Severe COVID-19 Respiratory Disease: Randomised Clinical Trial (HYDRA Trial)

    Double blinded randomized clinical trial designed to evaluate the security and efficacy of hydroxychloroquine as treatment for COVID-19 severe respiratory disease. The investigators hypothesize that a 400mg per day dose of hydroxychloroquine for 10 days will reduce all-cause hospital mortality in patients with severe respiratory COVID-19 disease.

    NCT04315896
    Conditions
    1. COVID-19
    2. Severe Acute Respiratory Syndrome
    Interventions
    1. Drug: Hydroxychloroquine
    2. Drug: Placebo oral tablet
    MeSH:Severe Acute Respiratory Syndrome Coronavirus Infections

    Primary Outcomes

    Description: incidence of all-cause mortality

    Measure: All-cause hospital mortality

    Time: From date of randomization until the date of hospital discharge or date of death from any cause, whichever came first, assessed up to120 days

    Secondary Outcomes

    Description: Days from ER admission to hospital discharge

    Measure: Length of hospital stay

    Time: From date of randomization until the date of hospital discharge or date of death from any cause, whichever came first, assessed up to120 days

    Description: need of invasive or non invasive mechanical ventilation

    Measure: Need of mechanical ventilation

    Time: From date of randomization until the date of hospital discharge or date of death from any cause, whichever came first, assessed up to120 days

    Description: 28 minus days without invasive ventilation support in patients with invasive mechanical ventilation at randomization

    Measure: Ventilator free days

    Time: From date of randomization until the date of hospital discharge or date of death from any cause, whichever came first, assessed up to120 days

    Description: Adverse Reactions

    Measure: Grade 3-4 adverse reaction

    Time: From date of randomization until the date of hospital discharge or date of death from any cause, whichever came first, assessed up to120 days
    2 Chemoprophylaxis With Hydroxychloroquine in Healthcare Personnel in Contact With COVID-19 Patients: A Randomized Controlled Trial (PHYDRA Trial)

    Triple blinded, phase III randomized controlled trial with parallel groups (200mg of hydroxychloroquine per day vs. placebo) aiming to prove hydroxychloroquine's security and efficacy as prophylaxis treatment for healthcare personnel exposed to COVID-19 patients.

    NCT04318015
    Conditions
    1. COVID-19
    2. Severe Acute Respiratory Syndrome
    Interventions
    1. Drug: Hydroxychloroquine
    2. Drug: Placebo oral tablet
    MeSH:Severe Acute Respiratory Syndrome Coronavirus Infections

    Primary Outcomes

    Description: Symptomatic infection rate by COVID-19 defined as cough, dyspnea, fever, myalgia, arthralgias or rhinorrhea along with a positive COVID-19 real-time polymerase chain reaction test.

    Measure: Symptomatic COVID-19 infection rate

    Time: From date of randomization until the appearance of symptoms or study completion 60 days after treatment start

    Secondary Outcomes

    Description: Symptomatic infection rate by other non-COVID-19 viral etiologies defined as cough, dyspnea, fever, myalgia, arthralgias or rhinorrhea along with a positive viral real time polymerase chain reaction test.

    Measure: Symptomatic non-COVID viral infection rate

    Time: From date of randomization until the appearance of symptoms or study completion 60 days after treatment start

    Description: Number of days absent from labor due to COVID-19 symptomatic infection

    Measure: Days of labor absenteeism

    Time: From date of randomization until study completion 60 days after treatment start

    Description: Absenteeism from labor rate due to COVID-19 symptomatic infection

    Measure: Rate of labor absenteeism

    Time: From date of randomization until study completion 60 days after treatment start

    Description: Rate of severe respiratory COVID-19 disease in healthcare personnel

    Measure: Rate of severe respiratory COVID-19 disease in healthcare personnel

    Time: From date of randomization until the appearance of symptoms or study completion 60 days after treatment start
    3 Hydroxychloroquine Post Exposure Prophylaxis (PEP) for Household Contacts of COVID-19 Patients: A NYC Community-Based Randomized Clinical Trial

    The purpose of this study is to test the hypothesis that post-exposure prophylaxis with hydroxychloroquine will reduce the symptomatic secondary attack rate among household contacts of known or suspected COVID-19 patients.

    NCT04318444
    Conditions
    1. COVID-19
    2. Corona Virus Infection
    Interventions
    1. Drug: Hydroxychloroquine
    2. Drug: Placebo oral tablet
    MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome

    Primary Outcomes

    Description: This is defined as either 1. COVID-19 infection confirmed within 14 days of enrollment, following self-report of COVID-19 symptoms to the research study; OR, 2. COVID-19 infection confirmed within 14 days of enrollment, with self-report of COVID-19 symptoms to a treating physician.

    Measure: Number of participants with symptomatic, lab-confirmed COVID-19.

    Time: Date of enrollment to 14 days post-enrollment date
    4 The Impact of Camostat Mesilate on COVID-19 Infection: An Investigator-initiated Randomized, Placebo-controlled, Phase IIa Trial

    SARS-CoV-2, one of a family of human coronaviruses, was initially identified in December 2019 in Wuhan city. This new coronavirus causes a disease presentation which has now been named COVID-19. The virus has subsequently spread throughout the world and was declared a pandemic by the World Health Organisation on 11th March 2020. As of 18 March 2020, there are 198,193 number of confirmed cases with an estimated case-fatality of 3%. There is no approved therapy for COVID-19 and the current standard of care is supportive treatment. SARS-CoV-2 exploits the cell entry receptor protein angiotensin converting enzyme II (ACE-2) to access and infect human cells. The interaction between ACE2 and the spike protein is not in the active site. This process requires the serine protease TMPRSS2. Camostat Mesilate is a potent serine protease inhibitor. Utilizing research on severe acute respiratory syndrome coronavirus (SARS-CoV) and the closely related SARS-CoV-2 cell entry mechanism, it has been demonstrated that SARS-CoV-2 cellular entry can be blocked by camostat mesilate. In mice, camostat mesilate dosed at concentrations similar to the clinically achievable concentration in humans reduced mortality following SARS-CoV infection from 100% to 30-35%.

    NCT04321096
    Conditions
    1. Corona Virus Infection
    Interventions
    1. Drug: Camostat Mesilate
    2. Drug: Placebo oral tablet
    MeSH:Infection Communicable Diseases Coronavirus Infections Severe Acute Respiratory Syndrome

    Primary Outcomes

    Description: Clinical improvement defined as live hospital discharge OR a 2 point improvement (from time of enrolment) in disease severity rating on the 7-point ordinal scale

    Measure: Cohort 1: Days to clinical improvement from study enrolment

    Time: 30 days

    Description: Days to clinical improvement from study enrolment defined no fever for at least 48 hrs AND improvement in other symptoms (e.g. cough, expectoration, myalgia, fatigue, or head ache)

    Measure: Cohort 2: Days to clinical improvement from study enrolment

    Time: 30 days

    Secondary Outcomes

    Measure: Safety evaluation, as measured by AEs, Adverse Reactions (ARs), SAEs, Serious ARs (SARs)

    Time: 30 days

    Description: The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen; 6) Not hospitalized, limitation on activities; 7) Not hospitalized, no limitations on activities.

    Measure: Cohort 1: Clinical status as assessed by the 7-point ordinal scale at day 7, 14 and 30

    Time: 30 days

    Description: Mortality

    Measure: Cohort 1: Day 30 mortality

    Time: 30 days

    Description: NEWS2

    Measure: Cohort 1: Change in NEW(2) score from baseline to day 30

    Time: 30 days

    Description: ICU

    Measure: Cohort 1: Admission to ICU

    Time: 30 days

    Description: invasive mechanical ventilation or ECMO

    Measure: Cohort 1: Use of invasive mechanical ventilation or ECMO

    Time: 30 days

    Description: Nasal or high-flow oxygen

    Measure: Cohort 1: Duration of supplemental oxygen (days)

    Time: 30 days

    Description: Subjective clinical improvement

    Measure: Cohort 1+2: Days to self-reported recovery (e.g. limitations in daily life activities) during telephone interviews conducted at day 30

    Time: 30 days

    Description: No of new COVID-19 infections in the household

    Measure: Cohort 2: Number participant-reported secondary infection of housemates

    Time: 30 days

    Description: Hospital admission

    Measure: Cohort 2: Time to hospital admission related to COVID-19 infection

    Time: 30 days
    5 Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID: A Randomized, Placebo-controlled Double-blinded Trial Evaluating Treatment With Azithromycin and Hydroxychloroquine to Patients With COVID-19

    This study explores whether patients acutely hospitalized may have shorter hospitalization and fewer admittances at Intensive Care Units by treatment with azithromycin and hydroxychloroquine.

    NCT04322396
    Conditions
    1. Virus Diseases
    2. Infection Viral
    3. Corona Virus Infection
    Interventions
    1. Drug: Azithromycin
    2. Drug: Hydroxychloroquine
    3. Drug: Placebo oral tablet
    4. Drug: Placebo oral tablet
    MeSH:Infection Communicable Diseases Virus Diseases Coronavirus Infections Severe Acute Respiratory Syndrome

    Primary Outcomes

    Measure: Number of days alive and discharged from hospital within 14 days

    Time: 14 days

    Secondary Outcomes

    Description: The patient will becategorized into one of the following 8 categories depending on status of their hospitalization: Dead (yes/no) Hospitalized and receiving mechanical ventilation or ExtraCorporalMembraneOxygenation (ECMO) (yes/no) Hospitalized and receiving Non-invasive ventilation or "high-flow oxygen device" (yes/no) Hospitalized and given oxygen supplements different from (2) and (3) (yes/no) Hospitalized and without oxygen treatment, but receiving other treatment (both related to COVID-19 or other) (yes/no) Hospitalized for observation (yes/no) Discharged from hospital with restriction of activity level (yes/no) Discharged from hospital without any restrictions of activity level (yes/no) Only one category can be "yes".

    Measure: Categorization of hospitalization status

    Time: 14 days

    Measure: Admitted to intensive care unit, if admitted to ICU then length of stay

    Time: 14 days

    Measure: Have used Non-invasive ventilation (NIV) during hospitalization

    Time: 14 days

    Measure: Mortality

    Time: 30 days

    Measure: Length of hospitalization

    Time: 14 days

    Measure: Days alive and discharged from hospital

    Time: 30 days

    Measure: Mortality

    Time: 90 days

    Measure: Mortality

    Time: 365 days

    Measure: Number of readmissions (all causes)

    Time: 30 days

    Measure: Number of days using non-invasive ventilation (NIV)

    Time: 14 days

    Description: Delta PaO2 measured in arterial puncture

    Measure: Change in patient's oxygen partial pressure

    Time: 4 days

    Description: Delta PaCO2 measured in arterial puncture

    Measure: Change in patient's carbondioxid partial pressure

    Time: 4 days

    Description: pH measured in arterial puncture

    Measure: Level of pH in blood

    Time: 4 days

    Measure: Time for no oxygen supplement (or regular oxygen supplement "LTOT")

    Time: 14 days
    6 Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID: A Randomized, Placebo-controlled Double-blinded Trial Evaluating Treatment With Azithromycin and Hydroxychloroquine to Patients With COVID-19

    This study explores whether patients acutely hospitalized may have shorter hospitalization and fewer admittances at Intensive Care Units by treatment with azithromycin and hydroxychloroquine.

    NCT04322396
    Conditions
    1. Virus Diseases
    2. Infection Viral
    3. Corona Virus Infection
    Interventions
    1. Drug: Azithromycin
    2. Drug: Hydroxychloroquine
    3. Drug: Placebo oral tablet
    4. Drug: Placebo oral tablet
    MeSH:Infection Communicable Diseases Virus Diseases Coronavirus Infections Severe Acute Respiratory Syndrome

    Primary Outcomes

    Measure: Number of days alive and discharged from hospital within 14 days

    Time: 14 days

    Secondary Outcomes

    Description: The patient will becategorized into one of the following 8 categories depending on status of their hospitalization: Dead (yes/no) Hospitalized and receiving mechanical ventilation or ExtraCorporalMembraneOxygenation (ECMO) (yes/no) Hospitalized and receiving Non-invasive ventilation or "high-flow oxygen device" (yes/no) Hospitalized and given oxygen supplements different from (2) and (3) (yes/no) Hospitalized and without oxygen treatment, but receiving other treatment (both related to COVID-19 or other) (yes/no) Hospitalized for observation (yes/no) Discharged from hospital with restriction of activity level (yes/no) Discharged from hospital without any restrictions of activity level (yes/no) Only one category can be "yes".

    Measure: Categorization of hospitalization status

    Time: 14 days

    Measure: Admitted to intensive care unit, if admitted to ICU then length of stay

    Time: 14 days

    Measure: Have used Non-invasive ventilation (NIV) during hospitalization

    Time: 14 days

    Measure: Mortality

    Time: 30 days

    Measure: Length of hospitalization

    Time: 14 days

    Measure: Days alive and discharged from hospital

    Time: 30 days

    Measure: Mortality

    Time: 90 days

    Measure: Mortality

    Time: 365 days

    Measure: Number of readmissions (all causes)

    Time: 30 days

    Measure: Number of days using non-invasive ventilation (NIV)

    Time: 14 days

    Description: Delta PaO2 measured in arterial puncture

    Measure: Change in patient's oxygen partial pressure

    Time: 4 days

    Description: Delta PaCO2 measured in arterial puncture

    Measure: Change in patient's carbondioxid partial pressure

    Time: 4 days

    Description: pH measured in arterial puncture

    Measure: Level of pH in blood

    Time: 4 days

    Measure: Time for no oxygen supplement (or regular oxygen supplement "LTOT")

    Time: 14 days
    7 Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)

    This is a phase 3, randomized, double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of colchicine in adult patients diagnosed with COVID-19 infection and have at least one high-risk criterion. Approximately 6000 subjects meeting all inclusion and no exclusion criteria will be randomized to receive either colchicine or placebo tablets for 30 days.

    NCT04322682
    Conditions
    1. Corona Virus Infection
    Interventions
    1. Drug: Colchicine
    2. Drug: Placebo oral tablet
    MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome

    Primary Outcomes

    Description: The primary endpoint will be the composite of death or the need for hospitalization due to COVID-19 infection in the first 30 days after randomization.

    Measure: Number of participants who die or require hospitalization due to COVID-19 infection

    Time: 30 days post randomization

    Secondary Outcomes

    Description: The secondary endpoint is the occurrence of death in the 30 days following randomization.

    Measure: Number of participants who die

    Time: 30 days post randomization

    Description: The secondary endpoint is the need for hospitalization due to COVID-19 infection in the 30 days following randomization.

    Measure: Number of participants requiring hospitalization due to COVID-19 infection

    Time: 30 days post randomization

    Description: The secondary endpoint is the need for mechanical ventilation in the 30 days following randomization.

    Measure: Number of participants requiring mechanical ventilation

    Time: 30 days post randomization
    8 The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine)

    The PATCH trial (Prevention And Treatment of COVID-19 with Hydroxychloroquine) is funded investigator-initiated trial that includes 3 cohorts. Cohort 1: a double-blind placebo controlled trial of high dose HCQ as a treatment for home bound COVID-19 positive patients; Cohort 2: a randomized study testing different doses of HCQ in hospitalized patients; Cohort 3: a double blind placebo controlled trial of low dose HCQ as a preventative medicine in health care workers.

    NCT04329923
    Conditions
    1. COVID-19
    Interventions
    1. Drug: Hydroxychloroquine Sulfate 400 mg twice a day
    2. Drug: Hydroxychloroquine Sulfate 600 mg twice a day
    3. Drug: Hydroxychloroquine Sulfate 600 mg once a day
    4. Drug: Placebo oral tablet

    Primary Outcomes

    Description: Cohort 1 (home quarantined COVID-19 patients): Median time to release from quarantine by meeting the following criteria: 1) No fever for 72 hours 2) improvement in other symptoms and 3) 7 or 10 days (depending on CDC guidance at the time) have elapsed since the beginning of symptom onset.

    Measure: Time to Release From Quarantine Time

    Time: until quarantine release or hospitalization

    Description: Cohort 2 (hospitalized COVID-19 patients): median number of days until hospital discharge

    Measure: Time to Hospital Discharge

    Time: until hospital discharge

    Description: Cohort 3 Physicians and nurse prophylaxis: Rate of COVID-19 infection at 2 months

    Measure: Number of Health Care Workers Who Developed SARS-COV-2 Infection

    Time: 2 months

    Secondary Outcomes

    Description: Cohort 1 rate of participant-reported secondary infection of housemates

    Measure: Rate of Housemate Infection

    Time: until quarantine release, or approximately <20 days

    Description: Cohort 1 rate of hospitalization

    Measure: Rate of Hospitalization

    Time: until quarantine release
    9 Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine Trial (HERO-HCQ Trial)

    This is a double blind, placebo controlled study in approximately 2,000 health care workers at risk for being exposed to COVID-19. Eligible participants will be randomly assigned (1:1) to either treatment group (HCQ) or placebo in a double-blind fashion. Course of treatment is 30 days.

    NCT04334148
    Conditions
    1. COVID-19
    Interventions
    1. Drug: Hydroxychloroquine
    2. Drug: Placebo oral tablet

    Primary Outcomes

    Description: Number of participants with clinical infection with COVID-19 infection(hydroxychloroquine vs placebo)

    Measure: Number of participants with clinical infection with COVID-19 infection

    Time: 30 days

    Secondary Outcomes

    Description: Number of participants with COVID-19 infection shedding (hydroxychloroquine vs placebo)

    Measure: Number of participants with COVID-19 viral shedding

    Time: 30 days

    Description: Safety as measured by number of adverse events (hydroxychloroquine vs placebo)

    Measure: Safety as measured by number of adverse events

    Time: 30 days
    10 PRAETORIAN-COVID: A Double-blind, Placebo-controlled Randomized Clinical Trial With Valsartan for PRevention of Acute rEspiraTORy dIstress Syndrome in hospitAlized patieNts With SARS-COV-2 (COVID-19) Infection Disease

    Rationale: The current SARS-CoV-2 pandemic has a high burden of morbidity and mortality due to development of the so-called acute respiratory distress syndrome (ARDS). The renin-angiotensin-system (RAS) plays an important role in the development of ARDS. ACE2 is one of the enzymes involved in the RAS cascade. Virus spike protein binds to ACE2 to form a complex suitable for cellular internalization. The downregulation of ACE2 results in the excessive accumulation of angiotensin II, and it has been demonstrated that the stimulation of the angiotensin II type 1a receptor (AT1R) increases pulmonary vascular permeability, explaining the increased lung pathology when activity of ACE2 is decreased. Currently available AT1R blockers (ARBs) such as valsartan, have the potential to block this pathological process mediated by angiotensin II. There are presently two complementary mechanisms suggested: 1) ARBs block the excessive angiotensin-mediated AT1R activation, and 2) they upregulate ACE2, which reduces angiotensin II concentrations and increases the production of the protective vasodilator angiotensin 1-7. In light of the above, ARBs may prevent the development of ARDS and avert morbidity (admission to intensive care unit (ICU) and mechanical ventilation) and mortality. Objective: To investigate the effect of the ARB valsartan in comparison to placebo on the occurrence of one of the following items, within 14 days of randomization:1) ICU admission; 2) Mechanical ventilation; 3) Death. Study design: A double-blind, placebo-controlled 1:1 randomized clinical trial Study population: Adult hospitalized SARS-CoV-2-infected patients (n=651). Intervention: The active-treatment arm will receive valsartan in a dosage titrated to blood pressure up to a maximum of 160mg b.i.d. and the placebo arm will receive a matching placebo also titrated to blood pressure. Treatment duration will be 14 days or up to hospital discharge < 14 days or occurrence of the primary endpoint if < 14 days. Main study endpoint: The primary study endpoint is the occurrence within 14 days of randomization of either: 1) ICU admission; 2) Mechanical ventilation; 3) Death.

    NCT04335786
    Conditions
    1. Acute Respiratory Distress Syndrome
    2. SARS-CoV-2
    3. CO
    4. COVID
    5. COVID-19
    6. Severe Acute Respiratory Syndrome
    Interventions
    1. Drug: Valsartan (Diovan)
    2. Drug: Placebo oral tablet
    MeSH:Severe Acute Respiratory Syndrome Coronavirus Infections Respiratory Distress Syndrome, Newborn Respiratory Distress Syndrome, Adult Acute Lung Injury Syndrome

    Primary Outcomes

    Description: Death is defined as all-cause mortality

    Measure: first occurrence of intensive care unit admission, mechanical ventilation or death

    Time: within 14 days

    Secondary Outcomes

    Description: All-cause mortality; and time to all-cause mortality

    Measure: Death

    Time: Within 14 days, 30 days, 90 days and at 1 year

    Description: Occurrence of mechanical ventilation and time to ventilation

    Measure: Mechanical ventilation

    Time: within 14 days

    Description: Occurrence of ICU admission and time to admission

    Measure: Intensive care unit admission

    Time: within 14 days

    Description: Defined as a 50% decline in estimated glomerular filtration rate relative to baseline, or decrease of >30 ml/min/1.73m2 and to a value below 60 ml/min/1.73m2

    Measure: Occurrence of acute kidney injury

    Time: Within 14 days
    11 Exploratory Studies of the Effect of Tranexamic Acid Treatment on the Progression of COVID19 in Outpatients

    A controlled trial of the drug tranexamic acid (TXA) in outpatients who were recently diagnosed with COVID-19. It is hypothesized that TXA will reduce the infectivity and virulence of the virus.

    NCT04338074
    Conditions
    1. COVID-19
    Interventions
    1. Drug: Tranexamic acid tablets
    2. Drug: Placebo oral tablet

    Primary Outcomes

    Description: Admission to hospital for COVID-19 treatment

    Measure: Hospitalization

    Time: Randomization to 7 days after randomization
    12 Exploratory Studies of the Effect of Tranexamic Acid Treatment on the Progression of COVID19 in Inpatients

    A controlled trial of the drug tranexamic acid (TXA) in inpatients recently admitted to the hospital with the diagnosis of COVID19. It is hypothesized that TXA will reduce the infectivity and virulence of the virus.

    NCT04338126
    Conditions
    1. COVID19
    Interventions
    1. Drug: Tranexamic acid
    2. Drug: Placebo oral tablet

    Primary Outcomes

    Description: Transfer to Intensive Care Unit for deteriorating clinical condition

    Measure: Admission to Intensive Care Unit

    Time: Randomization to 7 days after randomization
    13 Will Hydroxychloroquine Impede or Prevent COVID-19: WHIP COVID-19 Study

    This is a prospective, multi-site study designed to evaluate whether the use of hydroxychloroquine in healthcare workers (HCW), Nursing Home Workers (NHW), first responders (FR), and Detroit Department of Transportation bus drivers (DDOT) in SE, Michigan, can prevent the acquisition, symptoms and clinical COVID-19 infection The primary objective of this study is to determine whether the use of daily or weekly oral hydroxychloroquine (HCQ) therapy will prevent SARS-CoV-2 infection and COVID-19 viremia and clinical COVID-19 infection healthcare workers (HCW) and first responders (FR) (EMS, Fire, Police, bus drivers) in Southeast Michigan. Preventing COVID-19 transmission to HCW, FR, and Detroit Department of Transportation (DDOT) bus drivers is a critical step in preserving the health care and first responder force, the prevention of COVID-19 transmission in health care facilities, with the potential to preserve thousands of lives in addition to sustaining health care systems and civil services both nationally and globally. If efficacious, further studies on the use of hydroxychloroquine to prevent COVID-19 in the general population could be undertaken, with a potential impact on hundreds of thousands of lives.

    NCT04341441
    Conditions
    1. COVID-19
    2. Coronavirus
    3. Coronavirus Infections
    4. SARS-CoV 2
    Interventions
    1. Drug: Hydroxychloroquine - Daily Dosing
    2. Drug: Hydroxychloroquine - Weekly Dosing
    3. Other: Placebo oral tablet
    4. Diagnostic Test: Monitoring Visit - Baseline
    5. Diagnostic Test: Monitoring Visit - Week 4
    6. Diagnostic Test: Monitoring Visit - Week 8
    7. Other: Weekly Assessment
    MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome

    Primary Outcomes

    Description: We will measure the difference in new cases of COVID-19 disease between randomized treatment arms. Plan statistical analyses will include the assumption that up 10% of HCW at risk will become infected if no prophylactic treatment is provided. Therefore we expect that HCQ treatment arm will provide a reduction in the number of SARS-CoV 2 infections by 30%, with an expected study retention rate of 90%, a sample size of ~1500 participants per group, will have an 80% power to detect the difference at p=0.05.

    Measure: To determine if the use of hydroxychloroquine as preventive therapy decreases the rate of acquisition of SARS-CoV 2 infections and clinical COVID-19 disease in Study Participants for each randomized treatment arm as compared to placebo.

    Time: 8 Weeks

    Secondary Outcomes

    Description: Compare the rates of SARS-CoV 2 infections between the randomized treatment arms and the control arms to determine the effect of HCQ dose in the prevention of COVID-19 viremia and disease as determined by study visits, weekly questionnaires, and blood samples.

    Measure: Determine the effect of hydroxychloroquine dose in the prevention of COVID-19 viremia and disease.

    Time: 8 Weeks

    Description: Comparison of the rates of SARS-CoV 2 infections in the non-randomized comparator arm to the randomized groups to assess the impact of chronic weight-based dosing of HCQ for COVID-19 prevention via weekly questionnaire and/or blood samples.

    Measure: Assess the impact of chronic weight-based dosing of HCQ for COVID-19 prevention.

    Time: 8 Weeks

    Description: Measurement of the rate of SARS-CoV 2 infections as measured by IgM/IgG seroconversion in study participants receiving randomized HCQ versus placebo via blood samples.

    Measure: Comparison of the rate of SARS-CoV 2 infections as measured by IgM/IgG seroconversion in study participants receiving randomized HCQ versus placebo.

    Time: 8 Weeks

    Description: Measurement of the seroprevalence of SARS-CoV 2 IgM/IgG positive samples at study entry and study conclusion in all participants receiving HCQ compared to those receiving placebo via blood samples.

    Measure: Compare the seroprevalence of SARS-CoV 2 IgM/IgG positive samples at study entry and study conclusion in all participants receiving HCQ compared to those receiving placebo.

    Time: 8 Weeks

    Description: Measurement of the emergence of clinical symptoms or COVID-19 diagnosis in participants presenting asymptomatically at study entry but identified as seropositive by serology at entry between the randomized treatment arms and comparator arm and via weekly questionnaire and/or blood samples.

    Measure: Comparison of the emergence of clinical symptoms or COVID-19 diagnosis in participants presenting asymptomatically at study entry but identified as seropositive by serology at entry between the randomized treatment arms and comparator arm.

    Time: 8 Weeks

    Description: Review of the level of care needed by participants in each arm developing COVID19 as measured as requiring emergency room visit, hospitalization or able to stay home without hospital care via weekly questionnaire.

    Measure: To examine the level of care needed by participants in each arm developing COVID19 as measured as requiring emergency room visit, hospitalization or able to stay home without hospital care.

    Time: 8 Weeks

    Description: Measurement of the safety and tolerability of HCQ dosing for preventive strategy against COVID-19 as measured by adverse events and serious adverse events reported via weekly questionnaire.

    Measure: Determine the safety and tolerability of HCQ dosing for preventive strategy against COVID-19 as measured by adverse events and serious adverse events.

    Time: 8 Weeks

    Description: Examination of other clinical determinants contributing to the risk of SARS-CoV 2 infection including demographics, work type and location, positive COVID-19 partners, possible exposures and clinical symptoms via study visits and weekly questionnaire.

    Measure: To examine other clinical determinants contributing to the risk of SARS-CoV 2 infection in healthcare workers and first responders.

    Time: 8 Weeks

    Description: Examine the association between HCQ drug levels and development of COVID-19 symptoms or positive test results via weekly questionnaire and/or blood samples.

    Measure: Examine the association between HCQ drug levels and development of COVID-19 symptoms or positive test results.

    Time: 8 Weeks

    Description: Identification of immunologic, serological and inflammatory markers associated with acquisition and response to COVID-19 in both HCQ and placebo Participants developing laboratory or clinical confirmed disease via study visits, weekly questionnaire, and blood samples.

    Measure: identify immunologic, serological and inflammatory markers associated with acquisition and response to COVID-19 in both HCQ and placebo Participants developing laboratory or clinical confirmed disease.

    Time: 8 weeks
    14 Hydroxychloroquine for Outpatients With Confirmed COVID-19

    A novel coronavirus, SARS-CoV-2, is responsible for a rapidly spreading pandemic that has reached 160 countries, infecting over 500,000 individuals and killing more than 24,000 people. SARS-CoV-2 causes an acute and potentially lethal respiratory illness, known as COVID-19, that is threatening to overwhelm health care systems due to a dramatic surge in hospitalized and critically ill patients. Patients hospitalized with COVID-19 typically have been symptomatic for 5-7 days prior to admission, indicating that there is a window during which an effective intervention could significantly alter the course of illness, lessen disease spread, and alleviate the stress on hospital resources. There is no known treatment for COVID-19, though in vitro and one poorly controlled study have identified a potential antiviral activity for HCQ. The rationale for this clinical trial is to measure the efficacy and safety of hydroxychloroquine for reducing viral load and shedding in adult outpatients with confirmed COVID-19.

    NCT04342169
    Conditions
    1. Coronavirus Infection
    2. Coronavirus
    3. Infectious Disease
    Interventions
    1. Drug: Hydroxychloroquine
    2. Drug: Placebo oral tablet
    MeSH:Communicable Diseases Infection Coronavirus Infections Severe Acute Respiratory Syndrome

    Primary Outcomes

    Measure: Duration of viral shedding

    Time: Days 1-14

    Secondary Outcomes

    Measure: Duration of COVID-19-attributable symptoms

    Time: Everyday through 6 months

    Measure: Hospitalization

    Time: within 14 days of enrollment

    Measure: Duration of viral shedding

    Time: Days 1-14 and Day 28

    Measure: Adult household contact viral acquisition

    Time: Days 1-14 and Day 28
    15 Phase IIb Study to Evaluate the Efficacy and Safety of Chloroquine Diphosphate in the Treatment of Patients With Comorbidities, Without Severe Acute Respiratory Syndrome, Under the New Coronavirus (SARS-CoV2): a Double-blind, Randomized, Placebo-controlled Clinical Trial

    This is a double-blind, randomized, placebo-controlled clinical trial. A total of 210 individuals aged over 18 years old, without a diagnosis of severe respiratory disease, who came to the study site with clinical and radiological suspicion of SARS-CoV2, will be randomized into two treatment groups at a 1:1 ratio to receive a 5-day CQ diphosphate tablets or placebo (tablet without active ingredient produced with the same physical characteristics).

    NCT04342650
    Conditions
    1. COVID-19
    2. SARS-CoV Infection
    3. Severe Acute Respiratory Syndrome (SARS) Pneumonia
    4. Clinical Trial
    Interventions
    1. Drug: Chloroquine Diphosphate
    2. Drug: Placebo oral tablet
    MeSH:Infection Severe Acute Respiratory Syndrome Coronavirus Infections Pneumonia Syndrome
    HPO:Pneumonia

    Primary Outcomes

    Description: Evaluate if CQ diphosphate prevents the onset of SARS in patients on intervention group through standardized questionnaires.

    Measure: Proportion of patients with onset of severe acute respiratory syndrome (SARS)

    Time: 7 days after randomization

    Secondary Outcomes

    Description: Mortality rate between intervention and placebo group on days 7, 14, and 28 after randomization

    Measure: Mortality rate

    Time: after randomization, up to 28 days

    Description: Proportion of participants in need and duration of intensive care support after randomization

    Measure: Number of participants in need of intensive care support

    Time: during and after intervention, up to 28 days

    Description: Viral load change in blood and oropharyngeal swab samples

    Measure: Viral concentration

    Time: After randomization, up to 7 days

    Description: Incidence of serious adverse events during and after treatment

    Measure: Cumulative incidence of serious adverse events

    Time: During and after intervention, up to 28 days

    Description: Incidence of grade 3 and 4 adverse events during and after treatment

    Measure: Cumulative incidence of grade 3 and 4 adverse events

    Time: During and after intervention, up to 28 days

    Description: proportion of discontinuation or temporary suspension of treatment (for any reason)

    Measure: Proportion of patients with discontinued treatment

    Time: after randomization, up to 28 days

    Description: proportion of patients with increased levels of troponin I

    Measure: Incidence of cardiac lesions

    Time: after randomization, up to 120 days

    Description: proportion and magnitude of QTcF interval increases higher than 500ms

    Measure: Incidence of cardiac disfunctions

    Time: after randomization, up to 120 days

    Description: Changes measured on day 120 will be compared to baseline, through spirometry.

    Measure: Change in respiratory capacity

    Time: Day 120 after randomization
    16 The Effect of Spironolactone on Oxygenation in Covid-19 ARDS Patients

    This study intended to evaluate the effects of commonly used diuretic, spironolactone, on oxygenation in covid-19 ARDS patients.

    NCT04345887
    Conditions
    1. Respiratory Distress Syndrome, Adult
    Interventions
    1. Drug: Spironolactone 100mg
    2. Drug: Placebo oral tablet
    MeSH:Respiratory Distress Syndrome, Newborn Respiratory Distress Syndrome, Adult Acute Lung Injury

    Primary Outcomes

    Description: improvement in oxygenation

    Measure: p/f ratio

    Time: 5 days

    Secondary Outcomes

    Description: improvement in SOFA Score

    Measure: SOFA

    Time: 5 days
    17 Immune Monitoring of Prophylactic Effect of Hydroxychloroquine in Healthcare Providers Highly Exposed to SARS-Cov-2

    This is a PILOT STUDY, a Phase III double-blind, randomized, placebo-controlled clinical study in which we assess the clinical effect of the prophylactic administration of hydroxychloroquine vs. placebo to healthcare workers working at our University Hospital (HUN). Participants in each arm (n = 43) will be administered with a unique loading dose of 800 mg of hydroxychloroquine the first day followed by 400 mg/week for 90 days. The population to be studied (uninfected healthcare personnel) will be highly exposed to SARS-CoV-2 infection. An active search should be made for individuals who become infected while participating in the study, hence, once the informed consent form is signed, the molecular test for the diagnosis of SARS-CoV-2 infection by RT-PCR will be carried out every 4 days in order to determine as closely as possible the moment the participant becomes positive. The results of the diagnostic RT-qPCR tests will be confronted with: (i) the results of immune monitoring of at least 30 immunological parameters in leukocytes and in plasma (levels of selected cytokines and chemokines analyzed by automated flow cytometry software and (ii) the daily recording of data for the presence or absence of signs and symptoms associated with SARS-Cov-2 infection. For the recording of immune monitoring 20mL blood samples will be taken at eight-time points throughout the 90 days of the stud.

    NCT04346329
    Conditions
    1. COVID
    Interventions
    1. Drug: Hydroxychloroquine
    2. Drug: Placebo oral tablet

    Primary Outcomes

    Description: Number of participants with treatment-related adverse events as associated administration of hydroxychloroquine or placebo.

    Measure: Adverse effects

    Time: six months after administration of hydroxychloroquine or placebo

    Secondary Outcomes

    Description: Percentage of expression of immune senescence in cells of the immune system of individuals highly exposed to COVID-19 who receive hydroxychloroquine prophylactically vs. placebo.

    Measure: Immune-score

    Time: six months after administration of hydroxychloroquine or placebo

    Description: Correlate the immunological profile of highly exposed individuals with SARS-CoV-2 with the clinic of COVID-19.

    Measure: COVID-19 prevention

    Time: six months after administration of hydroxychloroquine or placebo

    Description: Determine the clinical outcome in observation timeframe of highly exposed personnel when receiving hydroxychloroquine vs. placebo prophylactically.

    Measure: Clinical response

    Time: six months after administration of hydroxychloroquine or placebo
    18 Assessment of the Efficacy and Safety of Hydroxychloroquine (HCQ) Administered as a Prophylaxis for Health Professionals Exposed to COVID19 and Working in Medical Intensive Care Units, in Tunisia. Multicentric Randomized Comparative Study

    Assessment of the Efficacy and Safety of Hydroxychloroquine (HCQ) Administered as a Prophylaxis for Health Professionals Exposed to COVID19 and Working in Medical Intensive Care Units, in Tunisia. Multicentric, Randomized Comparative Study

    NCT04349228
    Conditions
    1. COVID19
    2. Sars-CoV2
    3. Hydroxychloroquine
    4. Prophylaxis
    5. Healthcare Worker
    Interventions
    1. Drug: Hydroxychloroquine (HCQ)
    2. Drug: Placebo oral tablet

    Primary Outcomes

    Description: Clinical Examination: Symptomatic COVID(+) infection rate (from randomization to the onset of signs suggestive of Covid19 infection or to the end of the study at 60 days) The rate of COVID19 infections is defined by the occurrence of the clinical signs below: Cough Dyspnea Fever Myalgia Arthralgia Rhinorrhea Anosmia Asthenia, fatigability Confirmation of the above symptoms and COVID(+) PCR infection during the 60days treatment period. Biological Examination : Measurement of viral load Ion, liver, kidney, haematological assessment Electrical Examination: ECG

    Measure: Symptomatic COVID(+) infection rate

    Time: 60 days
    19 Chloroquine (CQ) Prophylaxis for Health Care Workers at Risk for COVID

    The primary objective is to determine the clinical efficacy of Chloroquine (CQ) in health care workers with moderate to high risk of exposure to COVID-19 in preventing symptomatic COVID-19 infections. Secondary endpoints will explore the efficacy of CQ in preventing any infection as defined by seroconversion to positive anti-COVID antibody status.

    NCT04349371
    Conditions
    1. COVID
    Interventions
    1. Drug: Chloroquine
    2. Drug: Placebo oral tablet

    Primary Outcomes

    Description: Symptomatic illness is defined as COVID infection guidelines and confirmed with anti-COVID antibodies that will be done on serum collect at the final visit. Symptoms include fever, chills, muscle pain, cough, shortness of breath, and diarrhea.

    Measure: Number of symptomatic illness in at risk healthcare workers

    Time: Up to 3 months

    Description: Diagnosis is based on symptoms of COVID-19 and confirmatory anti-COVID antibodies and when available, COVID-19 PCR.

    Measure: Number of healthcare workers with symptomatic COVID infections

    Time: Up to 3 months

    Description: Severe illness includes worsening of symptoms.

    Measure: Number of severe illness in at risk healthcare workers

    Time: Up to 3 months

    Secondary Outcomes

    Description: Confirmation with polymerase chain reaction (PCR) when available.

    Measure: Number of sero-conversions in at risk healthcare workers

    Time: Up to 3 months

    Description: Adverse events that are NCI-CTCAE Grade 3 or higher will be counted.

    Measure: Percentage of patients with adverse events Grade 3 or higher

    Time: Up to 3 months

    Description: GI intolerance to chloroquine will be documented and recorded.

    Measure: Percentage of patients with GI intolerance

    Time: Up to 3 months
    20 Protecting Health Care Workers From COVID-19 With Hydroxychloroquine Pre-exposure Prophylaxis: A Randomized, Placebo-controlled Trial

    This is a double-blinded, randomized placebo-controlled trial to determine if pre-exposure prophylaxis (PrEP) with 400mg hydroxychloroquine (HCQ), taken orally once daily, for health care workers in the hospital reduces symptomatic and asymptomatic COVID-19 disease during the pandemic. 374 health care workers will be randomized at a 1:1 allocation between the intervention and placebo arms and followed for 90 days. The cumulative incidence of COVID-19 infection in the intervention group will be compared to the cumulative incidence of COVID-19 in the placebo group with relative (risk ratio and 95% CI) and absolute measures (risk difference and 95% CI).

    NCT04352946
    Conditions
    1. Prophylaxis
    2. COVID-19
    3. Health Care Worker
    4. Hydroxychloroquine
    Interventions
    1. Drug: Hydroxychloroquine Pre-Exposure Prophylaxis
    2. Drug: Placebo oral tablet

    Primary Outcomes

    Description: Incidence of symptomatic and asymptomatic COVID-19 infection in health care workers

    Measure: Cumulative Incidence of COVID-19 Infection

    Time: 90 days

    Secondary Outcomes

    Description: Incidence of reported and grade of adverse events

    Measure: Adverse events incidence

    Time: 90 days

    Description: Duration in days of symptomatic COVID-19 disease in HCW who had disease

    Measure: Duration of symptomatic COVID-19 disease

    Time: 90 days

    Description: Duration in days of hospitalization attributed to COVID-19 disease in HCW who had disease

    Measure: Days hospitalized attributed to COVID-19

    Time: 90 days

    Description: Number of HCW with respiratory failure attributable to COVID-19 disease requiring i) non-invasive ventilation or ii) intubation/mechanical ventilation in HCW who developed disease

    Measure: Number or respiratory failure attributable to COVID-19 disease

    Time: 90 days

    Description: Cumulative Incidence of Mortality attributed to COVID-19 disease in HCW who developed disease

    Measure: Mortality Incidence

    Time: 90 days

    Description: Number of days unable to work attributed to COVID-19 in HCW who developed disease

    Measure: Days of work lost

    Time: 90 days

    Other Outcomes

    Description: Proportion of participants with plasma able to neutralize SARS-CoV-2 virus (plaque reduction neutralization test) in vitro.

    Measure: Proportion of HCW with plasma able to neutralize SARS-CoV-2 virus

    Time: 90 days

    Description: Number of participants with severity markers of host immune and endothelial activation measured at clinical presentation and their ability to predict severity and outcome.

    Measure: Number of participants with severity markers of host immune and endothelial activation

    Time: 90 days
    21 Multicenter Randomized Controlled Trial of the Efficacy of Melatonin in the Prophylaxis of SARS-coronavirus-2 Infection Among High Risk Contacts.

    There is an urgent need to evaluate interventions that can prevent the infection with SARS-CoV 2 of healthcare workers at risk. Melatonin is an inexpensive and safe product with protective effect in both bacterial and viral infections likely due to its anti-inflammatory and anti-oxidative effects. This randomized controlled trial seeks to evaluate is efficacy as a prophylaxis in healthcare workers exposed to the virus in their clinical practice.

    NCT04353128
    Conditions
    1. Covid19
    2. SARS-CoV 2
    3. Coronavirus Infection
    Interventions
    1. Drug: Melatonin 2mg
    2. Drug: Placebo oral tablet
    MeSH:Infection Coronavirus Infections Severe Acute Respiratory Syndrome

    Primary Outcomes

    Description: Number of confirmed (positive CRP) symptomatic infections in each treatment group

    Measure: SARS-CoV 2 infection rate

    Time: up to 12 weeks
    22 Randomized Trial Evaluating Effect of Outpatient Hydroxychloroquine on Reducing Hospital Admissions in Pregnant Women With SARS-CoV-2 Infection: HyPreC Trial

    COVID-19 was declared a pandemic on March 11th. Efforts to save lives are essential as we will face increasing morbidity with rising demands on health care resources. Since pregnant women with COVID-19 have systematically been excluded from drug trials, potential treatment options for these high-risk individuals remain untested. The aim of our trial is to determine whether hydroxychloroquine given to COVID-19 positive pregnant women can reduce COVID-19-related hospital admissions, thereby allowing women to stay at home while limiting utilization of hospital resources and resulting exposure of health care providers.

    NCT04354441
    Conditions
    1. COVID-19
    2. SARS-CoV-2
    3. Pregnant Women
    4. Hydroxychloroquine
    Interventions
    1. Drug: hydroxychloroquine sulfate 200 MG
    2. Drug: Placebo oral tablet

    Primary Outcomes

    Description: COVID-19-related hospital admissions will be reported by the participants throughout pregnancy until delivery.

    Measure: COVID-19-related hospital admissions

    Time: Hospital Admission at any point from study enrollment to delivery

    Secondary Outcomes

    Description: Measurement of reported symptoms using a validated questionnaire on Day 3, 7, 10, and every 2 weeks. The FLU-PRO Questionnaire instructs respondents to rate the severity of 37 influenza symptoms over the past 24 hours, including those related to the nose, throat, eye, chest, head, stomach, fatigue, and body aches/pains. For 32 of 37 items, respondents rated the severity of each symptom on 5-point Likert-type scales from 0 ("Not at all), 1 ("A little bit"), 2 ("Somewhat"), 3 ("Quite a bit"), to 4 ("Very much"). For the five remaining items, severity is expressed as frequency of occurrence: vomiting or diarrhea (0 times, 1 time, 2 times, 3 times, or 4 or more times), and sneezing, coughing, and coughed up mucus or phlegm on a scale from 0 ("Never") to 4 ("Always"), with higher scores indicating more severe symptoms.

    Measure: Symptoms related to COVID-19 infection

    Time: Participants will be contacted at day 3, 7, and 10 post-randomization, and every 2 weeks up to to delivery

    Description: Side effects related to hydroxychloqoruine

    Measure: Adverse Events

    Time: Participants will be contacted at day 3, 7, and 10 post-randomization, and every 2 weeks up to to delivery

    Description: Type of delivery (elective non-urgent cesarean, elective urgent cesarean section, non-elective cesarean within labor, instrumental vaginal, spontaneous vaginal)

    Measure: Maternal outcomes

    Time: Participants will be contacted within 2 weeks after delivery to obtain information about their labor and delivery.

    Description: If had cesarean delivery, indication for cesarean section

    Measure: Maternal outcomes

    Time: Participants will be contacted within 2 weeks after delivery to obtain information about their labor and delivery.

    Description: Miscarriage or stillbirth (Yes/No)

    Measure: Maternal outcomes

    Time: Participants will be contacted within 2 weeks after delivery to obtain information about their labor and delivery.

    Description: Labor induction or augmentation (Yes/No) and indication

    Measure: Maternal outcomes

    Time: Participants will be contacted within 2 weeks after delivery to obtain information about their labor and delivery.

    Description: Epidural use (Yes/No)

    Measure: Maternal outcomes

    Time: Participants will be contacted within 2 weeks after delivery to obtain information about their labor and delivery.

    Description: Gestational age at delivery (weeks)

    Measure: Newborn outcomes

    Time: Participants will be contacted within 2 weeks after delivery to obtain information about their baby.

    Description: Sex (female/male)

    Measure: Newborn outcomes

    Time: Participants will be contacted within 2 weeks after delivery to obtain information about their baby.

    Description: Birth weight (kg) Birth weight (kg)

    Measure: Newborn outcomes

    Time: Participants will be contacted within 2 weeks after delivery to obtain information about their baby.

    Description: Need for resuscitation (Yes/No)

    Measure: Newborn outcomes

    Time: Participants will be contacted within 2 weeks after delivery to obtain information about their baby.

    Description: NICU admission (Yes/No)

    Measure: Newborn outcomes

    Time: Participants will be contacted within 2 weeks after delivery to obtain information about their baby.

    Description: Medical conditions (jaundice, IVH, RDS, pneumothorax, PDA, NEC)

    Measure: Newborn outcomes

    Time: Participants will be contacted within 2 weeks after delivery to obtain information about their baby.

    Description: Current disposition of baby (home or hospital)

    Measure: Newborn outcomes

    Time: Participants will be contacted within 2 weeks after delivery to obtain information about their baby.
    23 VA Remote and Equitable Access to COVID-19 Healthcare Delivery (VA-REACH TRIAL)

    We propose a 3-arm RCT to determine the efficacy of hydroxychloroquine or azithromycin in treating mild to moderate COVID-19 among Veterans in the outpatient setting.

    NCT04363203
    Conditions
    1. SARS-CoV-2
    2. COVID-19
    Interventions
    1. Drug: Hydroxychloroquine
    2. Drug: Azithromycin
    3. Drug: Placebo oral tablet

    Primary Outcomes

    Measure: Days to resolution of cough, fever and shortness of breath

    Time: 30-days

    Secondary Outcomes

    Measure: Days to resolution of all COVID-19 symptoms

    Time: 30-days

    Measure: All cause hospitalization

    Time: 30-days

    Measure: All cause mortality

    Time: 30-days

    Measure: COVID-19 specific mortality

    Time: 30-days

    Measure: COVID-19 specific hospitalization

    Time: 30-days
    24 Double-blind, Placebo-controlled Clinical Trial of the Use of Colchicine for the Management of Patients With Mild and Severe SARS-Cov2 Infection

    The world is currently facing a pandemic due to the outbreak of a new coronavirus causing acute respiratory failure called SARS-Cov2. The majority of patients (8 out of 10) are known to have mild disease, manifested by respiratory tract symptoms associated with fever, headache, and body pain. However, it is possible that the disease progresses to a severe stage, whith the need for mechanical ventilation support associated with high morbidity and mortality. The progression of the disease is mainly due to the appearance of uncontrolled inflammation that also favors the development of disseminated clots. So far, there is no effective treatment to combat coronavirus; however, the use of anti-inflammatory drugs is potentially effective in preventing complications from the disease. In this regard, low dose colchicine is relatively safe and effective as an anti-inflammatory. It has been used for many years in the control of inflammation secondary to the accumulation of uric acid crystals. The aim of this study is to test if the administration of colchicine at a dose of 1.5 mg the first day and subsequently 0.5 mg BID until completing 10 days of treatment is effective as a treatment for inflammation related symptoms in patients with mild and severe disease secondary to coronavirus infection. The primary outcome is improvement of symptoms related to inflammation and avoiding progression to severe and critical stages of the disease. Colchicine can be discontinued before the end of 10 days in case of serious adverse effects or if the patient progresses to the critical stages of the disease.

    NCT04367168
    Conditions
    1. COVID
    Interventions
    1. Drug: Colchicine
    2. Drug: Placebo oral tablet
    MeSH:Inflammation

    Primary Outcomes

    Description: Resolution of fever, myalgia and arthralgia and 50% improvement of total lymphocyte count, D-dimer, fibrinogen and ferritin

    Measure: Number of patients with improvement in body temperature, myalgia, arthralgia, total lymphocyte count, D-dimer, fibrinogen and ferritin levels

    Time: Up to 24 days

    Description: At least one of the following: respiratory failure, respiratory rate > 30 rpm, oxygen saturation < 92%, PaO2/FiO2 < 300 mmHg

    Measure: Progression to severe disease

    Time: Up to 10 days
    25 Efficacy and Safety of Hydroxychloroquine in Primary Prophylaxis of SARS-CoV-2 Infection in Healthcare Workers at Risk of Exposure: Randomised Control Trial

    Healthcare personnel are at an increased risk of exposure to SARS-CoV-2 infection while handling such patients. Currently, there is no treatment available for SARS-CoV-2 and stringent preventive measures are advised to avoid or minimize risk of exposure to healthcare workers. There are in vitro studies available which show inhibition of corona virus by hydroxychloroquine, a widely-used agent against malaria and certain autoimmune conditions and of low-cost and limited toxicity. However, evidence regarding its effects in patients is limited. We plan to conduct a randomized controlled trial to evaluate the safety and potential prophylactic efficacy of hydroxychloroquine in preventing secondary SARS-CoV-2 infection among healthcare workers at high-risk of exposure while managing such patients.

    NCT04370015
    Conditions
    1. SARS-CoV-2
    2. Healthcare Workers
    Interventions
    1. Drug: Hydroxychloroquine
    2. Drug: Placebo oral tablet
    MeSH:Infection

    Primary Outcomes

    Description: Negative RT-PCR for SARS-CoV-2 both at baseline and at end of 12 weeks in experimental arm

    Measure: Prevention of SARS-CoV-2 as determined by negative RT-PCR at the end of 12 week study period

    Time: From date of randomization until study completion 12 weeks after treatment initiation

    Description: To assess the presence or absence of side effects from HCQ treatment.

    Measure: Safety as determined by presence or absence of any adverse event related with hydroxychloroquine treatment

    Time: From date of randomization until the appearance of symptoms or study completion 12 weeks after treatment initiation

    Secondary Outcomes

    Description: Symptomatic infection by SARS-CoV-2 defined as cough, dyspnea, fever, myalgia, arthralgia or rhinorrhea.

    Measure: Confirmed SARS-CoV-2 infection based on symptoms and confirmed by RT-PCR

    Time: From date of randomization until the appearance of symptoms or study completion 12 weeks after treatment initiation

    Description: Disease severity including i) asymptomatic. ii) Mild symptoms but ambulatory. iii) Moderate symptoms requiring hospitalisation. iv) severe symptoms requiring ICU care and oxygen. v) Severe symptoms requiring assisted mechanical ventilation. vi) Death.

    Measure: Clinical disease severity in confirmed SARS-CoV-2 participants

    Time: From date of randomization until the appearance of symptoms or study completion 12 weeks after treatment initiation

    Description: Symptomatic non-COVID viral infection (any other acute respiratory illness with fever but without evidence of epidemiological risk factors such as close contact with SARS-CoV-2 positive patient or travel to or residence in high-risk area).

    Measure: Incidence of any acute respiratory infection

    Time: From date of randomization until the appearance of symptoms or study completion 12 weeks after treatment initiation
    26 Protecting Frontline Health Care Workers From COVID-19 With Hydroxychloroquine Pre-exposure Prophylaxis: A Randomized, Placebo-controlled Multi-Site Trial in Toronto, Canada

    On 11 March 2020, the World Health Organization declared SARS-CoV-2 (commonly called COVID-19) a global pandemic. As in any pandemic, maintaining the health and safety of the healthcare workforce is of great importance as health care workers (HCW) remain a critical line of defence against the spread of COVID-19 and play a vital role in the recovery of those already infected. Frontline HCW, such as those in the emergency department (ED), are at high risk of contracting COVID-19 due to their close proximity to patients who may have the virus. The impact of frontline HCW becoming ill and thus unable to go to work is equally high, and of grave risk to the function of the healthcare system and the ability to minimize the impact of the current pandemic. This study aims to evaluate whether hydroxychloroquine (HCQ), a well-tolerated drug typically used in the prevention of malaria transmission and rheumatic disease, taken before and during exposure to patients with COVID-19, is effective at reducing COVID-19 infections among ED health care workers.

    NCT04374942
    Conditions
    1. Pre-Exposure Prophylaxis
    2. Coronavirus
    3. SARS-CoV 2
    Interventions
    1. Drug: Hydroxychloroquine
    2. Drug: Placebo oral tablet
    MeSH:Coronavirus Infections

    Primary Outcomes

    Description: This is a composite endpoint which includes any positive result from a validated SARS-CoV-2 diagnostic assay including detection of viral RNA, or seroconversion by day 104 (14 days after end of the randomization period).

    Measure: Microbiologically confirmed COVID-19 (SARS-CoV-2 infection)

    Time: Samples collected at day 0, 30, 60, 90 and 120

    Secondary Outcomes

    Description: Assessed using the DAIDS Table for Grading the Severity of Adverse Events

    Measure: Adverse events

    Time: Assessed at day 30, 60, 90, and day 120

    Description: Collected weekly from participants via self-report, sent by email

    Measure: Symptom duration of COVID-19

    Time: Collected every 7 days from day 7 to day 120

    Description: The number of days (or partial days) spent admitted to an acute care hospital during the study period

    Measure: Days of hospitalization attributable to COVID-19

    Time: Collected every 7 days from day 7 to day 120

    Description: the number of days (or partial days) requiring i) non-invasive and ii) endotracheal intubation with ventilation during the study period

    Measure: Respiratory failure requiring ventilatory support attributable to COVID-19

    Time: Collected every 7 days from day 7 to day 120

    Description: Mortality attributable to COVID-19 and all-cause mortality during the study period

    Measure: Mortality

    Time: Collected every 7 days from day 7 to day 120

    Description: Number of days ineligible/unable to work due to COVID-19

    Measure: Impact on work eligibility

    Time: Collected every 7 days from day 7 to day 120

    Description: COVID-19 reactive serology

    Measure: Seropositivity

    Time: Blood collected at day 0, 30, 60, 90, 120

    Description: Short-term psychological impact of exposure to COVID-19 measured using the K10, a validated measure of non-specific psychological distress, with a standard cutoff score of ≥16

    Measure: Short-term psychological impact

    Time: Measured at day 1, 60, 120
    27 Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19

    The most severe manifestations of COVID-19 include respiratory failure, coagulation problems, and death. Inflammation and blood clotting are believed to play an important role in these manifestations. Research in humans has shown that dipyridamole can reduce blood clotting. This research study is being conducted to learn whether 14 days of treatment with dipyridamole will reduce excessive blood clotting in COVID-19. This study will enroll participants with confirmed coronavirus (SARS-CoV)-2 infection that are admitted. Eligible participants will be randomized to receive dipyridamole or placebo for 14 days in the hospital. In addition, data will be collected from the medical record, and there will also be blood draws during the hospitalization.

    NCT04391179
    Conditions
    1. COVID
    2. Corona Virus Infection
    3. Covid-19
    4. SARS-CoV-2 Infection
    Interventions
    1. Drug: Dipyridamole 100 Milligram(mg)
    2. Drug: Placebo oral tablet
    MeSH:Infection Communicable Diseases Coronavirus Infections Severe Acute Respiratory Syndrome

    Primary Outcomes

    Description: Increase in plasma D-dimer level compared with baseline at enrollment.

    Measure: Change in D-dimer

    Time: baseline, up to approximately 28 days after last study drug administration

    Secondary Outcomes

    Description: Global composite rank score of death, mechanical ventilation, oxygen saturation (SpO2)/fraction of inspired oxygen (FiO2), and World Health Organization (WHO) Ordinal score.

    Measure: Global composite rank score

    Time: up to approximately 28 days after last study drug administration
    28 Randomised, Double-blind, Placebo-controlled Phase 2 Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycine in Patients With COVID-19 and Hematological Malignancies

    The primary objective of this phase 2, multicentric, placebo-controlled double-blind, randomized study is to evaluate the efficacy of the combination of hydroxychloroquine and azithromycine on the viral load drop at day 5 among patients with COVID-19 and hematological malignancies.

    NCT04392128
    Conditions
    1. COVID19
    2. Hematologic Malignancy
    Interventions
    1. Drug: Hydroxychloroquine Sulfate 200 MG [Plaquenil]
    2. Drug: Azithromycin 250 MG Oral Capsule
    3. Drug: Placebo oral tablet
    4. Drug: Placebo oral capsule
    MeSH:Neoplasms Hematologic Neoplasms
    HPO:Hematological neoplasm Leukemia Neoplasm

    Primary Outcomes

    Description: Locally evaluated rate of viral response. Favorable response is defined as (1) complete response : negative PCR (absence of detectable signal with a minimum of 40 cycles) or (2) major response : detectable signal but with an increased number of cycles > or egal to 10 compared to initial PCR. Response failure is defined as (1) minor response : detectable signal but with an increased number of cycles < 10 compared to initial PCR or (2) stabilisation or worsening of the viral load.

    Measure: Evaluation of the efficacy of hydroxychloroquine and azithromyncine on the viral load drop at day 5.

    Time: 5 days of treatment

    Secondary Outcomes

    Description: Duration of fever - duration of respiratory symptoms (cough, dyspnea) - duration of other COVID-19 related symptoms (digestive symptoms, ageusia, anosmia)

    Measure: Clinical evolution

    Time: up to 3 months

    Description: Less or equal to 94% oxygen saturation - need to initiate oxygenotherapy - occurrence of respiratory distress - patient transfer in intensive care unit - need of mechanical ventilation - occurrence of non-respiratory organ failure - occurrence of septic shock

    Measure: Proportion of patients progressing to a severe form

    Time: up to 3 months

    Description: Date and cause of death

    Measure: Mortality

    Time: up to 1 and 3 months

    Description: SARS-CoV-2 viral load by PCR on nasopharyngeal swab at day 10 (if positive at day 5) : rate of negativation and comparison of number of cycles with previous samples

    Measure: Evaluation of viral load drop

    Time: at day 10

    Description: Frequence and causality of all-grade cardiac adverse events - frequence and causality of grade > 1 adverse events for other adverse events - frequence and causality of serious adverse events (CTCAE v5)

    Measure: Tolerance of study treatment

    Time: up to 3 months

    Description: Collection of serum to realize serological tests

    Measure: Evaluation of the seroconversion

    Time: at inclusion, day 10, day 30 and day 90 after treatment

    Description: Phenotypic and functional study of NK lymphocytes at inclusion, Retrospective analysis on frozen cells.

    Measure: NK immunological study

    Time: at day 10 and day 30 after treatment

    Description: Duration of hospitalisation (conventional, intensive care, reanimation)

    Measure: Hospitalisation duration

    Time: up to 3 months

    Description: Patient follow-up during 3 months : hematological status and associated therapy

    Measure: Impact of the study treatment on the treatment of the hematological disease

    Time: up to 3 months

    Description: ECG (using connected machine to allow monitoring at home)

    Measure: Monitoring of the QT space

    Time: at inclusion, day 2, day 5, day 10

    Description: Dosage of residual concentration of azithromycine and hydroxychloroquine.

    Measure: Dosage of residual concentration of azithromycine and hydroxychloroquine.

    Time: at day 5 and day 10

    Description: Phenotypic and functional study of T lymphocytes at inclusion, Retrospective analysis on frozen cells.

    Measure: T immunological study

    Time: at day 10 and day 30 after treatment
    29 Randomized Double-Blind Placebo-Controlled Trial on the Safety and Efficacy of Imatinib for Hospitalized Adults With COVID-19

    This study is a randomized Double-Blind Placebo-Controlled Trial on the Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19

    NCT04394416
    Conditions
    1. COVID-19
    Interventions
    1. Drug: Imatinib
    2. Drug: Placebo oral tablet

    Primary Outcomes

    Description: The ordinal scale is an evaluation of the clinical status at the first assessment of a given study day. The scale is as follows: 1) Not hospitalized, no limitations on activities; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 5) Hospitalized, requiring supplemental oxygen; 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 8) Death.

    Measure: The proportion of patients with a two-point change using the 8-category ordinal scale

    Time: Day 14 from baseline

    Secondary Outcomes

    Description: All-cause mortality post baseline

    Measure: All-Cause mortality

    Time: Day 28 and Day 60 post baseline

    Description: Time to a 2-point clinical change difference

    Measure: Time to a 2-point clinical change

    Time: Up to 60 days post baseline

    Description: Duration of hospitalization

    Measure: Hospitalization

    Time: Up to 60 days post baseline

    Description: For subjects who are on ECMO or mechanical ventilation at Day 1

    Measure: Duration of ECMO or invasive mechanical ventilation

    Time: Up to 60 days post baseline

    Description: For subjects who are in ICU at Day 1

    Measure: Duration of ICU stay

    Time: Up to 60 days post baseline

    Description: Time to SARS-CoV-2 negative by reverse transcriptase-polymerase chain reaction (RT-PCR)

    Measure: SARS-CoV-2 negative

    Time: Up to 60 days post baseline

    Description: Proportion of patients with negative oropharyngeal or nasopharyngeal swab for SARS-CoV-2 by quantitative RT PCR on days 5, 10, 14, 21, and 28 after starting treatment

    Measure: Negative oropharyngeal or nasopharyngeal swab

    Time: Up to 28 days post baseline

    Description: Proportion of subjects with serious adverse events

    Measure: Serious adverse events (SAEs)

    Time: Up to 60 days post baseline

    Description: Proportion of subjects who discontinue study drug due to adverse events

    Measure: Discontinuation due to adverse events

    Time: Up to 60 days post baseline
    30 Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP Canada)

    Study Objective: To test if early preemptive hydroxychloroquine therapy can prevent disease progression in persons with known symptomatic COVID-19 disease, decreasing hospitalizations and symptom severity.

    NCT04421664
    Conditions
    1. Corona Virus Infection
    2. SARS-CoV Infection
    3. Coronavirus
    Interventions
    1. Drug: Hydroxychloroquine
    2. Drug: Placebo oral tablet
    MeSH:Infection Communicable Diseases Coronavirus Infections Severe Acute Respiratory Syndrome

    Primary Outcomes

    Description: Participants will self-report disease severity status as one of the following 3 options; no COVID19 illness (score of 1), COVID19 illness with no hospitalization (score of 2), or COVID19 illness with hospitalization or death (score of 3). Increased scale score indicates greater disease severity. Outcome is reported as the percent of participants who fall into each category per arm.

    Measure: Ordinal Scale of COVID19 Disease Severity at 14 days

    Time: 14 days

    Secondary Outcomes

    Description: Outcome reported as the number of participants in each arm who require hospitalization for COVID19-related disease.

    Measure: Incidence of Hospitalization

    Time: 14 days

    Description: Outcome reported as the number of participants in each arm who expire due to COVID-19-related disease.

    Measure: Incidence of COVID-19 related Death

    Time: 90 days

    Description: Outcome reported as the number of participants in each arm who expire due to all causes.

    Measure: Incidence of all-cause Death

    Time: 90 days

    Description: Outcome reported as the number of participants in each arm who discontinue or withdraw medication use for any reason.

    Measure: Incidence of All-Cause Study Medicine Discontinuation or Withdrawal

    Time: 14 days

    Description: Visual Analog Scale 0-10 score of rating overall symptom severity (0 = no symptoms; 10 = most severe)

    Measure: Overall symptom severity at 5 and 14 days

    Time: 5 and 14 days

    Description: Repeated Measure mixed regression model of change in: Visual Analog Scale 0-10 score of rating overall symptom severity (0 = no symptoms; 10 = most severe)

    Measure: Overall change in disease severity over 14 days among those who are symptomatic at baseline

    Time: 14 days
    31 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Losmapimod in Adult Subjects With COVID-19 (LOSVID STUDY)

    The therapeutic hypothesis for the use of losmapimod in COVID-19 disease is that increased mortality and severe disease is caused by p38 mitogen-activated protein kinase (MAPK)-mediated exaggerated acute inflammatory response resulting from SARS-CoV-2 infection. The study Sponsor hypothesize's that the early initiation of p38α/β inhibitor therapy in patients hospitalized with moderate COVID-19 who are at increased risk of a poor prognosis based on older age and elevated systemic inflammation will reduce clinical deterioration including progression to respiratory failure and death. To address this hypothesis, Fulcrum Therapeutics is conducting a Phase 3, multicenter, randomized, double-blind, placebo-controlled study that will evaluate the safety and efficacy of losmapimod versus placebo in subjects 50 and older who are hospitalized with moderate COVID-19 disease.

    NCT04511819
    Conditions
    1. COVID-19
    Interventions
    1. Drug: Losmapimod oral tablet
    2. Drug: Placebo oral tablet

    Primary Outcomes

    Description: The efficacy of Losmapimod will be assessed by the development of progression to critical disease as evidence of mortality or development of respiratory failure by Day 28.

    Measure: Day 28 Mortality

    Time: Day 28

    Secondary Outcomes

    Description: The change from baseline in clinical disease status will be evaluated using the 9-point World Health Organization (WHO) ordinal scale: 0 indicating, no clinical evidence of SARS-CoV-2 infection and 8 indicating death.

    Measure: Clinical Status Assessment

    Time: Day 7 and Day 14

    Description: The response to treatment with Losmapimod in COVID-19 patients will be assessed by the total number of study days not requiring oxygen supplementation.

    Measure: Respiratory Failure Assessment

    Time: Day 28

    Description: To assess the effect on survival following treatment with Losmapimod, mortality will be evaluated by the number of days alive by Day 28.

    Measure: Treatment Survival

    Time: Day 28

    Description: To evaluate the safety and tolerability of Losmapimod, the incidence of treatment-emergent adverse events will be assessed by clinically significant changes in laboratory test results and vital signs.

    Measure: Treatment-Emergent Adverse Events

    Time: Screening, Date of enrollment and Days 2-14 and 7 and 14 days after the last dose of study drug

    Description: To characterize changes in SARS-CoV-2 infection following treatment with losmapimod versus placebo.

    Measure: Treatment-Emergent Adverse Events

    Time: Day 7

    Other Outcomes

    Description: The change from baseline in levels of C-reactive protein (CRP), a biomarker of systemic inflammatory response to infection with the SARS-CoV-2 virus will be evaluated in serum by immunoturbidimetric assay.

    Measure: Changes in C-Reactive Protein

    Time: Days 1, 4, 7 and 14

    Description: The change from baseline in the levels of cytokines (IFNγ, IL-2, IL-10 in normalized protein expression (NPX)) in response to the SARS-CoV-2 virus in serum will be evaluated using the Olink immunoassay panel.

    Measure: Changes in Levels of Cytokines

    Time: Days 1, 4, 7 and 14

    Description: The change from baseline in the levels of chemokines (CXCL10, CXCL9 in normalized protein expression (NPX)) in response to the SARS-CoV-2 virus in serum will be evaluated using the Olink immunoassay panel.

    Measure: Changes in Levels of Chemokines

    Time: Days 1, 4, 7 and 14
    32 Adaptive Study to Demonstrate Efficacy and Safety of Metformin Glycinate for the Treatment of Hospitalized Patients With Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2. Randomized, Double-Blind, Phase IIIb

    The purpose of this study is to evaluate the efficacy and safety of the metformin glycinate and standard treatment of the hospital in hospitalized patients with Severe Acute Respiratory Syndrome secondary to SARS-CoV2.

    NCT04625985
    Conditions
    1. Severe Acute Respiratory Syndrome Coronavirus 2
    Interventions
    1. Drug: Metformin Glycinate
    2. Drug: Placebo oral tablet
    MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome Syndrome

    Primary Outcomes

    Description: Assess differences in SARS-CoV-2 viral load between participants that receive placebo vs metformin glycinate

    Measure: Viral load

    Time: Day 0 to Day 28 or patient discharge day

    Description: Clinical status assessed by measurement of consciousness level: alertness

    Measure: consciousness level

    Time: Day 0 to Day 28 or patient discharge day

    Description: Clinical status assessed by measurement of axillary body temperature in °C: <37.2.

    Measure: temperature

    Time: Day 0 to Day 28 or patient discharge day

    Description: Clinical status assessed by measurement of systolic blood pressure in mmHg: >90.

    Measure: systolic blood pressure

    Time: Day 0 to Day 28 or patient discharge day

    Description: Clinical status assessed by measurement of oxygen saturation in %: >90.

    Measure: Oxigen saturation

    Time: Day 0 to Day 28 or patient discharge day

    Description: Clinical status assessed by measurement of heart rate in beats per minute: <100 bpm.

    Measure: Heart rate

    Time: Day 0 to Day 28 or patient discharge day

    Description: Clinical status assessed by measurement of respiratory rate in breaths per minute: <24 bpm,

    Measure: respiratory rate

    Time: Day 0 to Day 28 or patient discharge day

    Description: Assess length of hospitalization

    Measure: Days of hospitalization

    Time: Day 0 to Day 28 or patient discharge day

    Description: Assess length of supplementary oxygen

    Measure: Days of supplementary oxygen if applies

    Time: Day 0 to Day 28 or patient discharge day

    Description: Assess length of mechanical ventilation

    Measure: Days of supplementary mechanical ventilation

    Time: Day 0 to Day 28 or patient discharge day

    Secondary Outcomes

    Description: Assess by incidence of Grade 3, Grade 4, and Serious Adverse Events (AEs)

    Measure: Toxicity of study drug assessed by incidence of adverse events (grade 3 or 4)

    Time: Day 0 to Day 28 or patient discharge day

    Description: Changes in serum levels from security laboratories compared to baseline levels and between groups.

    Measure: Changes in laboratory test results

    Time: Day 0 to Day 28 or patient discharge day
    33 Adaptive Study for Efficacy and Safety of Metformin Glycinate for the Treatment of Patients With MS and DM2, Hospitalized With Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2. Randomized, Double-Blind, Phase IIIb.

    The purpose of this study is to evaluate the efficacy and safety of metformin glycinate at dose of 620 mg twice per day plus standard treatment comparing to standard treatment alone (we will use placebo) of patients who have metabolic syndrome or type 2 diabetes, which have severe acute respiratory syndrome secondary to SARS-CoV-2.

    NCT04626089
    Conditions
    1. Severe Acute Respiratory Syndrome Coronavirus 2
    2. Metabolic Syndrome
    3. Type 2 Diabetes
    Interventions
    1. Drug: metformin glycinate
    2. Drug: Placebo oral tablet
    MeSH:Coronavirus Infections Severe Acute Resp Severe Acute Respiratory Syndrome Diabetes Mellitus, Type 2 Metabolic Syndrome Syndrome
    HPO:Type II diabetes mellitus

    Primary Outcomes

    Description: Assess differences in SARS-CoV-2 viral load between participants that receive placebo vs metformin glycinate

    Measure: Viral Load

    Time: Day 0 to Day 8 or patient discharge day

    Secondary Outcomes

    Description: Assess length of supplementary oxygen

    Measure: Days of supplementary oxygen if apply

    Time: Day 0 to day 28 or patient discharge day

    Description: Assess length of mechanical ventilation

    Measure: Days of supplementary mechanical ventilation if apply

    Time: Day 0 to day 28 or patient discharge day

    Description: Assess length of hospitalization

    Measure: Days of Hospitalization

    Time: Day 0 to day 28 or patients discharge day

    Description: Assess the difference in the Proportion of participants with normalization of fever between participants that receive placebo vs the patients with metformin glycinate

    Measure: Normalization of fever

    Time: Day 0 to day 28 or patient discharge day

    Description: Assess the difference in the Proportion of participants with normalization of oxygen saturation between participants that receive placebo vs the patients with metformin glycinate

    Measure: Normalization of oxigen saturation

    Time: Day 0 to day 28 or patient discharge day

    Description: Assess the difference in the number of deaths between participants who received placebo versus the patients with metformin glycinate

    Measure: Number of deaths

    Time: Day 0 to day 28 or patient discharge day

    Description: Evaluate if the level increase or decrease in serum creatinine compared to baseline. units: mg/dl

    Measure: Change in Serum creatinine levels

    Time: Day 0 to day 28 or patients discharge day

    Description: Evaluate if the level increase or decrease in serum Creatine kinase-MB compared to baseline. Units: UI/l

    Measure: Change in serum Troponin I

    Time: Day 0 to day 28 or patients discharge day

    Description: Evaluate if the level increase or decrease in serum aspartate aminotransferase compared to baseline. units: IU/l

    Measure: Change in serum aspartate aminotransferase levels

    Time: Day 0 to day 28 or patients discharge day

    Description: Evaluate if the level increase or decrease in serum Creatine kinase-MB compared to baseline. Units: UI/l

    Measure: Change in serum Creatine kinase-MB levels

    Time: Day 0 to day 28 or patients discharge day

    Description: Assess by incidence of grade 3, grade 4 and Serious adverse events

    Measure: Incidence of adverse event

    Time: Day 0 to day 28 or patients discharge day

    Related HPO nodes (Using clinical trials)


    HP:0004377: Hematological neoplasm
    Genes 350
    CHD7 GFI1B FANCG NSUN2 RPS7 DNAJC21 NAGS SH3GL1 IGH SRP54 MS4A1 GATA2 TINF2 F13B COL14A1 CD19 DYNC2LI1 NUMA1 ELANE RPS26 PIGA CTPS1 APC HSPA9 POLE RPS17 APC2 CDKN2A FANCM RPS15A PIGL DDX41 RAG2 CBFB MALT1 BCL10 PIGL NSD1 GLI1 CD70 PGM3 SH2B3 BAX GATA1 ATM FANCE MPL TP53 BUB1 TET2 PALB2 KLHDC8B TNFSF12 RARA MLH1 GINS1 RAD51C EVC BUB1B FANCE WIPF1 RUNX1 PDGFRA MYD88 IGH TNFRSF1B ETV6 MDM2 TP63 FANCD2 NBEAL2 RNASEH2C SAMD9L NF1 DNMT3A CBL LPP FANCC TP53 BRIP1 GATA2 CD19 ASXL1 NRAS PICALM CD81 SF3B1 TNFRSF13B SMPD1 SMARCD2 BRCA1 TYROBP MPL LIG4 ABL1 MYD88 ATM RPS10 ATRX FANCG ASXL1 TET2 NUTM1 BCR FLT3 KRAS SRP72 MPL RPL27 EVC2 CBL CD28 BRCA2 SRSF2 XRCC4 RAF1 RPL11 THPO FASLG NOP10 CHEK2 SRSF2 CREBBP BUB1B TET2 PRKCD CALR GATA2 DNMT3A LIG4 BLM BCL2 FOXP1 TNFRSF13C TERT SF3B1 RPL15 TERC ADA2 PDGFRB TERT RPS14 TNFRSF1B FANCD2 RTEL1 RUNX1 IL7R USB1 SCN9A RASGRP1 CR2 IGH POT1 JAK2 NBN NRAS LIG4 TCF4 DNAJC21 MAD2L2 SH2D1A NTHL1 RPL35 FANCL KRAS ADA FAS CHIC2 STAT3 SETBP1 PGM3 CALR FANCB TAL2 PIK3R1 STAT3 PNP SAMD9L TET2 MLLT10 ICOS BRD4 NUP214 SLX4 LIG4 NBN NUP214 DCLRE1C JAK2 AAGAB BLM RECQL4 RAG1 CCND1 RPL31 MSH2 MCM4 TREX1 TINF2 ZAP70 MAGT1 GATA2 BCR MPL TNFRSF13B TET2 IFIH1 ASXL1 WAS CR2 SAMD9 RPL5 KIT RPS27 RMRP RPS24 WRAP53 FANCF RPL35A FAS SAMHD1 TP53 MLH1 TET2 PTEN PIK3CA TCIRG1 UBE2T SRP54 RPS19 DKC1 JAK2 RPS14 CASP10 FLT3 SRP54 JAK2 RMRP TNFRSF13C NFKB1 RPL18 TERT RUNX1 MYC DNAJC21 RECQL4 SBDS CCND1 KIF11 BIRC3 NFKB2 GFI1 CD27 ADA RNASEH2B BCL10 RNF43 KRAS SETD2 FANCC ERCC4 CTLA4 BCL6 GBA RAD51 TREM2 JAK2 TERT NBN BRAF XRCC2 FANCI ITK CALR GATA1 CD28 CTC1 ADA2 PTPN11 TSR2 JAK2 HLA-DRB1 TET2 CEP57 NPM1 CTLA4 ADAR RFWD3 SBDS ICOS EFL1 TERC BUB3 KIT EP300 RNASEH2A IL2RG F13A1 TRIP13 LIG4 PARN RHOH MPL DNASE1L3 RASGRP1 ATRX NF1 RFWD3 FANCA STS PRKCD DKC1 SCN10A PTPN11 RPS19 RPS29 RPL26 ABL1 HAX1 LRBA ELANE FANCA NHP2 NPM1 RUNX1 PRKCD ANAPC1 TERC SCN11A CEBPA TCF4 GATA2 IL2RG RB1 GNB1 CBL BRCA2 SH2B3 BCR MSH6 ARHGAP26 TET2 TAL1 GFI1 TNFSF12 RPS28 MYSM1 XIAP ERBB3 TET2
    Protein Mutations 0
    SNP 0
    HP:0002664: Neoplasm
    Genes 1522
    SF3B1 GFI1B IGF2 FIBP RPS7 WT1 COL7A1 TREX1 HSPG2 CASP8 SLC22A18 MC1R TFE3 KRAS PLAG1 OFD1 BRAF NUMA1 KRT16 PSENEN CTPS1 APC SOX9 FANCM OPCML CDKN2A RPS15A CTNNB1 SDHD EDN3 FCN3 NELFA GJC2 MALT1 HPGD GLI1 CD70 SPINK1 LETM1 PMS1 LRP5 HNF1B EXT1 TCF4 ELMO2 MET ANTXR1 KRT16 KRT10 PAX4 SETBP1 TERT WT1 SMARCB1 GJB6 HRAS STK11 BUB1B GNPTAB MYD88 MCC GJB2 BRCA1 TP63 PDGFRL TARS1 NF1 FGFR3 KARS1 BARD1 BRIP1 GATA2 IL1RN BRAF CD81 TNFRSF13B TYROBP AR LIG4 KLF11 ABL1 MVK BMPR1A PIK3CA B3GALT6 SLC37A4 SOS1 TSC1 FGFR3 ATRX FANCG TET2 KIT SRP72 MPL TP53 SMAD4 EVC2 MAPRE2 DLST BRCA1 DICER1 HRAS AKT1 RNR1 TSC1 TNPO3 XRCC4 DNMT3A NEUROD1 THPO MN1 NOD2 SRSF2 PPM1D FLT4 ATP7A IL7 KRAS GDNF WNT10A EPAS1 COL1A1 IL1B MRAP ADAMTS3 PRKCD SUFU PTCH1 ERCC3 KRT14 CXCR4 HOXD13 IGF2 LIG4 PALB2 BLM NRAS ERCC3 FOXP1 SDHD TP53 PKD2 PDX1 TINF2 ADA2 MYF6 RHBDF2 POU6F2 PHKG2 CDKN2A RUNX1 ERCC2 MAP2K2 WT1 USB1 GATA4 FGFR2 ACD CR2 MUTYH ARL6IP6 FAH MSH2 RASA1 NEK1 SOX6 NR0B1 LIG4 CDKN2B NF1 NF1 POLE RPL35 SRY SDHAF2 FANCL CPLX1 FAS PRKAR1A PHB SDHA CALR PIK3R1 FAN1 TET2 TMEM216 RSPO1 SEMA3D MDM4 SDHD HRAS NUP214 GJA1 PIK3CA CCND1 RNF6 MSH2 C11ORF95 MVK MCM4 FLI1 TINF2 KIAA0753 ECM1 ARSA ERCC2 SOX2 SDHC SLC26A2 MPL VANGL1 PUF60 RAD51D POT1 CR2 ESCO2 FOXE1 PMVK SRY GJB4 TRIM37 KIT EXT2 PDGFB KIF1B FANCF IGF2R MLH1 GDNF PIK3CA ASCC1 ASCL1 TCIRG1 APPL1 RPS19 BCL10 IGF2 NRAS FLT3 STAT1 BCL10 RMRP GNAI3 KRAS GPR101 BAP1 NKX2-1 MAX BMPR1A DDB2 SMARCB1 RAD51 FGFR3 ALX4 BTK MSH6 NOTCH3 DICER1 CXCR4 CCBE1 RET WT1 TP53 PALLD RNASEH2B WT1 ATR CCND1 KCNQ1OT1 SMAD4 AHCY STK11 FANCC TRNK BCL6 SMAD4 SKIV2L HMBS TP53 TERT PHOX2B SNAI2 BRAF TCOF1 FANCI NRAS REST SDHC HBB HFE CREBBP MET SEC23A CEP57 CTLA4 TRIM28 SMAD7 GNAS BRCA2 PALB2 FGF8 SBDS RET ALK GJB2 CPLANE1 GPC3 TCTN3 PTEN RB1 INTU CYP26C1 LEMD3 PRLR CDON NLRP1 GPR101 DHH HNF4A MMEL1 DNASE1L3 RASGRP1 ATRX CHEK2 FANCA SPRED1 DNM2 FLT4 CHEK2 RPS19 KLLN HACE1 HNF1A PTPN11 CDKN1B GAS1 BRCA2 KCNQ1OT1 NPM1 FGFR3 MC1R MINPP1 PTPN11 TSC2 ABCA5 BRCA2 PLCB4 SCN11A HNF1A BRAF RB1 CBL ARHGAP26 SUFU PTPRJ C1S APC IRF5 GNAQ GDNF TERT MYSM1 XPC TMC8 COL4A5 ERBB3 SLC26A4 CD96 NSUN2 PDGFRA FERMT1 TYR DNAJC21 MSH2 SH3GL1 TUBB RET BRAF ESR1 PAX3 RHBDF2 RTL1 WRN DYNC2LI1 ELANE EXOC6B RPS26 EWSR1 VHL PIGA GCGR POU6F2 RNF43 POLE BRAF MNX1 SFTPA2 CDH23 ASCL1 APC ACVR1 PIGL BAX RAG2 RSPO1 MSH3 PGM3 FGF3 FANCE MPL TP53 COL7A1 BUB1 TET2 PALB2 ACTB PNP SDHC EDN3 XPA TMC6 NEK1 GNA11 KAT6B KRT1 RUNX1 PAX7 NOTCH1 ENG CTNNB1 ETV6 MPLKIP PARN CDKN2A PTPN3 STAG3 MDM2 TP53 LAMC2 NBEAL2 VAMP7 GNA14 DCLRE1C CBL GCDH FANCC AXIN2 PYGL SOS1 BLK WRAP53 IDH1 KRAS CCM2 APC ASXL1 ATP7B ERCC3 SF3B1 EP300 BRCA2 MGAT2 NRTN CDKN2A DICER1 PMS1 RPS10 TBC1D24 FAH BRCA2 ASXL1 BCR C2CD3 KRAS IDH1 IGLL1 RASA1 BRCA2 CHEK2 PTCH1 RNF113A BRAF MBTPS2 EDNRB IGHM PDGFRB RAF1 MEN1 FASLG TUBB NDUFAF6 FOXI1 TGFBR1 EPCAM CYLD SDHB APC CYP2D6 TAF1 KRT17 BRCA1 BUB1B BAP1 GDF2 BUB1B ERCC2 TP53 KRT5 GATA2 BRCA1 RAD54B MRE11 STAC3 DNMT3A MLH1 BCHE EDN3 CDKN1B AURKA NRAS FLCN IDH2 EDN1 ESCO2 USF3 IGH POT1 ACVRL1 JAK2 NBN NRAS SQSTM1 TMEM127 ZFPM2 SLC12A3 NTHL1 ADA CHIC2 STAT3 SETBP1 FANCB FIBP STAT3 STK11 MLLT10 SFTPC HDAC4 NUP214 GLI2 SLX4 TSC1 ERCC6 TP53 CLCNKB KLF6 OGG1 JAK2 PAX6 RECQL4 RPL31 MYO1H FH RPGRIP1L SLC45A2 RPL10 RPL10 HMBS GDF5 TNFRSF10B PIK3CA GABRD TP53 BRCA2 SEMA4A BCR PALB2 ASXL1 KRT6B CCDC22 SAMD9 DMPK DCC ERCC5 RPL5 CTNNB1 RPS27 TRNS2 PTCH1 PTEN TFAP2A RPS24 RPL35A RET AXIN1 HNF1B ARMC5 UBE2T SRP54 SSX2 DKC1 ERCC3 JAK2 GNA11 LAMB3 GJB2 NFKB1 KCNQ1 GLI3 PIK3CA KANSL1 CASP8 MYC RECQL4 ACAN CACNA1S BDNF KIF11 MDH2 MSL3 FGFR1 TERF2IP HFE NFKB2 TOP2A GFI1 SRD5A3 PHKA2 MAX POLE MAP2K1 EYA1 RNF43 ALX3 SETD2 ERCC4 CTLA4 SIX3 LEMD3 OCRL CDH23 DZIP1L MSH3 AR CDC73 PDGFRL TWIST1 POU2AF1 DKC1 CALR LIN28B KRT6A GATA1 MC1R DIS3L2 CD28 CDC73 ADA2 UROD CIB1 TSR2 WNT5A TET2 PHOX2B BMPER KIT DLC1 MSTO1 H19-ICR SLC25A13 ADAR TMEM67 BMPR1A MLH3 POLR1C KRT6B FH EFL1 TERC BUB3 FOXC2 NOTCH3 KIT NSD1 FGFR2 SLC6A17 MAP3K1 TRIP13 MEG3 RRAS2 BMPR1A NF1 DPM1 LIG4 PARN RHOH BRCA2 NF1 TAF15 RFWD3 VHL H19 BCR KRAS VANGL2 KRAS SDHD DVL3 BIN1 ABL1 GPC3 HAX1 FANCA GDNF NHP2 IGF2 VHL CCL2 EXTL3 RUNX1 PRKCD BLNK MSH6 SLC22A18 IL2RG PTH1R SDHB AIP WDPCP APC KCNJ10 ASPSCR1 OCA2 TP53 WT1 SPRTN TET2 TAL1 L2HGDH KIT SDHC ERCC4 GPR143 PRKN SMAD4 SEMA3C TRNS1 BRCA1 SHOX PCNA FANCG CREB1 TRNH VHL MYLK BAP1 SUFU ANTXR1 POLD1 NODAL IGH JAK2 MS4A1 MEN1 TSC2 GATA2 DHCR7 TINF2 F13B RB1 COL7A1 SCN4A BMPR1A DDB2 CDKN2A SDHD CYP11B2 IL7 ARID1B KIT FGFR1 RET CDKN2A LAMA3 CHEK2 TBX2 TBX18 HNF4A GPC4 SHH LMNA BMP2 YY1 AKT1 WT1 BAP1 FZD2 SH2B3 BTK GATA1 RAD54L ATM CTBP1 PTEN SRY RYR1 CTHRC1 MFN2 PTEN RAD21 PTEN MYC SLC26A2 TP53 CTNNB1 RAD51C NAB2 NLRP1 SUFU DLL1 PSAP SDHB REST TGFBR2 TRIP13 IGH ABCC8 IL6 CPLANE1 H19 FANCD2 FGFR2 RET PKD1 DNMT3A REST CHEK2 GNAQ MXI1 BRIP1 DYNC2LI1 GNAS TP53 GLI3 DIS3L2 NRAS PICALM WT1 BAP1 MEN1 TXNRD2 MGMT PTEN MYD88 GNAS POT1 AGGF1 BUB1 PTEN PORCN HFE NUTM1 PHOX2B MSX2 PMS2 SLX4 H19 USP9X RPL27 GNAS SEC23B CBL CD28 PKHD1 AXIN2 TRPV3 KLLN SSX1 TSC1 PPOX KRT17 CARD14 HRAS TCF3 RPL11 CC2D2A GREM1 CHEK2 AP2S1 NRAS TRNL1 ALX1 CREBBP TCTN3 TET2 ESCO2 DOCK8 NRAS STK11 GCM2 TTC37 WT1 SMAD4 DAXX MITF BCL2 DIS3L2 POLR1D TDGF1 KRAS TNFRSF13C KIT PHOX2B SF3B1 RPL15 NF1 TERT TNFRSF1B FANCD2 MLH3 IL7R GPC4 H19-ICR SLC17A9 MEN1 MST1R KIT RAD50 TJP2 DNAJC21 PDCD10 MUTYH IL12RB1 SH2D1A FGFR2 NBN KRAS KIT CASR ENPP1 SDHB HRAS IKBKG PNP EXT2 BRD4 SMARCB1 REST COL11A2 TG KIT LIG4 SUFU NBN RSPRY1 CYSLTR2 SDHD AAGAB BLM RAG1 RNF139 RB1CC1 ACD PTPN11 SLC26A2 TREX1 BMPR1B DDR2 ZAP70 MNX1 MAGT1 AIP GATA2 AR STAR IFIH1 IDH2 BRCA1 USP8 RB1 FGFRL1 SMO USP8 RMRP SLC25A11 MLH3 FUZ DOCK8 SUFU NF2 KDR KRAS RPS14 CASP10 SRP54 ZSWIM6 TBXT PTCH2 EWSR1 TNFRSF13C MTAP NQO2 RPL18 DNAJC21 GCK ERCC6 KDM6B EXT1 SBDS CCND1 SDHAF2 KCNH1 CYLD LMOD1 PDGFRA CAT CHRNG TRNQ ADA NRAS TLR2 SHOX FGFR3 BCL10 TYR KRAS COL2A1 PTCH2 SMO GBA MSTO1 TREM2 JAK2 TMEM231 MSH2 ASXL1 RET DHCR7 NBN PIK3CA NSD2 SDHB EIF2AK4 PALB2 KIF7 PTPN11 PIK3CA HLA-DRB1 STIM1 TMC6 KIF1B TNFSF15 RELA AKT1 NPM1 APC SDHA SDHB STAT6 CDKN1C CDC73 PTCH2 KANSL1 ZSWIM6 FLCN HBB LZTS1 FN1 TRAF7 ACP5 CTNNB1 MLH1 EXT2 RNASEL RNASEH2A IL2RG ATP7A CDK4 CYP11B1 MMP1 SDHB ATRX ACTG2 FOXH1 OFD1 NEK9 STS MUC5B PRKCD PTPN11 PTCH2 LRRC8A RPL26 MSH6 NNT LZTR1 CDC73 PTEN AKT1 AKT1 SASH1 HRAS ANAPC1 PTPN12 KCNJ11 TCF4 GATA2 MLH3 ERCC4 GNB1 DISP1 IDH1 BCR GANAB MSH6 NR5A1 TSC2 GFI1 TNFSF12 TRNP MAPK1 IFNG FLT4 MTM1 WWOX HABP2 RPS28 HRAS SLCO2A1 ND5 SDHB CHD7 BRIP1 SLC37A4 MC2R XRCC3 TNFRSF4 NAGS PHF21A ZIC2 PCGF2 SMARCE1 CTNNB1 SRP54 CDH1 CDK4 RPS20 KCNJ10 RAD21 RNF6 COL14A1 SMO CD19 WRN SRGAP1 CDKN2C AXIN2 GPC6 WWOX HSPA9 FOXI1 CPOX RPS17 APC2 MYH8 SERPINA1 ATM LMX1B ENG POLH TGFBR2 DHX37 VEGFC KIF1B KRT17 DDX41 SPIB CBFB HRAS BCL10 PIGL FGFR1 NSD1 F5 KCNN3 BAX PIEZO2 RECQL4 CREBBP KIT PDGFB PDE6D ABCA5 AKT1 KLHDC8B TNFSF12 EPCAM RARA MLH1 GINS1 EVC PIK3CA FANCE WIPF1 NF2 PDGFRA PRKAR1A CDH1 SDHD PRCC TRNF PTCH1 TNFRSF1B WNT10A WWOX MAD1L1 MTOR WDPCP RNASEH2C NSD2 SAMD9L FH LPP NF1 KRIT1 NTHL1 IL12A HNF1A CDH1 SMARCB1 SMARCE1 CD19 FH FDPS TRPS1 ERCC4 SMPD1 SMARCD2 BRCA1 MPL CRKL SEC23A EXT1 PERP ATM FOXE1 CDKN2B CTSC SIX1 FAM149B1 CDH1 RAD51C ALX3 DLST TRIP13 ING1 PDGFRB FLT3 COL18A1 MST1 TGIF1 TMEM107 SRSF2 TRIM28 BAP1 ANTXR2 CD79A PIK3R1 MAP3K1 NOP10 PIK3CA POLD1 KDSR CCND1 TP53 TMC8 ALK MAP2K1 CD79B SDHC ECE1 PALLD CTSA PRDM16 IVNS1ABP CALR FLNA GPR101 BRCA2 ERCC2 DYNC2H1 TFAP2A COL2A1 DVL1 TERT APC TERT TEK EXT2 TERC ALX4 OFD1 LMO1 PDGFRB RPS14 DCC RTEL1 INS TSC2 FAM20C MYH11 GPC3 SCN9A SMAD4 RASGRP1 HBB TGFBR2 RERE NDP PLA2G2A TCF4 MAD2L2 SKI AIP HMMR SDHC SNAI2 PIK3CA LMNA PGM3 ABCB11 TAL2 WT1 VHL PIK3CA TCTN3 SAMD9L ICOS GLI3 RB1 SLC25A13 SDHC DCLRE1C GCM2 VANGL1 SIX6 WT1 PMS2 KCNH1 BARD1 H19-ICR GNAS TERT CIB1 B3GALT6 GJB3 ERBB2 SDHA KRAS CDC73 TNFRSF13B TET2 FGFR3 WAS SEC23B TGFBR2 TP53 NF2 SMARCA4 NF2 SLC26A4 ANTXR2 WRAP53 FAS SAMHD1 TP53 TET2 ATP7A PTEN SH3KBP1 CARMIL2 MVD PDGFB ABCC6 G6PC1 TRNK KRAS GPC3 PTEN NF2 JAK2 DMRT3 GNAQ RAD51 GTF2H5 TMEM127 TERT RUNX1 FAT4 AR HABP2 NR4A3 EP300 MINPP1 OFD1 RASA1 DLEC1 BIRC3 AIP CD27 PHOX2B BMPR1A KCNE3 PLCD1 RAD51 KRT1 MSH3 MITF EPHB2 DHCR24 RABL3 KRT17 XRCC2 NRAS ITK VHL BICC1 RECQL4 SMARCAD1 MYCN RET CTC1 PTCH1 JAK2 SRC SDHB PHOX2B AKT1 KEAP1 JAG1 VHL LETM1 NLRP1 MEN1 BRCA2 FLCN C2CD3 RFWD3 XPA APC APC SDHD FOXO1 MAFA WHCR GPC4 MLH1 ICOS CDKN1B MTMR14 KIT DICER1 EP300 ZFHX3 MMP1 PRKAR1A KRT9 F13A1 CTNNB1 MPL INPP5E NF1 DKC1 TERT DLK1 SCN10A STS RPS29 PTEN FLCN LRBA ELANE GTF2E2 ATM PIK3CA GPR35 CYLD RAD51C CDKN1A WT1 DICER1 PIK3CA TERC PIK3CA SLC25A11 GNAS CEBPA ATP6V1B2 RET XPC EXT1 BRCA2 SH2B3 ERCC3 BRCA2 RTEL1 WASHC5 ERCC2 AKT1 KCNAB2 CYLD STK4 POLH ERCC5 CDH1 CEL XIAP MSR1 TP53 TET2 DHH PRKAR1A
    HP:0002090: Pneumonia
    Genes 280
    TLL1 CHD7 TGIF1 KMT2D ACP5 PIGN JAK3 NOS1 SFTPB SRP54 MS4A1 NODAL USB1 CD79B SGCG ACTC1 CASP8 TGFB1 OFD1 CD19 CD247 NHLRC1 SHH NTRK1 EGFR LAMA3 PLOD1 FANCF JAK3 RAG2 PGM3 CACNA1C BTK IL2RG PIK3CD CREBBP KCNJ6 FMO3 ACTA1 TNFSF12 GATA6 ZAP70 PLOD1 UNC119 FGF8 GAS1 DNAI1 WAS GNPTAB FOXH1 CYBC1 LAMC2 RAG1 PEPD PDHA1 PMM2 PAFAH1B1 CD19 CD3D SIX3 CD81 DLL1 LTBP3 EP300 TNFRSF13B SIX3 GLI2 SMARCD2 TIMM8A MYH6 DCLRE1C ABCA3 IL7R TBC1D24 STAT3 CFB FOXH1 FOXP3 FCGR2A P4HTM AP3B1 POLA1 TK2 CDON PKHD1 TAF1 CDON NIPBL GRHL3 GAS1 EFEMP2 CRLF1 SLC35A1 SLC25A24 DOCK8 ZIC2 LEP AFF4 DDR2 CD3E PTPRC BLM RNU4ATAC TNFRSF13C KNSTRN CDON SELENON FOXH1 ORC6 RAG1 RNF168 SHH DISP1 CYBA IL7R CARD11 LONP1 COL11A2 CR2 FGF8 ZIC2 CARD11 CYBB NBN ICOS DNAJC21 DNMT3B DISP1 TGIF1 HLA-DQB1 ADA SETBP1 MED25 FOXH1 SLC35C1 ACADVL TDGF1 PNP SP110 SMC1A ICOS SREBF1 TDGF1 NBN DCLRE1C ALMS1 GLI2 MCIDAS FGF8 NCF1 RAG1 PTCH1 NADK2 IL2RG ZBTB24 ZAP70 GLI2 FGFR1 GAS1 TNFRSF13B GAS1 IFNGR1 CFTR COL11A2 CR2 SAMD9 CD247 TGIF1 TREX1 CARMIL2 TCIRG1 BLNK UBB SRP54 LAMB3 DISP1 RMRP TNFRSF13C NFKB1 STAG2 IRF8 PTCH1 SIX3 KPTN TBX20 TDGF1 CSPP1 IGHM BTK NFIX RNU4ATAC CXCR4 NFKB2 RAC1 CD27 TGIF1 ADA TBX20 ZIC2 MTHFD1 RAG2 GATA4 TNFRSF11A DZIP1L FGF8 KIAA0586 SHH TDGF1 RYR1 ODAD1 WDR1 CREBBP CITED2 DLL1 NCF2 TBCD SHH NODAL RAC2 SIX3 GBA PTCH1 DNAI2 ZIC2 TNFRSF13C ALMS1 PURA STAG2 DLL1 SBDS ICOS EFL1 ACP5 SFTPC CFAP410 MASP2 IL2RG IGLL1 AFF4 BTK LIG4 NFKB2 WDR19 CD55 CDON GAS8 EPM2A NKX2-1 RNF125 DCLRE1C NODAL LRBA ELANE MAN2B1 DLL1 PTCH1 HLA-DQA1 EXTL3 SLC35C1 MAN2B1 FOXN1 PRKCD GLI2 RANBP2 MID1 IL2RG FBLN5 NKX2-5 NODAL GFI1 TNFSF12 RAG2 ADA IL21R KDM6A OSTM1 ASAH1 DISP1 PANK2 FGFR1
    SNP 0

    HPO

    Alphabetical listing of all HPO terms. Navigate: Correlations   Clinical Trials


    Related HPO nodes (Using clinical trials)


    HP:0004377: Hematological neoplasm
    Genes 350
    CHD7 GFI1B FANCG NSUN2 RPS7 DNAJC21 NAGS SH3GL1 IGH SRP54 MS4A1 GATA2 TINF2 F13B COL14A1 CD19 DYNC2LI1 NUMA1 ELANE RPS26 PIGA CTPS1 APC HSPA9 POLE RPS17 APC2 CDKN2A FANCM RPS15A PIGL DDX41 RAG2 CBFB MALT1 BCL10 PIGL NSD1 GLI1 CD70 PGM3 SH2B3 BAX GATA1 ATM FANCE MPL TP53 BUB1 TET2 PALB2 KLHDC8B TNFSF12 RARA MLH1 GINS1 RAD51C EVC BUB1B FANCE WIPF1 RUNX1 PDGFRA MYD88 IGH TNFRSF1B ETV6 MDM2 TP63 FANCD2 NBEAL2 RNASEH2C SAMD9L NF1 DNMT3A CBL LPP FANCC TP53 BRIP1 GATA2 CD19 ASXL1 NRAS PICALM CD81 SF3B1 TNFRSF13B SMPD1 SMARCD2 BRCA1 TYROBP MPL LIG4 ABL1 MYD88 ATM RPS10 ATRX FANCG ASXL1 TET2 NUTM1 BCR FLT3 KRAS SRP72 MPL RPL27 EVC2 CBL CD28 BRCA2 SRSF2 XRCC4 RAF1 RPL11 THPO FASLG NOP10 CHEK2 SRSF2 CREBBP BUB1B TET2 PRKCD CALR GATA2 DNMT3A LIG4 BLM BCL2 FOXP1 TNFRSF13C TERT SF3B1 RPL15 TERC ADA2 PDGFRB TERT RPS14 TNFRSF1B FANCD2 RTEL1 RUNX1 IL7R USB1 SCN9A RASGRP1 CR2 IGH POT1 JAK2 NBN NRAS LIG4 TCF4 DNAJC21 MAD2L2 SH2D1A NTHL1 RPL35 FANCL KRAS ADA FAS CHIC2 STAT3 SETBP1 PGM3 CALR FANCB TAL2 PIK3R1 STAT3 PNP SAMD9L TET2 MLLT10 ICOS BRD4 NUP214 SLX4 LIG4 NBN NUP214 DCLRE1C JAK2 AAGAB BLM RECQL4 RAG1 CCND1 RPL31 MSH2 MCM4 TREX1 TINF2 ZAP70 MAGT1 GATA2 BCR MPL TNFRSF13B TET2 IFIH1 ASXL1 WAS CR2 SAMD9 RPL5 KIT RPS27 RMRP RPS24 WRAP53 FANCF RPL35A FAS SAMHD1 TP53 MLH1 TET2 PTEN PIK3CA TCIRG1 UBE2T SRP54 RPS19 DKC1 JAK2 RPS14 CASP10 FLT3 SRP54 JAK2 RMRP TNFRSF13C NFKB1 RPL18 TERT RUNX1 MYC DNAJC21 RECQL4 SBDS CCND1 KIF11 BIRC3 NFKB2 GFI1 CD27 ADA RNASEH2B BCL10 RNF43 KRAS SETD2 FANCC ERCC4 CTLA4 BCL6 GBA RAD51 TREM2 JAK2 TERT NBN BRAF XRCC2 FANCI ITK CALR GATA1 CD28 CTC1 ADA2 PTPN11 TSR2 JAK2 HLA-DRB1 TET2 CEP57 NPM1 CTLA4 ADAR RFWD3 SBDS ICOS EFL1 TERC BUB3 KIT EP300 RNASEH2A IL2RG F13A1 TRIP13 LIG4 PARN RHOH MPL DNASE1L3 RASGRP1 ATRX NF1 RFWD3 FANCA STS PRKCD DKC1 SCN10A PTPN11 RPS19 RPS29 RPL26 ABL1 HAX1 LRBA ELANE FANCA NHP2 NPM1 RUNX1 PRKCD ANAPC1 TERC SCN11A CEBPA TCF4 GATA2 IL2RG RB1 GNB1 CBL BRCA2 SH2B3 BCR MSH6 ARHGAP26 TET2 TAL1 GFI1 TNFSF12 RPS28 MYSM1 XIAP ERBB3 TET2
    Protein Mutations 0
    SNP 0
    HP:0002664: Neoplasm
    Genes 1522
    SF3B1 GFI1B IGF2 FIBP RPS7 WT1 COL7A1 TREX1 HSPG2 CASP8 SLC22A18 MC1R TFE3 KRAS PLAG1 OFD1 BRAF NUMA1 KRT16 PSENEN CTPS1 APC SOX9 FANCM OPCML CDKN2A RPS15A CTNNB1 SDHD EDN3 FCN3 NELFA GJC2 MALT1 HPGD GLI1 CD70 SPINK1 LETM1 PMS1 LRP5 HNF1B EXT1 TCF4 ELMO2 MET ANTXR1 KRT16 KRT10 PAX4 SETBP1 TERT WT1 SMARCB1 GJB6 HRAS STK11 BUB1B GNPTAB MYD88 MCC GJB2 BRCA1 TP63 PDGFRL TARS1 NF1 FGFR3 KARS1 BARD1 BRIP1 GATA2 IL1RN BRAF CD81 TNFRSF13B TYROBP AR LIG4 KLF11 ABL1 MVK BMPR1A PIK3CA B3GALT6 SLC37A4 SOS1 TSC1 FGFR3 ATRX FANCG TET2 KIT SRP72 MPL TP53 SMAD4 EVC2 MAPRE2 DLST BRCA1 DICER1 HRAS AKT1 RNR1 TSC1 TNPO3 XRCC4 DNMT3A NEUROD1 THPO MN1 NOD2 SRSF2 PPM1D FLT4 ATP7A IL7 KRAS GDNF WNT10A EPAS1 COL1A1 IL1B MRAP ADAMTS3 PRKCD SUFU PTCH1 ERCC3 KRT14 CXCR4 HOXD13 IGF2 LIG4 PALB2 BLM NRAS ERCC3 FOXP1 SDHD TP53 PKD2 PDX1 TINF2 ADA2 MYF6 RHBDF2 POU6F2 PHKG2 CDKN2A RUNX1 ERCC2 MAP2K2 WT1 USB1 GATA4 FGFR2 ACD CR2 MUTYH ARL6IP6 FAH MSH2 RASA1 NEK1 SOX6 NR0B1 LIG4 CDKN2B NF1 NF1 POLE RPL35 SRY SDHAF2 FANCL CPLX1 FAS PRKAR1A PHB SDHA CALR PIK3R1 FAN1 TET2 TMEM216 RSPO1 SEMA3D MDM4 SDHD HRAS NUP214 GJA1 PIK3CA CCND1 RNF6 MSH2 C11ORF95 MVK MCM4 FLI1 TINF2 KIAA0753 ECM1 ARSA ERCC2 SOX2 SDHC SLC26A2 MPL VANGL1 PUF60 RAD51D POT1 CR2 ESCO2 FOXE1 PMVK SRY GJB4 TRIM37 KIT EXT2 PDGFB KIF1B FANCF IGF2R MLH1 GDNF PIK3CA ASCC1 ASCL1 TCIRG1 APPL1 RPS19 BCL10 IGF2 NRAS FLT3 STAT1 BCL10 RMRP GNAI3 KRAS GPR101 BAP1 NKX2-1 MAX BMPR1A DDB2 SMARCB1 RAD51 FGFR3 ALX4 BTK MSH6 NOTCH3 DICER1 CXCR4 CCBE1 RET WT1 TP53 PALLD RNASEH2B WT1 ATR CCND1 KCNQ1OT1 SMAD4 AHCY STK11 FANCC TRNK BCL6 SMAD4 SKIV2L HMBS TP53 TERT PHOX2B SNAI2 BRAF TCOF1 FANCI NRAS REST SDHC HBB HFE CREBBP MET SEC23A CEP57 CTLA4 TRIM28 SMAD7 GNAS BRCA2 PALB2 FGF8 SBDS RET ALK GJB2 CPLANE1 GPC3 TCTN3 PTEN RB1 INTU CYP26C1 LEMD3 PRLR CDON NLRP1 GPR101 DHH HNF4A MMEL1 DNASE1L3 RASGRP1 ATRX CHEK2 FANCA SPRED1 DNM2 FLT4 CHEK2 RPS19 KLLN HACE1 HNF1A PTPN11 CDKN1B GAS1 BRCA2 KCNQ1OT1 NPM1 FGFR3 MC1R MINPP1 PTPN11 TSC2 ABCA5 BRCA2 PLCB4 SCN11A HNF1A BRAF RB1 CBL ARHGAP26 SUFU PTPRJ C1S APC IRF5 GNAQ GDNF TERT MYSM1 XPC TMC8 COL4A5 ERBB3 SLC26A4 CD96 NSUN2 PDGFRA FERMT1 TYR DNAJC21 MSH2 SH3GL1 TUBB RET BRAF ESR1 PAX3 RHBDF2 RTL1 WRN DYNC2LI1 ELANE EXOC6B RPS26 EWSR1 VHL PIGA GCGR POU6F2 RNF43 POLE BRAF MNX1 SFTPA2 CDH23 ASCL1 APC ACVR1 PIGL BAX RAG2 RSPO1 MSH3 PGM3 FGF3 FANCE MPL TP53 COL7A1 BUB1 TET2 PALB2 ACTB PNP SDHC EDN3 XPA TMC6 NEK1 GNA11 KAT6B KRT1 RUNX1 PAX7 NOTCH1 ENG CTNNB1 ETV6 MPLKIP PARN CDKN2A PTPN3 STAG3 MDM2 TP53 LAMC2 NBEAL2 VAMP7 GNA14 DCLRE1C CBL GCDH FANCC AXIN2 PYGL SOS1 BLK WRAP53 IDH1 KRAS CCM2 APC ASXL1 ATP7B ERCC3 SF3B1 EP300 BRCA2 MGAT2 NRTN CDKN2A DICER1 PMS1 RPS10 TBC1D24 FAH BRCA2 ASXL1 BCR C2CD3 KRAS IDH1 IGLL1 RASA1 BRCA2 CHEK2 PTCH1 RNF113A BRAF MBTPS2 EDNRB IGHM PDGFRB RAF1 MEN1 FASLG TUBB NDUFAF6 FOXI1 TGFBR1 EPCAM CYLD SDHB APC CYP2D6 TAF1 KRT17 BRCA1 BUB1B BAP1 GDF2 BUB1B ERCC2 TP53 KRT5 GATA2 BRCA1 RAD54B MRE11 STAC3 DNMT3A MLH1 BCHE EDN3 CDKN1B AURKA NRAS FLCN IDH2 EDN1 ESCO2 USF3 IGH POT1 ACVRL1 JAK2 NBN NRAS SQSTM1 TMEM127 ZFPM2 SLC12A3 NTHL1 ADA CHIC2 STAT3 SETBP1 FANCB FIBP STAT3 STK11 MLLT10 SFTPC HDAC4 NUP214 GLI2 SLX4 TSC1 ERCC6 TP53 CLCNKB KLF6 OGG1 JAK2 PAX6 RECQL4 RPL31 MYO1H FH RPGRIP1L SLC45A2 RPL10 RPL10 HMBS GDF5 TNFRSF10B PIK3CA GABRD TP53 BRCA2 SEMA4A BCR PALB2 ASXL1 KRT6B CCDC22 SAMD9 DMPK DCC ERCC5 RPL5 CTNNB1 RPS27 TRNS2 PTCH1 PTEN TFAP2A RPS24 RPL35A RET AXIN1 HNF1B ARMC5 UBE2T SRP54 SSX2 DKC1 ERCC3 JAK2 GNA11 LAMB3 GJB2 NFKB1 KCNQ1 GLI3 PIK3CA KANSL1 CASP8 MYC RECQL4 ACAN CACNA1S BDNF KIF11 MDH2 MSL3 FGFR1 TERF2IP HFE NFKB2 TOP2A GFI1 SRD5A3 PHKA2 MAX POLE MAP2K1 EYA1 RNF43 ALX3 SETD2 ERCC4 CTLA4 SIX3 LEMD3 OCRL CDH23 DZIP1L MSH3 AR CDC73 PDGFRL TWIST1 POU2AF1 DKC1 CALR LIN28B KRT6A GATA1 MC1R DIS3L2 CD28 CDC73 ADA2 UROD CIB1 TSR2 WNT5A TET2 PHOX2B BMPER KIT DLC1 MSTO1 H19-ICR SLC25A13 ADAR TMEM67 BMPR1A MLH3 POLR1C KRT6B FH EFL1 TERC BUB3 FOXC2 NOTCH3 KIT NSD1 FGFR2 SLC6A17 MAP3K1 TRIP13 MEG3 RRAS2 BMPR1A NF1 DPM1 LIG4 PARN RHOH BRCA2 NF1 TAF15 RFWD3 VHL H19 BCR KRAS VANGL2 KRAS SDHD DVL3 BIN1 ABL1 GPC3 HAX1 FANCA GDNF NHP2 IGF2 VHL CCL2 EXTL3 RUNX1 PRKCD BLNK MSH6 SLC22A18 IL2RG PTH1R SDHB AIP WDPCP APC KCNJ10 ASPSCR1 OCA2 TP53 WT1 SPRTN TET2 TAL1 L2HGDH KIT SDHC ERCC4 GPR143 PRKN SMAD4 SEMA3C TRNS1 BRCA1 SHOX PCNA FANCG CREB1 TRNH VHL MYLK BAP1 SUFU ANTXR1 POLD1 NODAL IGH JAK2 MS4A1 MEN1 TSC2 GATA2 DHCR7 TINF2 F13B RB1 COL7A1 SCN4A BMPR1A DDB2 CDKN2A SDHD CYP11B2 IL7 ARID1B KIT FGFR1 RET CDKN2A LAMA3 CHEK2 TBX2 TBX18 HNF4A GPC4 SHH LMNA BMP2 YY1 AKT1 WT1 BAP1 FZD2 SH2B3 BTK GATA1 RAD54L ATM CTBP1 PTEN SRY RYR1 CTHRC1 MFN2 PTEN RAD21 PTEN MYC SLC26A2 TP53 CTNNB1 RAD51C NAB2 NLRP1 SUFU DLL1 PSAP SDHB REST TGFBR2 TRIP13 IGH ABCC8 IL6 CPLANE1 H19 FANCD2 FGFR2 RET PKD1 DNMT3A REST CHEK2 GNAQ MXI1 BRIP1 DYNC2LI1 GNAS TP53 GLI3 DIS3L2 NRAS PICALM WT1 BAP1 MEN1 TXNRD2 MGMT PTEN MYD88 GNAS POT1 AGGF1 BUB1 PTEN PORCN HFE NUTM1 PHOX2B MSX2 PMS2 SLX4 H19 USP9X RPL27 GNAS SEC23B CBL CD28 PKHD1 AXIN2 TRPV3 KLLN SSX1 TSC1 PPOX KRT17 CARD14 HRAS TCF3 RPL11 CC2D2A GREM1 CHEK2 AP2S1 NRAS TRNL1 ALX1 CREBBP TCTN3 TET2 ESCO2 DOCK8 NRAS STK11 GCM2 TTC37 WT1 SMAD4 DAXX MITF BCL2 DIS3L2 POLR1D TDGF1 KRAS TNFRSF13C KIT PHOX2B SF3B1 RPL15 NF1 TERT TNFRSF1B FANCD2 MLH3 IL7R GPC4 H19-ICR SLC17A9 MEN1 MST1R KIT RAD50 TJP2 DNAJC21 PDCD10 MUTYH IL12RB1 SH2D1A FGFR2 NBN KRAS KIT CASR ENPP1 SDHB HRAS IKBKG PNP EXT2 BRD4 SMARCB1 REST COL11A2 TG KIT LIG4 SUFU NBN RSPRY1 CYSLTR2 SDHD AAGAB BLM RAG1 RNF139 RB1CC1 ACD PTPN11 SLC26A2 TREX1 BMPR1B DDR2 ZAP70 MNX1 MAGT1 AIP GATA2 AR STAR IFIH1 IDH2 BRCA1 USP8 RB1 FGFRL1 SMO USP8 RMRP SLC25A11 MLH3 FUZ DOCK8 SUFU NF2 KDR KRAS RPS14 CASP10 SRP54 ZSWIM6 TBXT PTCH2 EWSR1 TNFRSF13C MTAP NQO2 RPL18 DNAJC21 GCK ERCC6 KDM6B EXT1 SBDS CCND1 SDHAF2 KCNH1 CYLD LMOD1 PDGFRA CAT CHRNG TRNQ ADA NRAS TLR2 SHOX FGFR3 BCL10 TYR KRAS COL2A1 PTCH2 SMO GBA MSTO1 TREM2 JAK2 TMEM231 MSH2 ASXL1 RET DHCR7 NBN PIK3CA NSD2 SDHB EIF2AK4 PALB2 KIF7 PTPN11 PIK3CA HLA-DRB1 STIM1 TMC6 KIF1B TNFSF15 RELA AKT1 NPM1 APC SDHA SDHB STAT6 CDKN1C CDC73 PTCH2 KANSL1 ZSWIM6 FLCN HBB LZTS1 FN1 TRAF7 ACP5 CTNNB1 MLH1 EXT2 RNASEL RNASEH2A IL2RG ATP7A CDK4 CYP11B1 MMP1 SDHB ATRX ACTG2 FOXH1 OFD1 NEK9 STS MUC5B PRKCD PTPN11 PTCH2 LRRC8A RPL26 MSH6 NNT LZTR1 CDC73 PTEN AKT1 AKT1 SASH1 HRAS ANAPC1 PTPN12 KCNJ11 TCF4 GATA2 MLH3 ERCC4 GNB1 DISP1 IDH1 BCR GANAB MSH6 NR5A1 TSC2 GFI1 TNFSF12 TRNP MAPK1 IFNG FLT4 MTM1 WWOX HABP2 RPS28 HRAS SLCO2A1 ND5 SDHB CHD7 BRIP1 SLC37A4 MC2R XRCC3 TNFRSF4 NAGS PHF21A ZIC2 PCGF2 SMARCE1 CTNNB1 SRP54 CDH1 CDK4 RPS20 KCNJ10 RAD21 RNF6 COL14A1 SMO CD19 WRN SRGAP1 CDKN2C AXIN2 GPC6 WWOX HSPA9 FOXI1 CPOX RPS17 APC2 MYH8 SERPINA1 ATM LMX1B ENG POLH TGFBR2 DHX37 VEGFC KIF1B KRT17 DDX41 SPIB CBFB HRAS BCL10 PIGL FGFR1 NSD1 F5 KCNN3 BAX PIEZO2 RECQL4 CREBBP KIT PDGFB PDE6D ABCA5 AKT1 KLHDC8B TNFSF12 EPCAM RARA MLH1 GINS1 EVC PIK3CA FANCE WIPF1 NF2 PDGFRA PRKAR1A CDH1 SDHD PRCC TRNF PTCH1 TNFRSF1B WNT10A WWOX MAD1L1 MTOR WDPCP RNASEH2C NSD2 SAMD9L FH LPP NF1 KRIT1 NTHL1 IL12A HNF1A CDH1 SMARCB1 SMARCE1 CD19 FH FDPS TRPS1 ERCC4 SMPD1 SMARCD2 BRCA1 MPL CRKL SEC23A EXT1 PERP ATM FOXE1 CDKN2B CTSC SIX1 FAM149B1 CDH1 RAD51C ALX3 DLST TRIP13 ING1 PDGFRB FLT3 COL18A1 MST1 TGIF1 TMEM107 SRSF2 TRIM28 BAP1 ANTXR2 CD79A PIK3R1 MAP3K1 NOP10 PIK3CA POLD1 KDSR CCND1 TP53 TMC8 ALK MAP2K1 CD79B SDHC ECE1 PALLD CTSA PRDM16 IVNS1ABP CALR FLNA GPR101 BRCA2 ERCC2 DYNC2H1 TFAP2A COL2A1 DVL1 TERT APC TERT TEK EXT2 TERC ALX4 OFD1 LMO1 PDGFRB RPS14 DCC RTEL1 INS TSC2 FAM20C MYH11 GPC3 SCN9A SMAD4 RASGRP1 HBB TGFBR2 RERE NDP PLA2G2A TCF4 MAD2L2 SKI AIP HMMR SDHC SNAI2 PIK3CA LMNA PGM3 ABCB11 TAL2 WT1 VHL PIK3CA TCTN3 SAMD9L ICOS GLI3 RB1 SLC25A13 SDHC DCLRE1C GCM2 VANGL1 SIX6 WT1 PMS2 KCNH1 BARD1 H19-ICR GNAS TERT CIB1 B3GALT6 GJB3 ERBB2 SDHA KRAS CDC73 TNFRSF13B TET2 FGFR3 WAS SEC23B TGFBR2 TP53 NF2 SMARCA4 NF2 SLC26A4 ANTXR2 WRAP53 FAS SAMHD1 TP53 TET2 ATP7A PTEN SH3KBP1 CARMIL2 MVD PDGFB ABCC6 G6PC1 TRNK KRAS GPC3 PTEN NF2 JAK2 DMRT3 GNAQ RAD51 GTF2H5 TMEM127 TERT RUNX1 FAT4 AR HABP2 NR4A3 EP300 MINPP1 OFD1 RASA1 DLEC1 BIRC3 AIP CD27 PHOX2B BMPR1A KCNE3 PLCD1 RAD51 KRT1 MSH3 MITF EPHB2 DHCR24 RABL3 KRT17 XRCC2 NRAS ITK VHL BICC1 RECQL4 SMARCAD1 MYCN RET CTC1 PTCH1 JAK2 SRC SDHB PHOX2B AKT1 KEAP1 JAG1 VHL LETM1 NLRP1 MEN1 BRCA2 FLCN C2CD3 RFWD3 XPA APC APC SDHD FOXO1 MAFA WHCR GPC4 MLH1 ICOS CDKN1B MTMR14 KIT DICER1 EP300 ZFHX3 MMP1 PRKAR1A KRT9 F13A1 CTNNB1 MPL INPP5E NF1 DKC1 TERT DLK1 SCN10A STS RPS29 PTEN FLCN LRBA ELANE GTF2E2 ATM PIK3CA GPR35 CYLD RAD51C CDKN1A WT1 DICER1 PIK3CA TERC PIK3CA SLC25A11 GNAS CEBPA ATP6V1B2 RET XPC EXT1 BRCA2 SH2B3 ERCC3 BRCA2 RTEL1 WASHC5 ERCC2 AKT1 KCNAB2 CYLD STK4 POLH ERCC5 CDH1 CEL XIAP MSR1 TP53 TET2 DHH PRKAR1A
    HP:0002090: Pneumonia
    Genes 280
    TLL1 CHD7 TGIF1 KMT2D ACP5 PIGN JAK3 NOS1 SFTPB SRP54 MS4A1 NODAL USB1 CD79B SGCG ACTC1 CASP8 TGFB1 OFD1 CD19 CD247 NHLRC1 SHH NTRK1 EGFR LAMA3 PLOD1 FANCF JAK3 RAG2 PGM3 CACNA1C BTK IL2RG PIK3CD CREBBP KCNJ6 FMO3 ACTA1 TNFSF12 GATA6 ZAP70 PLOD1 UNC119 FGF8 GAS1 DNAI1 WAS GNPTAB FOXH1 CYBC1 LAMC2 RAG1 PEPD PDHA1 PMM2 PAFAH1B1 CD19 CD3D SIX3 CD81 DLL1 LTBP3 EP300 TNFRSF13B SIX3 GLI2 SMARCD2 TIMM8A MYH6 DCLRE1C ABCA3 IL7R TBC1D24 STAT3 CFB FOXH1 FOXP3 FCGR2A P4HTM AP3B1 POLA1 TK2 CDON PKHD1 TAF1 CDON NIPBL GRHL3 GAS1 EFEMP2 CRLF1 SLC35A1 SLC25A24 DOCK8 ZIC2 LEP AFF4 DDR2 CD3E PTPRC BLM RNU4ATAC TNFRSF13C KNSTRN CDON SELENON FOXH1 ORC6 RAG1 RNF168 SHH DISP1 CYBA IL7R CARD11 LONP1 COL11A2 CR2 FGF8 ZIC2 CARD11 CYBB NBN ICOS DNAJC21 DNMT3B DISP1 TGIF1 HLA-DQB1 ADA SETBP1 MED25 FOXH1 SLC35C1 ACADVL TDGF1 PNP SP110 SMC1A ICOS SREBF1 TDGF1 NBN DCLRE1C ALMS1 GLI2 MCIDAS FGF8 NCF1 RAG1 PTCH1 NADK2 IL2RG ZBTB24 ZAP70 GLI2 FGFR1 GAS1 TNFRSF13B GAS1 IFNGR1 CFTR COL11A2 CR2 SAMD9 CD247 TGIF1 TREX1 CARMIL2 TCIRG1 BLNK UBB SRP54 LAMB3 DISP1 RMRP TNFRSF13C NFKB1 STAG2 IRF8 PTCH1 SIX3 KPTN TBX20 TDGF1 CSPP1 IGHM BTK NFIX RNU4ATAC CXCR4 NFKB2 RAC1 CD27 TGIF1 ADA TBX20 ZIC2 MTHFD1 RAG2 GATA4 TNFRSF11A DZIP1L FGF8 KIAA0586 SHH TDGF1 RYR1 ODAD1 WDR1 CREBBP CITED2 DLL1 NCF2 TBCD SHH NODAL RAC2 SIX3 GBA PTCH1 DNAI2 ZIC2 TNFRSF13C ALMS1 PURA STAG2 DLL1 SBDS ICOS EFL1 ACP5 SFTPC CFAP410 MASP2 IL2RG IGLL1 AFF4 BTK LIG4 NFKB2 WDR19 CD55 CDON GAS8 EPM2A NKX2-1 RNF125 DCLRE1C NODAL LRBA ELANE MAN2B1 DLL1 PTCH1 HLA-DQA1 EXTL3 SLC35C1 MAN2B1 FOXN1 PRKCD GLI2 RANBP2 MID1 IL2RG FBLN5 NKX2-5 NODAL GFI1 TNFSF12 RAG2 ADA IL21R KDM6A OSTM1 ASAH1 DISP1 PANK2 FGFR1
    SNP 0

    Reports

    Data processed on December 13, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,818 reports on interventions/drugs

    MeSH

    706 reports on MeSH terms

    HPO

    306 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook